Can PDE inhibition improve cognition? : Translational insights by Reneerkens, O.A.H.
  
 
Can PDE inhibition improve cognition? : Translational
insights
Citation for published version (APA):
Reneerkens, O. A. H. (2013). Can PDE inhibition improve cognition? : Translational insights. Maastricht:
Maastricht University.
Document status and date:
Published: 01/01/2013
Document Version:
Publisher's PDF, also known as Version of record
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page
numbers.
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 04 Dec. 2019
 
 
 
Can PDE inhibition improve cognition?  
Translational insights 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Olga A. H. Reneerkens, Maastricht, 2013 
ISBN: 978 94 91602 08 5 
 
Can PDE inhibition improve cognition? Translational insights 
 
All rights reserved. No part of this thesis may be reproduced or transmitted in any form or by any 
means, electronic or mechanical, including photocopying, recording or by any information storage and 
retrieval system, without permission in writing from the author, or, when appropriate, from the publishers 
of the publications.  
 
Cover illustration by Hans Klaasse  
Typesetting and layout by Olga A. H. Reneerkens  
Printed by Print Service Ede 
 
Financial support for the publication of this dissertation was kindly provided by the Van Leersumfonds 
(Koninklijke Nederlandse Akademie van Wetenschappen) and Internationale Stichting Alzheimer 
Onderzoek 
 
Additional financial support  
for this publication was  
granted by Alzheimer  
Nederland (Amersfoort) 
 
 
 
 
Can PDE inhibition improve cognition?  
Translational insights 
 
 
 
 
 
Proefschrift 
 
 
ter verkrijging van de graad van doctor  
aan de Universiteit Maastricht, 
op gezag van de Rector Magnificus,  
Prof. Dr. L.L.G. Soete, 
volgens het besluit van het College van Decanen, 
in het openbaar te verdedigen 
op donderdag 18 april 2013 om 14.00 uur 
 
door 
 
 
Olga Antonia Hendrika Reneerkens 
Geboren op 29 juni 1982 te Maastricht 
Promotor: 
Prof. Dr. H.W.M. Steinbusch 
 
Copromotor: 
Dr. J. Prickaerts 
 
Beoordelingscommissie: 
Prof. Dr. F. Verhey (voorzitter) 
Dr. M. Meeter (Vrije Universiteit Amsterdam, Nederland) 
Prof. Dr. J.G. Ramaekers 
Dr. T. Steckler (Janssen Pharmaceutica, Johnson & Johnson, België) 
 
 
 
 
 
 
 
 
 
 
 
 
Contents 
 
 
 
 
CHAPTER 1 General introduction 7 
   
CHAPTER 2 Selective phosphodiesterase inhibitors: a promising target 
for cognition enhancement 
15 
   
CHAPTER 3 Phosphodiesterase type 5 (PDE5) inhibition improves 
object recognition memory: Indications for central and 
peripheral mechanisms 
57 
   
CHAPTER 4 Inhibition of phoshodiesterase type 2 or type 10 reverses 
object memory deficits induced by scopolamine or MK-801 
79 
   
CHAPTER 5 The PDE5 inhibitor vardenafil does not affect auditory 
sensory gating in rats and humans 
97 
   
CHAPTER 6 PDE2 and PDE10, but not PDE5, inhibition affect basic 
auditory  information processing in rats: a pilot study 
115 
   
CHAPTER 7 The effects of the PDE5 inhibitor vardenafil on cognitive 
performance in healthy adults: a behavioural-EEG study 
127 
   
CHAPTER 8 General discussion 147 
   
 Summary 157 
   
 Samenvatting 161 
   
 Dankwoord 165 
   
 Curriculum Vitae 171 
   
 Publications 175 
   
 Abbreviations 179 
  
 
   
 
CHAPTER 1 
 
General introduction  
 
 
CHAPTER 1 
9 
GENERAL INTRODUCTION 
 
 Cognitive impairment is one of the major complaints people suffering from 
neurodegenerative and psychiatric disorders such as Alzheimer’s disease or other types of 
dementia and schizophrenia have to face (Keller 2006; O'Carroll 2000). This impairment has 
a large, negative impact on the quality of the daily life of these patients and their family and 
friends. In the US, the prevalence of Alzheimer’s disease among people of 71 years or older 
is 9.7%, but the total of people suffering from dementia is as high as 13.9%, which leads us 
to a number of approximately 3.4 million individuals (Plassman et al. 2007). The Alzheimer’s 
association (2009) estimated the cost implications related to Alzheimer’s disease and other 
dementias at 148 billion dollars in the United States (US) alone and did not include 94 billion 
dollars of unpaid services of an estimated 10 million caregivers. In Europe, the total 
prevalence of dementia in the population aged 65 and older was 4.9 million in 2004 and the 
total costs were estimated at 55 billion euros (Andlin-Sobocki et al. 2005). There are several 
drugs which have shown to be effective in improving symptoms of mild-to-moderate 
Alzheimer’s disease, such as donepezil and rivastigmine, but for more severe Alzheimer’s 
and other types of dementia, the options are very limited or non-existent so far (Burns 
2003). The lifetime prevalence of schizophrenia is about 4 per 1,000 (McGrath et al. 2008; 
Saha et al. 2005) and the total societal costs in the United Kingdom (UK) in 2004/2005 were 
estimated 6.7 billion pounds (Mangalore and Knapp 2007) and 62.7 billion dollars in the US 
in 2002 (McEvoy 2007). In Europe the costs were estimated at 35 billion euros in 2004, 
however, it was noted by the authors that indirect costs were not included in this estimation, 
but were expected to make up a substantial amount of the total costs (Andlin-Sobocki et al. 
2005). Despite the increased attention for cognitive deficits in schizophrenia and the wide 
range of pharmalogical targets, the results are generally disappointing (Goff et al. 2011). 
 Because of the high social as well as economical costs of cognitive impairments, it is of 
utmost importance to continue the search for cognitive enhancers. Recently, 
phosphodiesterases (PDEs) gained increased attention as a target for cognition 
enhancement (for review see e.g. Blokland et al. 2006; Menniti et al. 2006). PDEs are 
enzymes that degrade the second messenger molecules cyclic adenosine monophosphate 
(cAMP) and/or cyclic guanosine monophosphate (cGMP). In total, there are eleven classes 
of PDEs identified based on several criteria including molecular properties, substrate 
specifity, and regulation (Bender and Beavo 2006). PDEs are expressed throughout the 
body and in the central nervous system (CNS) (Lakics et al. 2010). One fundamental 
distinction between the PDE classes is made on the basis of the difference in affinity for the 
two distinct cyclic nucleotides. A differentiation is possible between cAMP-specific enzymes 
(PDE4, 7, and 8), cGMP-specific enzymes (PDE5, 6, and 9), and the so-called dual-
substrate PDEs, which have affinity for both cyclic nucleotides (PDE1, 2, 3, 10, and 11) 
(Bender and Beavo 2006). 
 The second messengers cAMP and cGMP play an important role in intracellular 
signaling and in processes such as neuroplasticity including long-term potentiation (LTP) 
(Chien et al. 2003; Frey et al. 1993; Son et al. 1998) that form the neurophysiological origin 
of learning and memory (Bliss and Collingridge 1993). It has indeed been demonstrated that 
central administration of analogues of these second messengers can improve memory 
function in animals (Bernabeu et al. 1996; Matsumoto et al. 2006; Prickaerts et al. 2002). 
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Furthermore, it has been found that specific PDE inhibitors (PDE-Is) facilitate for example 
LTP (e.g. Boess et al. 2004) and increase neuronal excitability (e.g. Threlfell et al. 2009). 
Consequently, the inhibition of PDEs could be a tool to modulate second messenger 
signaling and subsequently influence pathways involved in learning and memory. 
 
AIM AND OUTLINE OF THIS THESIS 
 
 In this thesis we investigated whether PDE inhibition can improve cognition. This was 
done by using a translational approach in which we studied the effects of PDE inhibition on 
memory function and sensory gating in rats as well as on cognition and sensory gating in 
humans.  
 
 First, we provide an overview of the literature on the effects of PDE-Is on cognition 
across species (Chapter 2). In this chapter we also discuss the possible underlying 
mechanisms of these effects, such as blood flow, emotional arousal and LTP. 
 
 Next, we start the description of our behavioural studies with Chapter 3 in which we 
examined the effects of PDE5 inhibition on memory function in rats. We used two different 
phosphodiesterase type 5 inhibitors (PDE5-Is): vardenafil, which is assumed to cross the 
blood-brain barrier (BBB), and UK-343,664 as a negative control as it is assumed not to 
cross the BBB. We examined the efficacy of these compounds in three variants of the object 
recognition task (ORT): a 1 h delay interval in which memory was disrupted by either the 
muscarinic antagonist scopolamine or the N-methyl-D-aspartate (NMDA) receptor agonist 
MK-801, and a 24 h delay interval where memory degrades over time. In addition, we 
investigated whether vardenafil and UK-343,664 were indeed able to penetrate the BBB or 
not, respectively. 
 
 In Chapter 4, we aim to further characterize the effects of PDE inhibition on memory 
function by studying the effects of a phosphodiesterase type 2 inhibitor (PDE2-I) and a 
phosphodiesterase type 10 inhibitor (PDE10-I) on object memory in rats. We investigated 
the effects of the PDE2-I BAY 60-7750 and PDE10-I PQ-10 in a 1 h delay interval in the 
ORT. We again used the scopolamine- and MK-801-induced deficit models, which are both 
commonly used preclinical models to assess cognitive deficits related to Alzheimer’s 
disease and schizophrenia, respectively. We also determined the concentrations of BAY 60-
7550 and PQ-10 in blood plasma and brain tissue after treatment to gain insight into their 
brain penetrating properties. 
 
 Chapter 5 describes a translational study in which we investigated the effects of PDE5 
inhibition on sensory gating, which is an automatic process involved in information 
processing that can be compromised in various clinical disorders including schizophrenia 
and Alzheimer’s disease. Rats were included because of the extensive learning and 
memory enhancing effects that have already been reported in rodents while to our 
knowledge basic auditory information processing has not been studied yet after PDE5 
inhibition. Likewise, the effects on sensory gating in humans were studied to gain further 
insight into the effects of PDE5 inhibition on information processing in humans, but also to 
CHAPTER 1 
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see whether the drug effects found in rodents can be translated to the human situation and 
vice versa. 
 
 In Chapter 6 we studied the effects of the PDE2-I BAY 60-7550 and PDE10-I PQ-10 on 
sensory gating in rats. Since both phosphodiesterase type 2 (PDE2) and type 10 (PDE10) 
are possible targets for cognition enhancement, it is important to gain further insight into the 
nature of the effects of PDE inhibition. In our case, we want to know as in line with Chapter 
5 whether putative positive effects on cognition are limited to higher cognitive processes or 
whether lower cognitive processes such as information processes are affected as well. 
 
 In contrast to the extensive report of the positive effects of PDE5 inhibition on cognition 
in animals, relatively little is known about the effects in humans. Therefore, in our final study 
presented in Chapter 7, we examined the effects of vardenafil on cognition, in particular 
memory and executive function, and its electrophysiological correlates in healthy human 
volunteers. Cognitive performances were assessed while simultaneously recording brain 
activity. The results will provide further information on the potential of vardenafil as cognitive 
enhancer and will increase our knowledge on the role of PDE5 in human cognition in 
general. 
 
 Lastly, in Chapter 8 we summarize and discuss our experimental findings. In addition, 
we address several recommendations for future research.  
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ABSTRACT  
 
 One of the major complaints most people face during aging, is an impairment in 
cognitive functioning. This has a negative impact on the quality of daily life and is even more 
prominent in patients suffering from neurodegenerative and psychiatric disorders including 
Alzheimer’s disease, schizophrenia and depression. So far, the majority of cognition 
enhancers are generally targetting one particular neurotransmitter system. However, 
recently phosphodiesterases (PDEs) have gained increased attention as a potential new 
target for cognition enhancement. Inhibition of PDEs increases the intracellular availability of 
the second messengers cGMP and/or cAMP. The aim of this review was to provide an 
overview of the effects of phosphodiesterase inhibitors (PDE-Is) on cognition, the possible 
underlying mechanisms and the relationship to current theories about memory formation. 
Studies of the effects of inhibitors of different PDE families (2, 4, 5, 9, and 10) on cognition 
were reviewed. In addition, studies related to PDE-Is and blood flow, emotional arousal and 
long-term potentiation (LTP) were described. PDE-Is have a positive effect on several 
aspects of cognition, including information processing, attention, memory and executive 
functioning. At present, these data are likely to be explained in terms of an LTP related 
mechanism of action. PDE-Is are a promising target for cognition enhancement; the most 
suitable candidates appear to be PDE2-Is or PDE9-Is. The future for PDE-Is as cognition 
enhancers lies in the development of isoform specific PDE-Is that have limited aversive side 
effects.   
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 One of the problems many people come to face as they age, is a decline in cognitive 
functions, which has a negative impact on their daily activities and quality of life (Mattson et 
al. 2002). The loss of cognitive functioning is even more serious in patients suffering from 
pathological conditions such as Alzheimer’s disease or other types of dementia. Also in 
depressed and schizophrenic patients, prominent cognitive deficits are present (Blaney 
1986; Frith 1996). Since these deficits have a major impact on the quality life of these 
patients, it is of utmost importance to develop strategies or drugs that counteract cognitive 
decline. So far, several preventive strategies have been described which could ameliorate or 
slow down the cognitive decline resulting from brain aging. Research has focused on 
avoiding genetic and environmental factors that cause neuronal dysfunction and death or by 
enhancement of the ability of neurons to adapt to the aging process (Mattson et al. 2002). 
Examples of avoiding genetic factors are genetic counseling or germ line gene therapy and 
examples of avoiding environmental factors are dietary restrictions or behavioral 
modification. These strategies can induce successful ageing and can reduce the risk of 
cognitive decline and dementia (for a review see Mattson et al. 2002). Despite these 
strategies, there is a great need for drugs that counteract the processes involved in ageing 
and more specifically the decline of cognitive functions and memory. 
 For cognition enhancement or reversal of cognitive deficits different drug targets have 
been suggested based on neurotransmitter systems. Serotonergic, cholinergic and 
monoaminergic neurotransmitter systems have been shown to be involved in cognition. 
Furthermore, cognitive performance, including memory, can be improved by numerous 
biological factors such as neuromodulators, hormones, intracellular molecules, plant 
extracts, and nutritional ingredients, which enhance neurotransmission, blood flow, glucose 
metabolism or have free radical scavenging properties (Cahill et al. 1994; Davis and Squire 
1984; DeZazzo and Tully 1995; Izquierdo et al. 1998; McGaugh 1989; Messier 2004; Parrott 
et al. 2004). 
  
SECOND MESSENGERS CAMP AND CGMP 
 
 A relatively novel and promising field in cognition research focuses on the involvement 
of second messenger systems. Neurotransmitter receptors can be divided into two main 
groups according to the way in which receptor and effector function are coupled. One group 
consists of ionotropic (ion channel) receptors and the other consists of the GTP-binding 
protein (G-protein) coupled receptor. G-protein activation engages second messenger 
cascades (Shah and Catt 2004). Traditionally, the cyclic adenosine monophosphate (cAMP) 
second messenger system (Gs and Gi linked) and the phosphoinositol second messenger 
system (Gq linked) received the most attention. The second messenger cAMP is 
synthesised by adenylate cyclase (AC), which is stimulated or inhibited by Gs or Gi, 
respectively. The second messenger complex inositol-1,4,5,triphosphate/diacylglycerol 
(IP3/DAG) is formed out of the hydrolysis of phosphatidylinositol 4,5-biphosphate (PIP2) by 
phospholipase C (PLC) after activation by Gq. cAMP activates cAMP-dependent protein 
kinase (PKA), which phosphorylates cAMP response element binding protein (CREB). P-
CREB is an activated transcription factor, which initiates transcription of specific genes. 
DAG activates calcium–dependent protein kinase (PKC) in the presence of calcium (Ca2+), 
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which is mobilized by IP3. PKC has an effect on CREB via the MAP kinase pathway. Of 
note, Ca2+ can also bind to calmodulin. This so-called Ca2+/CaM complex activates 
Ca2+/CaM protein kinase (CaMK), which can activate calium-dependent protein kinase 
(PKC) as well, but also PKA. On the other hand, PKA can also activate the MAP kinase 
pathway. Thus, interplay exists between the cAMP second messenger system and the 
phosphoinositol second messenger system. Recently, the cyclic guanosine monophosphate 
(cGMP) second messenger system receives more and more attention. cGMP is produced 
by guanylate cyclase (GC) which is stimulated by nitric oxide (NO) (Murad et al. 1978). 
cGMP activates cGMP-dependent protein kinase (PKG), which in turn phosphorylates 
certain proteins which influence the synthesis and/or release of other neurotransmitters, and 
thus signal transduction (Schmidt et al. 1993).  
 Cyclic nucleotide phosphodiesterases (PDEs) are enzymes which play an important 
role in the above mentioned intracellular signal transduction pathways. This is because 
these enzymes hydrolyze the second messengers cAMP and cGMP by breaking their 
phosphodiester bond with the corresponding monophosphate (Bender and Beavo 2006). 
There are eleven families of PDEs (PDE1-PDE11) and most of these families have more 
than one gene product (e.g. PDE4A, PDE4B, PDE4C, PDE4D). In addition, each gene 
product may have multiple splice variants (e.g. PDE4D1-PDE4D9). In total there are more 
than 100 specific human PDEs (Bender and Beavo 2006). 
 
LOCALIZATION OF PDES 
 
 PDE1 is predominantly localized in the brain, heart, smooth muscles and lungs (Dent et 
al. 1998; Sonnenburg et al. 1998; Yan et al. 1994). In addition, PDE2 can be found in the 
brain, heart, adrenal cortex and platelets (Ito et al. 1996; Martins et al. 1982; Van Staveren 
et al. 2003). Furthermore, the localization of PDE3 includes the brain, heart, smooth 
muscles, kidneys and platelets (Reinhardt et al. 1995; Shakur et al. 2001). PDE4 is 
expressed in a wide variety of tissues, e.g. brain, lungs and testes (Perez-Torres et al. 2000; 
Reyes-Irisarri et al. 2008; Richter et al. 2005; Salanova et al. 1999). PDE5 has been 
detected in the brain, lungs, smooth and skeletal muscles, kidneys and platelets (Giordano 
et al. 2001; Hotston et al. 2007; Kotera et al. 2000; Yanaka et al. 1998). In contrast, PDE6 
has been found in the pineal gland and the rod and cone cells of the photoreceptor layer of 
the retina (Holthues and Vollrath 2004; Morin et al. 2001; Stearns et al. 2007). PDE7 was 
identified in the brain, heart, liver, skeletal muscles, kidneys, testes and pancreas (Hetman 
et al. 2000; Miro et al. 2001), while the localization of PDE8 includes the brain, liver, 
kidneys, colon, testes, ovary, spleen and thyroid (Fisher et al. 1998a; Gamanuma et al. 
2003; Hayashi et al. 1998; Hayashi et al. 2002; Kobayashi et al. 2003; Soderling et al. 1998; 
Wang et al. 2001). Also, PDE9 is located in the brain, kidneys, spleen, prostate and various 
gastrointestinal tissues (Andreeva et al. 2001; Fisher et al. 1998b; Rentero et al. 2003; 
Soderling et al. 1998; van Staveren and Markerink-van Ittersum 2005; Van Staveren et al. 
2003; Wang et al. 2003). The localization of PDE10 comprises the brain, heart, muscles, 
testes and thyroid (Fujishige et al. 1999; Loughney et al. 1999; Soderling et al. 1999). And 
finally, it has been shown that PDE11 is primary located in the brain (pituitary), liver, skeletal 
muscles, kidneys, testes, prostate and thyroid (Fawcett et al. 2000). 
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Table 1 Localization of the different PDE isoforms in the adult brain of rodents and humans. Note that this 
table does not provide information with respect to the level of expression of the different isoforms in the brain. 
In addition, expression can implicate mRNA levels or protein levels dependent on the study referred to 
Isoform Localization in Brain Species Reference 
PDE1A Hippocampus, cortex, olfactory bulb, 
striatum, thalamus, cerebellum 
Human, rat, mouse (Billingsley et al. 1990; 
Cho et al. 2000; Lal et al. 
1999; Yan et al. 1994) 
PDE1B Hippocampus, cortex, olfactory bulb, striatum Mouse, rat (Cho et al. 2000; Polli 
and Kincaid 1994; Reed 
et al. 1998) 
PDE1C Hippocampus, cortex, amygdala, cerebellum Mouse (Yan et al. 1996) 
    
PDE2A Hippocampus, cortex, striatum, amygdala, 
hypothalamus, midbrain 
Human, rat, mouse (Bolger et al. 1994; 
Repaske et al. 1993; 
Reyes-Irisarri et al. 
2007; van Staveren et al. 
2004; Van Staveren et 
al. 2003) 
PDE3 Throughout brain Rat (Bolger et al. 1994) 
PDE4A Hippocampus, cortex, olfactory bulb, 
striatum, thalamus, hypothalamus, amygdala, 
midbrain, cerebellum 
Human, rat, mouse (Braun et al. 2007; 
Cherry and Davis 1999; 
Cho et al. 2000; D'Sa et 
al. 2005; Fujita et al. 
2007) 
PDE4B Hippocampus, cortex, striatum, 
hypothalamus, midbrain, cerebellum 
Human, rat, mouse (Braun et al. 2007; 
Cherry and Davis 1999; 
Cho et al. 2000; Fujita et 
al. 2007) 
PDE4D Hippocampus, cortex, striatum, 
hypothalamus, midbrain, cerebellum 
Human, rat, mouse (Cherry and Davis 1999; 
Cho et al. 2000; Fujita et 
al. 2007; McLachlan et 
al. 2007; Richter et al. 
2005) 
PDE5A Hippocampus, cortex, cerebellum Human, rat, mouse (Reyes-Irisarri et al. 
2007; van Staveren et al. 
2004; Van Staveren et 
al. 2003) 
PDE7A Hippocampus, cortex, olfactory bulb, striatum Human, rat (Miro et al. 2001; Perez-
Torres et al. 2003) 
PDE7B Hippocampus, cortex, striatum, midbrain Human, rat (Perez-Torres et al. 
2003; Sasaki et al. 2002) 
PDE8B Hippocampus, cortex, olfactory bulb, 
striatum, midbrain 
Human, rat (Kobayashi et al. 2003; 
Perez-Torres et al. 2003) 
PDE9A Hippocampus, cortex, olfactory bulb, 
striatum, thalamus, hypothalamus, amygdala, 
midbrain, cerebellum 
Human, rat, mouse (Reyes-Irisarri et al. 
2007; van Staveren et al. 
2004; Van Staveren et 
al. 2003) 
PDE10 Hippocampus, cortex, striatum, midbrain, 
cerebellum 
Rat (Seeger et al. 2003) 
 
 The localizations of the different PDE isoforms differ between specific brain areas as is 
illustrated in detail in Table 1. Since PDEs are involved in the regulation of second 
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messenger signaling in numerous important body and brain structures, specific inhibitors of 
the PDE families have been generated. PDE inhibitors (PDE-Is) increase the intracellular 
amount of cAMP and/or cGMP by inhibiting the enzymatic degradation of these second 
messengers, dependent on the substrate specificity of the corresponding PDE (see also 
Table 2). Several selective PDE-Is and the substrate, i.e. cAMP and/or cGMP, of their target 
PDEs are classified in Table 2. 
 
Table 2 Overview of PDEs. The properties and substrate specificity are depicted (Bender and Beavo 2006). In 
addition, commonly used selective PDE inhibitors are mentioned. PDE: phosphodiesterase; cAMP: cyclic 
adenosine monophosphate; cGMP: cyclic guanosine monophosphate 
Type Number of 
Genes 
Property Substrate Selective Inhibitors 
PDE1 3 Ca2+ -CaM 
stimulated 
cAMP/cGMP IBMX, calimidazolium, 
phenethiazines, vinpocetine, 
SCH51866 
PDE2 
 
1 cGMP stimulated cAMP/cGMP EHNA, BAY 60-7550, aptosyn 
PDE3 
 
2 cGMP inhibited cAMP Cilostamide, milrinone, SK&F 
95654 
PDE4 
 
4 cAMP specific cAMP Rolipram, rofluminast, Ariflo,  
HT0712, Ibudilast, Mesembrine 
PDE5 
 
1 cGMP specific cGMP Zaprinast, sildenafil, vardenafil, 
tadelafil, SK&F 96231, udenafil, 
avanafil, DA-8159 
PDE6 
 
4 Photoreceptor cGMP (Sildenafil) 
PDE7 
 
2 cAMP high affinity cAMP BRL 50481 
PDE8 
 
2 cAMP high affinity cAMP ? 
PDE9 
 
1 cGMP high affinity cGMP SCH 81566, BAY 73-6691 
PDE10 
 
1 cAMP-inhibited cGMP Papaverine, TP-10, PQ-10 
PDE11 1 Dual substrate cAMP/cGMP (Tadelafil) 
 
 By far, not all classes of PDEs have selective inhibitors. In addition, these inhibitors 
might have poor penetration properties concerning the blood-brain barrier. In the literature 
only five PDE-Is have been used in behavioral cognition studies, namely PDE 2, 4, 5, 9 and 
10 inhibitors, as will become evident in this review. These inhibitors are widely available, can 
be administered peripherally and show central effects. The existing literature on PDE-Is and 
cognition is rapidly emerging and pro-cognitive effects of PDE-Is have been described in 
fish, rodents, monkeys and man (e.g. Best et al. 2008; Rutten et al. 2008a; Rutten et al. 
2007b; Schultheiss et al. 2001). Studies were conducted to asses the effects of PDE-Is on 
intact cognition as well as in cognitive deficit models. In addition, knockout-models have 
been developed to study the role of PDEs in cognition processes. This review provides a 
comprehensive overview of the currently available literature on the effects of selective PDE-
Is on cognition in pre-clinical models. Furthermore, possible implications for human studies 
are discussed. Finally the underlying mechanisms of action for the pro-cognitive effects of 
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PDE-Is are discussed and a concomitantly novel theory describing the relationship between 
different stages of memory consolidation and different types of long-term potentiation (LTP) 
is proposed.  
 
EFFECTS OF SELECTIVE PDE-IS ON COGNITION 
 
PDE2 
 
Table 3 Overview of effects of PDE2-Is on cognition. T1: trial 1; T2: trial 2; po: per os; ip: intraperitoneal 
Task 
(cognitive 
process, area 
involved) 
Model 
(species) 
Treatment Results Reference 
Object 
recognition task  
(object memory, 
hippocampus 
and rhinal 
cortex) 
Unimpaired  
(rat) 
BAY 60-7550 
 (3mg/kg, po) 
immediately after, 1h, 
3h or 6h after first trial. 
(24h interval T1-T2) 
BAY 60-7550 (3 
mg/kg, immediately 
after T1 or 3h after 
T1) improved memory 
consolidation 
(Rutten et al. 
2007b) 
 Unimpaired  
(rat) 
BAY 60-7550 
 (0.3, 1 or 3 mg/kg, 
po) immediately after 
first trial. (24h interval 
T1-T2) 
BAY 60-7550 (1 or 3 
mg/kg, immediately 
after T1) improved 
memory consolidation 
(Boess et al. 
2004) 
 Impaired by age, 
3, 12 and 24 
months old  
(rat) 
BAY 60-7550 (0.3 
mg/kg, sc) 1h before 
first trial or 
immediately after first 
trial. (2h interval T1-
T2) 
BAY 60-7550 1h 
before T1 improved 
acquisition in all age 
groups. In addition, it 
improved 
consolidation in 
animals of 3 and 12 
months when given 
immediately after T1. 
(Domek-
Lopacinska and 
Strosznajder 
2008) 
 Unimpaired 
(mouse) 
BAY 60-7550 
 (0.3, 1 or 3 mg/kg, 
po) immediately after 
first trial. (24h interval 
T1-T2) 
BAY 60-7550 (0.3 or 
1 mg/kg, immediately 
after T1) improved 
memory consolidation 
(Boess et al. 
2004) 
Social 
recognition 
(social memory, 
hippocampus 
and amygdale) 
Unimpaired  
(rat) 
BAY 60-7550 
 (0.3, 0.6, 1, 2, 3 or 6 
mg/kg, po) 
immediately after first 
trial. (24h interval T1-
T2) 
BAY 60-7550 (1, 2, 3 
or 6 mg/kg, 
immediately after T1) 
improved memory 
consolidation 
(Boess et al. 
2004) 
T-maze  
(working 
memory, 
hippocampus) 
Impaired by MK-
801, 0.125 mg/kg, 
ip, 30 min before 
test session 
(mouse) 
BAY 60-7550 
 (0.3, 1 or 3 mg/kg, 
po) 30 min before test 
session.  
BAY 60-7550 (3 
mg/kg) reversed MK-
801 induced deficit 
(Boess et al. 
2004) 
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 So far, only a couple studies have been published that investigated the effects of PDE2 
inhibition in behavioral models. To our knowledge, BAY 60-7550 is the only selective PDE2-I 
which has been tested in animal models of cognition (Boess et al. 2004; Domek-Lopacinska 
and Strosznajder 2008; Rutten et al. 2007b). It has been shown that BAY 60-7550 improved 
memory acquisition and consolidation in the object recognition task in both rats and mice, 
and consolidation in the social recognition task in rats (Boess et al. 2004; Domek-
Lopacinska and Strosznajder 2008; Rutten et al. 2007b). In addition, this PDE2-I improved 
acquisition and consolidation in the object recognition task in age-impaired rats (Domek-
Lopacinska and Strosznajder 2008).  
 Furthermore, BAY 60-7550 reversed the MK-801 induced working memory deficit in the 
T-maze in mice (Boess et al. 2004). A more detailed overview of these studies is provided in 
Table 3. 
 
PDE4 
 
 The next section provides a general summary of the available literature on PDE4-Is and 
cognition. A more detailed overview is provided in Table 4. 
 It has been shown in several studies that acute as well as subchronic administration of 
the PDE4-I rolipram improved memory consolidation in unimpaired rats in the object 
recognition task (Rutten et al. 2007a; Rutten et al. 2007b; Rutten et al. 2008c). In addition, 
memory deficits caused by scopolamine or acute tryptophan depletion were reversed by 
rolipram in this task (Rutten et al. 2007a; Rutten et al. 2006). Several spatial memory tasks 
(e.g. water escape task and radial arm maze) showed that PDE4-Is did not only improve 
spatial memory in unimpaired rats and mice (Bach et al. 1999; Huang et al. 2007), but also 
in rats of which spatial memory was impaired by age or microsphere embolism-induced 
cerebral ischemia (Nagakura et al. 2002). An impairment of spatial reference memory 
caused by scopolamine, MK-801 or MEK (MAPK/ERK kinase) inhibition was also reversed 
by various PDE4-Is (Egawa et al. 1997; Zhang et al. 2000; Zhang et al. 2005; Zhang and 
O'Donnell 2000; Zhang et al. 2004).  
 In addition, various studies investigated the effects of PDE4-Is on passive avoidance 
learning and PDE4-Is reversed impairments caused by scopolamine, MK-801, anisomycin, 
and MEK inhibition in this task (Egawa et al. 1997; Ghelardini et al. 2002; Imanishi et al. 
1997; Randt et al. 1982; Zhang et al. 2005; Zhang and O'Donnell 2000; Zhang et al. 2004). 
Furthermore, it was shown that acute as well as chronic treatment of rolipram improved the 
performance of unimpaired rats and mice in contextual fear conditioning (Barad et al. 1998; 
Comery et al. 2005; Monti et al. 2006). 
 The effects of PDE4-Is on working memory in rats have been studied in various deficit 
models. It was shown that working memory deficits caused by scopolamine, MK-801, 
cerebral ischemia or electro convulsive shocks (ECS) were reversed by the administration of 
PDE4-Is in the radial arm maze and the 3-panel runway task (Egawa et al. 1997; Imanishi et 
al. 1997; Zhang et al. 2000; Zhang et al. 2005; Zhang et al. 2004). Of note, the effects of 
rolipram on spatial working memory are twofold; on one hand rolipram tended to improve 
working memory in young rhesus monkeys in a delayed responding task (Ramos et al. 
2003). However, on the other hand rolipram had a negative effect on working memory in 
aged monkeys in this task (Ramos et al. 2003; Ramos et al. 2006). 
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 The effects of rolipram on information processing have been studied in several 
behavioral setups in the prepulse inhibition and startle response task. Rolipram did not only 
facilitate information processing in unimpaired mice and zebrafish, but also reversed deficits 
caused by D-amphetamine in mice (Best et al. 2008; Kanes et al. 2007). In contrast, the 
PDE4-I RO-20-1724 did not reverse prepulse inhibition deficit caused by D-amphetamine 
(Halene and Siegel 2008). In another model of information processing, sensory gating, this 
PDE-I increased the amplitudes of P20 and N40 in the CA3 area during the first stimulus, 
and reversed the N40 deficit in the first click caused by D-amphetamine (Halene and Siegel 
2008). Additionally, executive functioning was improved in an object retrieval task in 
cynomolgus macaques after administration of rolipram (Rutten et al. 2008a). In this task 
monkeys try retrieve a food reward from a transparent box with one open side that 
alternates between trials. This is a prefrontal cortical mediated task likely to capture 
attention and response inhibition, and rolipram treatment significantly dose dependently 
enhanced performance, as measured by an increased percentage correct first reaches. 
 Besides deficit models based on pharmacological or surgical interventions, the use of 
transgenic animals, i.e. isoform specific knock-out models of PDE4B or PDE4D, have been 
recently introduced to study the role of PDE4 in the central nervous system (CNS). It was 
shown that PDE4B knock-out (KO) in mice had no effect on spatial memory performance in 
the water escape task and the passive avoidance task (Siuciak et al. 2008a). Furthermore, 
these mice showed an impairment in information processing in the prepulse inhibition task 
(Siuciak et al. 2008a), although they performed similar to wild-type animals on conditioned 
avoidance responding (Siuciak et al. 2007). A recent study showed more controversial data 
demonstrating enhanced LTP but impaired fear conditioning in PDE4D knock-out mice 
(Rutten et al. 2008b). 
 In addition, a variety of transgenic mice models was used in combination with the 
administration of PDE4-Is. It has been shown that acute as well as chronic treatment of 
PDE4-Is improved long-term memory functioning in a Rubenstein-Taybi syndrome and  two 
Alzheimer’s disease KO mouse models for cognitive impairment in the fear conditioning and 
object recognition task (Bourtchouladze et al. 2003; Comery et al. 2005; Gong et al. 2004). 
Also, the PDE4-I rolipram improved working memory and spatial memory in a transgenic 
model of Alzheimer’s disease, i.e. PS1/PDAPP KO mice in the radial arm water maze 
(Costa et al. 2007; Gong et al. 2004).  
 To our knowledge, no studies have been published in which the effects of PDE4-Is on 
cognition in humans are described. However, the PDE4-I MK 0952 is now entering phase 2 
clinical trials for cognition enhancement (Merck & Co. 2006). 
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Table 4 Overview of effects of PDE4-Is on cognition. KO: knock-out; im: intramuscular; ip: intraperitoneal; po: 
per os; sc: subcutaneous; MEK: MAPK/ERK kinase; T1: trial 1; T2: trial 2; ECS: electro convulsive shocks; 
ATD: acute tryptophan depletion; ORT: object recognition task 
Task 
(cognitive process, 
area involved) 
Model 
(species) 
Treatment Results 
 
Reference 
Water escape task 
(spatial memory, 
hippocampus) 
Impaired by 
microsphere 
embolism-induced 
cerebral ischemia 
(rat) 
Rolipram (3 
mg/kg, ip) 10 
days, after 
embolism 
 Rolipram attenuates 
acquisition deficit 
measured at days 7-9  
(Nagakura et al. 
2002) 
 Impaired by 
PDE4B KO 
(mouse) 
- No effect (Siuciak et al. 
2008a) 
Delayed matching 
to position 
watermaze (spatial 
memory, 
hippocampus) 
Unimpaired  
(rat) 
L-454,560 (0, 0.1, 
0.3 or 1 mg/kg, 
po) 30 min before 
testing 
L-454,560 (0.3 and 1 
mg/kg) improved 
performance 
(Huang et al. 
2007) 
Radial arm water 
maze 
(spatial memory, 
hippocampus) 
Impaired by APP-
PS1 Alzheimer 
KO  
(mouse) 
Rolipram (0.03 
mg/kg, sc) for 3 
weeks 
Improvement when 
tested at 2 months 
after 3-week treatment 
(Gong et al. 
2004) 
 Impaired by 
PS1/PDAPP KO 
(mouse) 
Rolipram (0.03 
mg/kg, s.c.) once 
a day for 2 weeks 
before testing 
Rolipram improved 
working memory 
(Costa et al. 
2007) 
Barnes circular 
maze 
(spatial memory, 
hippocampus) 
Impaired by age, 
18 months old 
(mouse) 
Rolipram (0.016 
mg/kg, ip) 40 min 
before training 
More mice acquire the 
task and number of 
errors is reduced 
(Bach et al. 
1999) 
Radial arm maze 
(working & 
reference memory, 
hippocampus) 
Impaired by 
scopolamine 
0.5/1.0mg/kg, ip,  
30 min before test 
(rat) 
Rolipram (0.01 – 
1 mg/kg, ip) 45 
min before test 
MED: 0.1 (working 
memory) and >0.1 
mg/kg (reference 
memory) 
(Zhang and 
O'Donnell 2000) 
 Impaired by 
scopolamine, 0.5 
mg/kg, ip, 30 min 
before test 
(rat) 
(±)-rolipram 0.01 
– 1 mg/kg, po 
 (-)-rolipram 
0.005-1mg/kg, po 
 (+)-rolipram 0.1-
50 mg/kg, po 
MED (working 
memory): 
(±)-rolipram 0.02-0.2 
mg/kg 
(-)-rolipram 0.01-0.02 
and 0.2/0.5 mg/kg (bi 
phasic) 
(+)-rolipram 20/50 
mg/kg 
(Egawa et al. 
1997) 
 Impaired by 
glutamate MK-
801, 0.l mg/kg, ip, 
60 min before test 
(rat) 
Rolipram (0.01 – 
0.1 mg/kg, ip) 30 
min before test 
MED: 0.05 (working 
memory) and 0.1 
mg/kg (reference 
memory) 
(Zhang et al. 
2000) 
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Task 
(cognitive process, 
area involved) 
Model 
(species) 
Treatment Results 
 
Reference 
 Impaired by MK-
801, 0.1 mg/kg, ip, 
60 min before 
testing  
(rat) 
Rolipram (0.1 
mg/kg, ip), MEM 
1018 or MEM 
1091 (0.1 – 2.5 
mg/kg, ip) 45 min 
before test 
MED: 0.1 mg/kg 
rolipram working 
memory,  
MED: 2.5 mg/kg MEM 
1018 working and 
reference memory 
MED:2.5 mg/kg MEM 
1091 on reference 
memory.  
(Zhang et al. 
2005) 
 Impaired by MEK 
inhibitor UO126, 
8ug/rat into 
hippocampus, 
given twice: 60 
and 30 min before 
test  
(rat) 
Rolipram (0.05, 
0.1, mg/kg, ip) 30 
min before test 
MED: 0.1 mg/kg 
(reference memory) 
(Zhang et al. 
2004) 
Passive avoidance 
learning 
(learning, 
hippocampus and 
amygdala) 
Impaired by 
1. Protein 
synthesis inhibitor 
anisomycin, 150 
mg/kg, sc, 30 min 
before training 
2. Low baseline 
(mouse) 
Rolipram (3 or 10 
mg/kg, ip, 
immediately after 
training  or 3 
hours after 
training  
MED 10 mg/kg, given 
immediately after 
training (1 + 2) 
 
 
(Randt et al. 
1982) 
 Impaired by 
scopolamine, 1 
mg/kg, ip, 30 min 
before acquisition 
(mouse) 
Rolipram (1-30 
mg/kg, ip) 30 min 
before acquisition 
MED: 10 mg/kg (Imanishi et al. 
1997) 
 Impaired by 
scopolamine, 1.5 
mg/kg, ip, 
immediately after 
training 
(mouse) 
Rolipram (10 or 
30 mg/kg, po) 30 
min before 
training 
MED: 30 mg/kg (Ghelardini et al. 
2002) 
 Impaired by 
scopolamine, 3 
mg/kg, ip, 30 min 
before retention 
test  
(rat) 
Given 60 min 
before retention 
test. 
(±)-rolipram 0.01 
– 0.1 mg/kg, po 
 (-)-rolipram 
0.005-0.02 mg/kg, 
po 
 (+)-rolipram 0.3-
10 mg/kg, po 
MED: 
(±)-rolipram 0.02-0.1 
mg/kg 
(-)-rolipram 0.01-0.02 
mg/kg 
(+)-rolipram 2 mg/kg; 
no effect at 10 mg/kg 
(Egawa et al. 
1997) 
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Task 
(cognitive process, 
area involved) 
Model 
(species) 
Treatment Results 
 
Reference 
 Impaired by 
glutamate 
antagonist MK-
801 0.l mg/kg, ip, 
60 min before test 
(rat) 
Rolipram (0.1 
mg/kg, ip) 30 min 
before test 
MED: ≤ 0.1 mg/kg (Zhang et al. 
2000) 
 Impaired by MK-
801, 0.1 mg/kg, ip, 
60 min before 
testing (rat) 
Rolipram 
(0.1mg/kg, ip), 
MEM 1018 or 
MEM 1091 (0.1 – 
2.5 mg/kg, ip) 45 
min before test 
MED: Rolipram 
0.1mg/kg, MEM1018 
0.1-2.5mg/kg and MEM 
1091 0.5-2.5 mg/kg on 
reversal latency 
(Zhang et al. 
2005) 
 Impaired by MEK 
inhibitor UO126, 
8ug/rat into 
hippocampus, 
given twice: 60 
and 30 min before 
test 
(rat) 
Rolipram (0.1, 
mg/kg, ip) 30 min 
before test or 30 
ug/rat into 
hippocampus, 20 
min before test 
Reversal retention 
deficit 48-h post 
training 
(Zhang et al. 
2004) 
 Impaired by 
PDE4B KO 
(mouse) 
- No effect (Siuciak et al. 
2008a) 
3-panel runway 
task 
(working memory, 
hippocampus and 
prefrontal cortex) 
Impaired by 
scopolamine, 0.56 
mg/kg, ip, 15 min 
before first trial 
(rat) 
Rolipram (0.032 
or 0.1 mg/kg, ip) 
30 min before first 
trial 
MED: 0.1 mg/kg for 
decrease errors 
(Imanishi et al. 
1997) 
 Impaired by 
cerebral ischemia 
by four-vessel 
occlusion 
(rat) 
Rolipram (0.032 
or 0.1 mg/kg, ip) 
30 min before first 
trial (immediately 
after reperfusion) 
MED: 0.1 mg/kg for 
decrease errors 
(Imanishi et al. 
1997) 
 Impaired by ECS 
immediately after 
training 
(rat) 
Rolipram (0.1 or 
0.32 mg/kg, ip) 
just before ECS 
MED: 0.32 mg/kg for 
decrease errors 
(Imanishi et al. 
1997) 
Inhibitory avoidance 
learning  
(learning, 
hippocampus and 
amygdala) 
 
Impaired by 
1. Protein 
synthesis inhibitor 
anisomycin, 150 
mg/kg, sc, 30 min 
before training 
2. Low baseline 
(mouse) 
Rolipram (3 or 10 
mg/kg, ip, 
immediately after 
training  or 3 
hours after 
training  
MED 10 mg/kg, given 
immediately after 
training (1 + 2) 
 
 
(Randt et al. 
1982) 
Contextual fear-
conditioning 
(learning, 
hippocampus and 
amygdala) 
Unimpaired  
(mouse) 
Rolipram (0.03 
mg/kg, sc) 30 min 
before training 
Improved retention 24 
h after training  
(Barad et al. 
1998) 
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Task 
(cognitive process, 
area involved) 
Model 
(species) 
Treatment Results 
 
Reference 
 Unimpaired 
(rat) 
Rolipram 0.5 
mg/kg per day for 
7 days chronic 
delivery by 
osmotic mini-
pumps 
Improved memory 
consolidation and 
slower extinction of 
conditioned fear 
(Monti et al. 
2006) 
 Impaired by 
TG2576 KO 
Alzheimer mice 
(mouse) 
Rolipram (0.1 
mg/kg, ip) 30 min 
prior to training 
Improvement in 
mutants and wild type 
(Comery et al. 
2005) 
 Impaired by APP-
PS KO Alzheimer 
mice 
(mouse) 
Rolipram 0.1 
uM/kg for 3 weeks 
Improvement when 
tested 2 months 
following 3-week 
treatment 
(Gong et al. 
2004) 
 Impaired by 
PDE4D KO 
(mouse) 
- Impairment long-term 
memory for context 
and cued fear 
(Rutten et al. 
2008b) 
Object recognition 
task (object 
memory, 
hippocampus and 
rhinal cortex) 
Unimpaired young 
(rat) 
Rolipram (0.01, 
0.03 or 0.1 mg/kg, 
ip) given: 
1. 30 min before 
training 
2. directly after 
training 
3. 3h after 
training. 
Rolipram (0.03 mg/kg 
3h after T1) improved 
memory consolidation 
in ORT 
(Rutten et al. 
2006) 
 Unimpaired young 
(rat) 
Rolipram (0.03 
mg/kg ip) given: 
1. directly after 
training 
2. 1h after training 
3. 3h after training 
4. 6h after training 
Rolipram (0.03 mg/kg 
3h after T1) improved 
memory consolidation 
in ORT 
(Rutten et al. 
2007b) 
 Impaired by 
scopolamine, 0.1 
mg/kg, ip, 30 min 
before training 
(rat) 
Rolipram (0.03, 
0.1 or 0.3 mg/kg, 
i.p.) 30 min before 
training. 
Rolipram (0.1 mg/kg) 
reversed the 
scopolamine induced 
short-term memory 
deficit 
(Rutten et al. 
2006) 
 Impaired by acute 
tryptophan 
depletion, 3h 
before training 
(rat) 
Rolipram (0.01, 
0.03 or 0.1 mg/kg, 
ip) 30 min before 
training 
Rolipram (0.1 mg/kg) 
reversed ATD induced 
short-term memory 
deficit 
(Rutten et al. 
2007a) 
SELECTIVE PDE-IS: A PROMISING TARGET FOR COGNITION ENHANCEMENT 
28 
Task 
(cognitive process, 
area involved) 
Model 
(species) 
Treatment Results 
 
Reference 
 Unimpaired (rat) Subchronic 
treatment of 
rolipram (0.5 
mg/kg, po) for 5 
days. Testing 
before, during 
(day 2-3) and 
after treatment 
(T1-T2 24h) 
Subchronic rolipram 
treatment improved 
object recognition 
memory. Timing of final 
dose did not affect 
performance 
(Rutten et al. 
2008c) 
 Impaired by 
heterozygous 
CBP mutation 
(mouse) 
Rolipram (0.1 
mg/kg, ip) or 
HT0712 (0.001 – 
0.5 mg/kg, ip) 20 
min before 
training 
 
MED: 0.1 mg/kg for 
both drugs. Improved 
object recognition at 24 
hours 
 
(Bourtchouladze 
et al. 2003) 
Delayed responding 
(spatial working 
memory, prefrontal 
cortex) 
Unimpaired young 
and aged-
impaired 
(rhesus monkey) 
Rolipram (0.01-
100 ug/kg, im) 1 
hour before 
testing 
At 0.1 ug/kg, trend for 
improvement in young 
subjects.  
Aged subjects impaired 
by 10 ug/kg. 
(Ramos et al. 
2003) 
 Impaired by age 
(rhesus monkey) 
Rolipram (0, 
0.001-0.05 μg/kg, 
im) 2h before 
testing and 
guanfacine (0, 
0.0001-0.01 
mg/kg, im (one 
animal 0.5 
mg/kg)) 
Rolipram alone no 
effect. Rolipram 
reversed beneficial 
effect of guanfacine on 
working memory 
(Ramos et al. 
2006) 
Object retrieval 
(execultive 
functioning and 
response inhibition, 
prefrontal cortex ) 
Unimpaired  
(cynomolgus 
macaque) 
Rolipram (0.003, 
0,01 or 0.03 
mg/kg, im) 30min 
before testing 
Rolipram (0.01, 0.33 
mg/kg) improved object 
retrieval performance. 
(Rutten et al. 
2008a) 
Prepulse inhibition 
(information 
processing, frontal 
cortex) 
Unimpaired 
(mouse) 
Rolipram (0.1, 
0.66, 1 or 10 
mg/kg, ip) 15 min 
before testing 
Rolipram (0.66, 1, 10 
mg/kg) increased PPI 
and decreased startle 
response 
(Kanes et al. 
2007) 
 Impaired by D-
amphetamine, 10 
mg/kg, ip, 15 min 
before testing 
(mouse) 
D-amphetamine 
(10 mg/kg, ip) and 
rolipram (0.66 
mg/kg, ip) 15 min 
before testing 
Rolipram attenuated 
the PPI deficit caused 
by D-amphetamine, but 
had no effect on startle 
response 
(Kanes et al. 
2007) 
 Impaired by 
PDE4B KO 
(mouse) 
- Increased startle 
response and 
decreased PPI 
(independent of startle 
response) 
(Siuciak et al. 
2008a) 
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Task 
(cognitive process, 
area involved) 
Model 
(species) 
Treatment Results 
 
Reference 
 Impaired by D-
amphetamine, 5 
mg/kg 
(mouse) 
RO-20-1724 
(0.25, 2.5 or 4 
mg/kg, sc) or 
rolipram ( mg/kg, 
sc), 5 min before 
testing 
RO-20-1724 did not 
reverse PPI deficit 
caused by D-
amphetamine 
(Halene and 
Siegel 2008) 
Startle response 
(non-associative 
learning) 
Unimpaired 
(zebrafish) 
Rolipram (3, 10 or 
30 μM) 
Rolipram (3 μM) 
enhanced  startle 
response 
(Best et al. 
2008) 
Acquisition of 
conditioned 
avoidance 
responding  
(learning, 
hippocampus)  
Impaired by 
PDE4B KO 
(mouse) 
- No effect (Siuciak et al. 
2007) 
Auditory event-
related potentials 
(information 
processing, frontal 
cortex) 
Unimpaired 
(mouse) 
RO-20-1724 (0.1, 
0.25, 0.5, 1, 2.5 
mg/kg, sc), 5 min 
before testing 
1st click: RO-20-1724 
increased amplitude of 
P20 (at a dose of 0.25, 
0.5, 1 mg/kg) and of 
N40 at a dose of (0.25, 
0.5, 2.5 mg/kg) in CA3 
area 
No effects on 2nd click 
(Halene and 
Siegel 2008) 
 Impaired by D-
amphetamine, 0.5 
mg/kg 
(mouse) 
RO-20-1724 (0.25 
mg/kg, sc), 5 min 
before testing 
1st click: P20 no effect. 
N40 RO-20-1734 
reversed deficit caused 
by D-amphetamine in 
CA3 area. 
No effects on 2nd click 
(Halene and 
Siegel 2008) 
This table is an adapted and updated version of the overview (Table 3) in Blokland et al. (2006) 
 
PDE5  
 
 Prickaerts et al. (1997) were the first to describe memory enhancing effects of PDE5 
inhibition, using the PDE5-I zaprinast. However, zaprinast is not selective for PDE5, as it 
also inhibits PDE1, 9, 10, and 11 (Bender and Beavo 2006). Recently, more highly selective 
PDE5 inhibitors have been developed mainly for the treatment of erection disorder, e.g 
sildenafil (Viagra), vardenafil (Levitra) and tadalafil (Cialis) (Setter et al. 2005). The next 
section will give a general summary of the available literature on PDE5-Is and cognition; a 
more detailed overview is provided in Table 5.  
 So far, several studies have shown positive effects of selective PDE5-Is on memory 
performance in the object recognition task in adult rats; zaprinast (Domek-Lopacinska and 
Strosznajder 2008; Prickaerts et al. 1997), sildenafil (Prickaerts et al. 2005; Prickaerts et al. 
2002b) and vardenafil (Prickaerts et al. 2002b; Rutten et al. 2007b) improved memory 
consolidation. In addition, Rutten et al. (2005) showed that sildenafil also improved memory 
consolidation in mice in this task. Previous work from our group showed that zaprinast 
reversed the object memory deficits induced by the NOS inhibitor 7-nitroindazole in rats in 
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the object recognition task (Prickaerts et al. 1997). However, zaprinast was unable to 
reverse memory deficits in aged rats in this task (Domek-Lopacinska and Strosznajder 
2008). 
 Several studies have shown spatial memory improvement in an adapted version of the 
elevated plus maze in mice (Patil et al. 2004a; Singh and Parle 2003) after treatment with a 
PDE5-I. Furthermore, sildenafil treatment ameliorated the deficits induced by diabetes or 
ECS in this task (Patil et al. 2004a; Patil et al. 2006). Previous studies showed no effects of 
PDE5-Is on spatial tasks in healthy rats, i.e. the water escape task or the Y maze (Prickaerts 
et al. 2004). However, since only one dose was tested in this study, further investigation will 
be needed. Finally, in hyperammonemia and portacaval shunt deficit models for liver failure, 
both sildenafil and zaprinast reversed spatial recognition deficits of rats in the Y maze 
(Erceg et al. 2006; Erceg et al. 2005a; Erceg et al. 2005b). Recent work adds to this since 
sildenafil reversed the effects the nitric oxide synthase (NOS) inhibitor L-NAME, in a 
complex maze learning paradigm (Devan et al. 2006; Devan et al. 2007).  
 Furthermore, various studies investigated the effects of PDE5-Is on active and passive 
avoidance learning in rats, mice and neonatal chicks. Although one study failed to show 
improvement in learning performance after sildenafil treatment in unimpaired and aged rats 
(Shafiei et al. 2006), others have shown improvements in unimpaired and aged mice and in 
neonatal chicks (Baratti and Boccia 1999; Campbell and Edwards 2006; Patil et al. 2004a). 
In contrast, Edwards et al. (2007) found that zaprinast could also have a negative effect on 
learning and memory when given at a high dose. Memory impairments in avoidance 
learning caused by scopolamine, diabetes or electro convulsive shocks in rats were 
reversed by sildenafil treatment (Devan et al. 2004; Patil et al. 2006). In addition, zaprinast 
as well as sildenafil reversed memory deficits caused by a model for diabetes in mice (Patil 
et al. 2004a). 
 Finally, a recent study showed that the PDE5-I sildenafil dose dependently improved 
performance in a prefrontal task, i.e. the object retrieval task (see above), in cynomolgus 
macaques (Rutten et al. 2008a). 
 Most research regarding the cognition enhancing effects of PDE5-Is so far has focused 
on animal preclinical models; there are only two papers in which the effects of the PDE5-I 
sildenafil on human cognition were investigated. Grass et al. (2001) have shown that 100 
mg sildenafil enhanced performance in a simple reaction time test when given 1 h before 
testing. However, no effects were found on short-term memory, divided attention and other 
psychomotor tasks (Grass et al. 2001). In addition, Schultheiss et al (2001) studied the 
effects of sildenafil (100 mg, 1 h before testing) on auditory attention and word recognition. 
Again, no cognition enhancing effects were found with regard to the behavioral measures 
 In both studies, short-term memory tasks were performed that are thought to measure 
memory performance processes comparable to the object recognition task in rats. However, 
the object recognition task in animals usually measures more aspects of memory, such as 
that for object and for location, even though only the object memory itself might have been 
measured. The human tasks, on the other hand, only assess memory for words or pictures, 
or location, but never the combination of these aspects. Possibly, the fact that spatial 
information was lacking in the human studies has caused this discrepancy in findings. 
 Sildenafil changed certain components of event-related potentials (ERPs) in the study 
of Schultheiss and collegues (2001). The Nd component, although it only showed a 
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marginally significant effect, was increased after treatment with sildenafil. This indicates 
improved focused attention. The P3 component, which measures controlled processes of 
target selection, was significantly enhanced after administration of sildenafil (Schultheiss et 
al. 2001). Again, this is evidence for improvements after treatment with sildenafil. Finally, a 
reduced negativity between 150-250 ms was found in the word recognition experiment after 
sildenafil treatment; this may also indicate an effect on information processing although the 
exact role of this component remains uncertain (Schultheiss et al. 2001).  
 Several possible explanations for not finding any cognition enhancing effects after 
PDE5-I treatment in humans in contrast to the results in animal studies exist. First, only one 
dose of sildenafil on one specific time point was tested in both studies. Investigating different 
doses, both higher and lower, at different administration time points might reveal possible 
cognition enhancing effects in humans. In addition, a ‘ceiling effect’ might have occurred in 
the cognitive tasks; this means that healthy subjects in these studies already perform at their 
maximal level, so their performance can not be further improved. A final explanation might 
be that the number of participants was not sufficient, since only 6 participants were tested by 
Grass et al. (2001), whereas Schultheiss and co-workers (2001) examined 10 healthy 
participants. 
 
Table 5 Overview of effects of PDE5-Is on cognition. icv: intracerebroventricular; ic: intracerebral; ip: 
intraperitoneal; LPS: lipopoly saccharine; NOS: nitric oxide synthase; ORT: object recognition task; po: per os; 
T1: trial 1; T2: trial 2; STZ: streptozotoon 
Task 
(cognitive process, 
area involved) 
Model 
(species) 
Treatment Results Reference 
Object recognition 
task  
(object memory, 
hippocampus and 
rhinal cortex) 
Unimpaired 
(rat) 
Sildenafil Citrate (1, 
3 or 10 mg/kg, po). 
30min before or 
immediately after 
first trial. (24h 
interval T1-T2) 
Sildenafil (3mg/kg 
T0  or 10mg/kg T1-
30min) improves 
memory 
consolidation  
(Prickaerts et 
al. 2005) 
 Unimpaired  
(rat) 
Zaprinast (3 or 
10mg/kg,ip) 
immediately after 
first trial. (4h interval 
T1-T2) 
Zaprinast (10mg/kg) 
improved memory 
consolidation. 
(Prickaerts et 
al. 1997) 
 Unimpaired  
(rat) 
Sildenafil (1, 3 or 
10mg/kg,po) 
immediately after 
first trial. (24h 
interval T1-T2) 
Sildenafil (3-10 
mg/kg) improved 
memory 
consolidation in 
ORT.  
(Prickaerts et 
al. 2002b) 
 Unimpaired  
(rat) 
Vardenafil (0.1, 0.3, 
1 or 3 mg/kg,po) 
immediately after 
first trial. (24h 
interval T1-T2) 
Vardenafil (0.3-3 
mg/kg) improved 
memory 
consolidation in 
ORT. 
(Prickaerts et 
al. 2002b) 
 Unimpaired  
(rat) 
Vardenafil (1mg/kg, 
po) immediately 
after, 1h, 3h or 6h 
after first trial. (24h 
interval T1-T2) 
Vardenafil (1 mg/kg 
immediately after 
T1) improved 
memory 
consolidation in ORT 
(Rutten et al. 
2007b) 
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Task 
(cognitive process, 
area involved) 
Model 
(species) 
Treatment Results Reference 
 Unimpaired (mouse) Sildenafil (0.3, 1 or 3 
mg/kg, po) 
immediately after 
first trial. (24h 
interval T1-T2) 
Sildenafil (1 mg/kg) 
improved memory 
consolidation in ORT 
(Rutten et al. 
2005)  
 Impaired by NOS 
inhibitor  
(rat) 
7-nitroindazole (10 
or 30mg/kg, ip) 
Zaprinast (3 or 
10mg/kg, ip) 
immediately after 
first trial. (1h interval 
T1-T2) 
Zaprinast (10 mg/kg) 
reversed the NOS-I 
(10mg/kg) deficit in 
ORT 
(Prickaerts et 
al. 1997) 
 Impaired by age, 3, 
12 and 24 months old  
(rat) 
Zaprinast (0.3 
mg/kg, sc) 1h before 
first trial or 
immediately after 
first trial. (2h interval 
T1-T2) 
Zaprinast 1h before 
T1 improved 
acquisition in 3 
month-old animals. 
In addition, it 
improved 
consolidation in 
animals of 3 months 
when given 
immediately after T1. 
(Domek-
Lopacinska 
and 
Strosznajder 
2008) 
Adapted version of 
elevated plus-
maze  
(spatial memory, 
hippocampus) 
 
Unimpaired  
(mouse) 
Sildenafil (2, 4 or 8 
mg/kg, ip) 30min 
before or 
immediately after 
first trial 
Sildenafil (8mg/kg) 
before T1 marginally 
increased spatial 
memory acquisition. 
Sildenafil (2, 4, 
8mg/kg) imm. after 
T1 increased spatial 
memory retention.  
(Singh and 
Parle 2003) 
 Unimpaired  
(mouse) 
Age impaired 
(mouse) 
Sildenafil (0.25, 0.5 
or 1mg/kg, ip) 
immediately after 
first trial  
Sildenafil improved 
spatial memory 
performance in 
young (0.5 and 
1.0mg/kg) and aged 
(0.25-1 mg/kg) 
animals. 
(Patil et al. 
2004a) 
 Unimpaired  
(mouse) 
Age impaired 
(mouse) 
Zaprinast (0.5, 1 or 
2mg/kg, ip) 
immediately after 
first trial 
Zaprinast improved 
spatial memory 
performance in 
young (1.0 and 
2.0mg/kg) and aged 
(0.5-2 mg/kg) 
animals. 
(Patil et al. 
2004a) 
 Impaired by diabetes-
STZ  
(rat) 
Streptozotocin (STZ) 
(60mg/kg, ip) 
Sildenafil (0.25, 0.5 
or 1 mg/kg, ip) 
immediately after 
training 
Sildenafil (all doses) 
reversed STZ spatial 
memory deficits. 
(Patil et al. 
2006) 
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Task 
(cognitive process, 
area involved) 
Model 
(species) 
Treatment Results Reference 
 Impaired by diabetes-
LPS  
(mouse) 
Lipopolysaccharine 
(LPS: 50ug, ip) and 
sildenafil (0.25, 0.5 
or 1 mg/kg, ip)  or 
zaprinast (0.5, 1 or 
2mg/kg, ip) 
immediately after 
training 
Sildenafil (0.5 and 1 
mg/kg) and 
Zaprinast (1 and 2 
mg/kg) reversed 
LPS spatial memory 
deficits.  
(Patil et al. 
2004a) 
 Impaired by Electro 
convulsive shock  
(rat) 
Shocks 
(0.2mA,0.2s/day for 
15 days) 
Sildenafil (0.5, 1 or 2 
mg/kg, ip) 
immediately after 
training 
Sildenafil (all doses) 
reversed  spatial 
memory deficits 
(Patil et al. 
2006) 
Y-maze 
(spatial memory, 
hippocampus and 
cerebellum) 
Unimpaired  
(rat) 
 
Vardenfil (3mg/kg, 
po) daily after last 
trial. 
No effects on spatial 
recognition 
(Prickaerts et 
al. 2004) 
 Impaired by 
Hyperammonemia 
(rat)  
Sildenafil (50mg/L) 
in drinking water two 
days before training. 
Sildenafil (in drink 
water) reversed 
spatial recognition 
deficits. 
(Erceg et al. 
2006) 
 Impaired by 
Hyperammonemia 
(rat) 
Ammonium acetate 
containing diet (28 
days before testing) 
Zaprinast (50uM, 
0.25 ul/h, 2 days 
before testing) in 
cerebral ventricle 
 
Zaprinast (through 
minipump) reversed 
spatial recognition 
deficits. 
(Erceg et al. 
2005a) 
 Impaired by 
Portacaval Shunts 
(rat) 
Portacaval shunt 
operation 28 days 
before test. 
Sildenafil (50mg/L) 
in drinking water two 
days before training. 
Sildenafil (in drink 
water) reversed 
spatial recognition 
deficits. 
(Erceg et al. 
2005b) 
Water escape task  
(spatial memory, 
(hippocampus) 
Unimpaired  
(rat) 
 
Zaprinast (10mg/kg, 
ip) daily after last 
trial. 
No effects on 
acquisition or 
retention of spatial 
memory 
(Prickaerts et 
al. 2004) 
Complex maze 
learning  
(learning, 
hippocampus) 
Impaired by NOS 
inhibitor  
(rat) 
L-NAME 
(60mg/kg,ip) 30min 
before training  
Sildenafil (1, 1.5, 3 
or 4.5 mg/kg, ip) 
15min before 
training 
Sildenafil (1.5mg/kg) 
attenuated the L-
NAME deficit in 
Maze learning. 
(Devan et al. 
2006) 
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Task 
(cognitive process, 
area involved) 
Model 
(species) 
Treatment Results Reference 
 Impaired by NOS 
inhibitor  
(rat) 
L-NAME (0, 45 
μg/kg, i.c.v.) 30min 
before training  
Sildenafil (0, 1.5 or 3 
mg/kg, ip) 15min 
before training 
Sildenafil (3 mg/kg) 
attenuated the L-
NAME deficit in 
Maze learning. 
(Devan et al. 
2007) 
Active avoidance 
learning  
(learning, 
hippocampus) 
Impaired by 
scopolamine, 0.75 
mg/kg, ip, 30 min 
before training 
(rat) 
Sildenafil (1.5, 3 or 
4.5mg/kg,ip) 15min 
before training. 
Sildenafil (3mg/kg) 
reversed the 
scopolamine deficit 
in active avoidance 
task. 
(Devan et al. 
2004) 
 Unimpaired 
(mouse) 
Sildenafil (1, 3, 10 or 
30 mg/kg, i.p.) 30 
min before training 
or immediately after 
training 
Sildenafil (3mg/kg) 
improved 
performance (both 
30min before and 
imm. after training) 
in active avoidance. 
(Baratti and 
Boccia 1999) 
Passive avoidance 
learning  
(learning, 
hippocampus) 
Unimpaired  
(rat) 
Sildenafil (1, 3, 10 or 
20 mg/kg, ip) 
immediately after 
training in young 
and old rats. 
Sildenafil has no 
effect on retention 
performance in 
passive avoidance. 
(Shafiei et al. 
2006) 
 Unimpaired 
(neonate chick) 
Zaprinast (0.1-
750μM/side, ic) 
immediately after 
training 
Zaprinast (>100uM) 
enhanced early 
consolidation.  
(Campbell 
and Edwards 
2006) 
 Unimpaired 
(young chick) 
Zaprinast (100 
μM/side, ic) 
immediately after 
training. Retention 
times between 10-
180 min. 
Zaprinast impaired 
performance (at a 
retention of 40, 60, 
90 and 120 min) 
(Edwards and 
Lindley 2007) 
 Unimpaired  
(mouse) 
Age impaired 
(mouse) 
Sildenafil (0.25, 0.5 
or 1mg/kg, ip) 
immediately after 
first trial 
Sildenafil improved 
consolidation in 
young (0.5 and 
1.0mg/kg) and aged 
(0.25-1 mg/kg) 
animals. 
(Patil et al. 
2004a) 
 Unimpaired  
(mouse) 
Age impaired 
(mouse) 
Zaprinast (0.5, 1 or 
2mg/kg,ip) 
immediately after 
first trial 
Zaprinast improved 
spatial memory 
performance in 
young (1.0 and 
2.0mg/kg) and aged 
(0.5-2 mg/kg) 
animals. 
(Patil et al. 
2004a) 
 Impaired by Diabetes  
(rat) 
STZ (60mg/kg,ip) 
Sildenafil (0.25, 0.5 
or 1 mg/kg, ip) 
immediately after 
training. 
Sildenafil (all doses) 
reversed STZ 
memory deficit 
caused by diabetes. 
(Patil et al. 
2006) 
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Task 
(cognitive process, 
area involved) 
Model 
(species) 
Treatment Results Reference 
 Impaired by Electro 
convulsive shock  
(rat) 
Shocks 
(0.2mA,0.2s/day for 
15 days) 
Sildenafil (0.5, 1, 2 
mg/kg, ip) 
immediately after 
training. 
Sildenafil (all doses) 
reversed memory 
deficit caused by 
ECS. 
(Patil et al. 
2006) 
 Impaired by diabetes-
LPS  
(mouse) 
Lipopolysaccharine 
(LPS: 50ug, ip) and 
sildenafil (0.25, 0.5 
or 1 mg/kg, ip)  or 
zaprinast (0.5, 1, 
2mg/kg,ip) 
immediately after 
training 
Sildenafil (0.5 and 1 
mg/kg) and 
Zaprinast (1 and 2 
mg/kg) reversed 
LPS induced 
memory deficits.  
(Patil et al. 
2004b) 
Object retrieval 
(execultive 
functioning and 
response 
inhibition, 
prefrontal cortex) 
Unimpaired 
(cynomolgus 
macaque) 
Sildenafil (0.3, 1 or 3 
mg/kg, im) 30 min 
before testing 
Sildenafil (1, 3 
mg/kg) improved 
object retrieval 
performance. 
(Rutten et al. 
2008a) 
7 different 
psychophysical 
tests 
(psychophysical 
performance, 
various brain 
areas) 
Unimpaired 
(humans) 
Sildenafil (100 mg, 
po) 1h before testing 
Sildenafil enhanced 
performance on the 
simple reaction time 
test; other tests no 
effect 
(Grass et al. 
2001) 
Auditory selective 
attention & ERPs 
(attention, 
prefrontal cortex) 
Unimpaired 
(humans) 
Sildenafil (100 mg, 
po) 1h before testing 
Sildenafil had no 
effect on the 
behavioral 
measurements of 
attention. However, 
an increase in the 
ERP components Nd 
and P3 indicates an 
improvement of 
attention. 
(Schultheiss 
et al. 2001) 
Verbal recognition 
memory & ERPs 
(memory & 
information 
processing, 
hippocampus & 
frontal cortex) 
Unimpaired 
(humans) 
Sildenafil (100 mg, 
po) 1h before testing 
Sildenafil had no 
effect on the 
behavioral 
measurements of 
memory. However, a 
reduction in 
negativity between 
150-250 ms might 
indicate an effect on 
information 
processing. 
(Schultheiss 
et al. 2001) 
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PDE9 
 
Table 6 Overview of effects of PDE9-I on cognition. po: per os; T1: trial 1; T2: trial 2; sc: subcutaneous 
Task 
(cognitive process, 
area involved) 
Model 
(species) 
Treatment Results Reference 
Object recognition 
task  
(object memory, 
hippocampus and 
rhinal cortex) 
Unimpaired 
(rat) 
BAY 73-6691 (0.1, 0.3, 1 
or 3 mg/kg, po) 30 min 
before T1 
(24h interval T1-T2) 
BAY 73-6691 (0.1, 
0.3 mg/kg) had an 
intermediate effect 
on memory 
consolidation 
(van der 
Staay et al. 
2008) 
Passive avoidance 
learning 
(learning, 
hippocampus) 
Impaired by 
scopolamine, 
0.03 mg/kg, sc, 
30 min before 
testing  
(rat) 
BAY 73-6691 (0.3, 1 or 3 
mg/kg, po) 60 minutes 
before testing 
BAY 73-6691 (1, 3 
mg/kg) attenuated 
the scopolamine 
induced retention 
deficit 
(van der 
Staay et al. 
2008) 
Social recognition 
(social memory, 
hippocampus and 
amygdala) 
Unimpaired 
(rat) 
BAY 73-6691 (0, 0.03, 0.3 
or 3 mg/kg, po) 60 min 
before the first trial (T1), 
immediately after T1 (24h 
interval T1-T2) 
BAY 73-6691 (0.3, 3 
mg/kg) 60 min 
before T1, or BAY 
73-6691 (0.03, 0.3, 3 
mg/kg) immediately 
after T1 and 60 min 
before T2 improved 
memory 
consolidation 
(van der 
Staay et al. 
2008) 
 Unimpaired 
(rat) 
BAY 73-6691 (0 or 1 
mg/kg, po) 60 min before 
the first trial (T1), with a 
familiar juvenile or BAY 
73-6691 (1 mg/kg, po) 60 
min before the first trial 
(T1), with a novel juvenile  
(24h interval T1-T2) 
BAY 73-6691 (1 
mg/kg) improved 
memory 
consolidation with a 
familiar as well as a 
novel juvenile 
(van der 
Staay et al. 
2008) 
 Unimpaired 
(mouse) 
BAY 73-6691 (0, 0.03, 0.3 
or 3 mg/kg, po) 30 min 
before the first trial (24h 
interval T1-T2) 
BAY 73-6691 (0.3, 3 
mg/kg) 30 min 
before T1 improved 
memory 
consolidation 
(van der 
Staay et al. 
2008) 
T-maze  
(working memory, 
hippocampus) 
Impaired by 
MK-801, 0.06 
mg/kg, sc, 30 
min before 
testing  
(mouse) 
BAY 73-6691 (0, 1, 3 or 
10 mg/kg, po) 60 min 
before testing  
BAY 73-6691 (10 
mg/kg) attenuated 
the MK-801 induced 
deficit in alternation 
rate 
(van der 
Staay et al. 
2008) 
 
 To our knowledge, only one paper has been published in which the effects of PDE9 
inhibition on cognition are described (van der Staay et al. 2008). In this paper the potent and 
selective PDE9-I BAY-73-6691 was used (Wunder et al. 2005). It was shown that this 
PDE9-I improved memory consolidation in unimpaired rats and mice in the object 
recognition and social recognition task (van der Staay et al. 2008). Furthermore, this PDE9-I 
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reversed the MK-801 or scopolamine induced memory deficit in T-maze and the passive 
avoidance task, respectively (van der Staay et al. 2008). More detailed information can be 
found in Table 6. 
 
PDE10 
 
 Only very recently, PDE10-Is have become a target for CNS research, especially 
concerning the cognitive deficits related to schizophrenia (Schmidt et al. 2008). In the next 
section, a summary of the available literature on PDE10-Is and cognition will be given; a 
more detailed overview can be found in Table 7. 
 Chronic treatment with the PDE10-I papaverine impaired spatial memory and reversal 
learning in unimpaired mice in the Morris water maze (Hebb et al. 2008). Administration of 
TP-10 did not have an effect on information processing in a prepulse inhibition task in 
unimpaired and MK-801 impaired mice (Schmidt et al. 2008). However, TP-10 reversed the 
auditory gating deficit caused by D-amphetamine in rats (Schmidt et al. 2008).  Papaverine 
improved attention in the attention shifting task in rats that were impaired by subchronic 
phenylcyclohexylpiperidine (PCP) treatment, a model of schizophrenia, whereas no effect 
was found in unimpaired rats (Rodefer et al. 2005). 
 Several studies also used KO models to study the role of PDE10 in cognition. It was 
shown that PDE10A knock-out in a DBA1LacJ background had no effect on learning and 
memory in the passive avoidance and water escape task in mice (Siuciak et al. 2006; 
Siuciak et al. 2008b). In addition, these mice showed the same conditioned avoidance 
response as wild-type mice; however, these KO mice required more training to reach 
performance of wild-type animals (Siuciak et al. 2006; Siuciak et al. 2008b). On the other 
hand, PDE10A KO mice with a C57BL/6N background were unable to reach the 
performance of the wild-tape mice in this task (Siuciak et al. 2008b).  
 The data discussed in the previous paragraphs showed that PDE10-Is can improve 
cognition in impaired animals, but can also induce a cognitive impairment in healthy 
animals. There are several explanations that might account for these contradictory findings. 
First, the cognitive impairment in healthy animals caused by papaverine was the result of a 
subchronic treatment, which was not found after acute treatment in impaired animals. 
Secondly, different aspects of cognition were addressed in these studies. In the healthy 
animals, learning and memory were studied, whereas in the impaired animals information 
processing and attention were investigated. Thirdly, improving cognition of a healthy 
individual is not the same as restoring impaired cognition; the underlying processes, and 
thus the effect of a compound, may differ.  
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Table 7 Overview of effects of PDE10-Is on cognition. CAR: conditioned avoidance responding; ip: 
intraperitoneal; iv: intravenous; KO: knock-out; PCP: phenylcyclohexylpiperidine; PPI: prepulse inhibition; sc: 
subcutaneous 
Task 
(cognitive process, 
area involved) 
Model 
(species) 
Treatment Results Reference 
Passive avoidance 
learning 
(hippocampus) 
Impaired 
PDE10A KO 
(mouse) 
- Apparent effect, but this 
could be explained by a 
locomotor effect 
(Siuciak et al. 
2006) 
 Impaired 
PDE10A KO 
(mouse) 
- No effect (Siuciak et al. 
2008b) 
Acquisition of 
conditioned 
avoidance 
responding (CAR) 
(learning, 
hippocampus) 
Impaired 
PDE10A KO 
(mouse) 
- PDE10A-/- mice learned 
the task as well as 
PDE10A+/+ mice, but 
needed more training.  
(Siuciak et al. 
2006) 
 Impaired by 
PDE10A KO; 
DBA1LacJ 
background 
(mouse) 
- KO mice learned the task 
as well as WT, but 
needed more training. 
(Siuciak et al. 
2008b) 
 Impaired by 
PDE10A KO; 
C57BL/6N 
background 
(mouse) 
- KO mice learned needed 
more training and did not 
reach performance of WT. 
(Siuciak et al. 
2008b) 
Morris water maze 
(spatial memory, 
hippocampus) 
Impaired 
PDE10A KO 
(mouse) 
- Apparent effect, but this 
could be explained by a 
locomotor effect 
(Siuciak et al. 
2006) 
 Unimpaired 
(mouse) 
Chronic treatment 
of papaverine (0, 
5, 10 or 20 mg/kg, 
sc) daily for 14 
days. Then, same 
treatment either 
prior of 30 min 
after testing. 
Papaverine (5 mg/kg, 
after testing) impaired 
latency and distance. In 
addition, papaverine (20 
mg/kg, 30min before 
testing and 5 mg/kg 30 
min after testing) 
increased the time spend 
in the old platform 
quadrant in reversal 
learning. 
(Hebb et al. 
2008) 
Auditory gating 
(anesthetized) 
(information 
processing, frontal 
cortex) 
Impaired by D-
amphetamine, 1 
mg/kg, iv, 5 min 
before testing  
(rat) 
TP-10 (0, 3 
mg/kg); 5 min 
before testing 
TP-10 reversed auditory 
gating deficit  
(Schmidt et 
al. 2008) 
Prepulse inhibition 
(information 
processing, frontal 
cortex) 
Unimpaired  
(mouse) 
TP-10 (0, 0.32, 1, 
3.2 or 10 mg/kg, 
sc) 30 min before 
testing 
TP-10 had no effect on 
PPI or startle response  
(Schmidt et 
al. 2008) 
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Task 
(cognitive process, 
area involved) 
Model 
(species) 
Treatment Results Reference 
 Impaired by MK-
801, 0.178 
mg/kg, sc, 30 
min before 
testing  
(mouse) 
TP-10 (0, 1, 3.2 or 
10 mg/kg, sc) 30 
min before testing 
 
TP-10 did not reverse PPI 
deficit   
(Schmidt et 
al. 2008) 
Attention set-shifting 
task (attention, 
prefrontal cortex) 
Impaired by 
subchronic PCP 
treatment, 5 
mg/kg, ip, twice a 
day for 7 days  
(rat) 
Papaverine (0, 3, 
10 or 30 mg/kg, 
ip) 
Papaverine attenuated 
PCP induced deficits at all 
doses. No effect of 
papaverine on saline 
treated rats 
(Rodefer et 
al. 2005) 
 
MECHANISMS OF ACTION 
 
 There are several mechanisms of action which could account for the cognition 
enhancing effects of PDE-Is. First, it has been proposed that these effects could be the 
result of vasodilatory properties of PDE-Is. Secondly, cognition enhancement could be a 
consequence of emotional arousal. Finally, positive effects may be due to enhanced second 
messenger signaling (cAMP and/or cGMP) resulting in facilitated LTP processes. All three 
mechanisms will be discussed in the next sections. 
 
Blood flow 
 
 An increase in blood flow and concomitantly an increase in glucose metabolism might 
be related to the observed cognitive enhancements after PDE inhibitor treatments as 
predominantly investigated and observed in rodents. This because PDE-Is increase levels of 
cAMP and cGMP, and vasodilatation properties can be attributed to both cyclic nucleotides 
(Dundore et al. 1993; Paterno et al. 1996). 
 Summarizing the rodent behavioural data with PDE5 inhibition (see Table 5) it appears 
that zaprinast and sildenafil are optimally effective at an oral dose of approximately 10 and 3 
mg/kg, respectively. The effects of both zaprinast and sildenafil on blood pressure, which is 
negatively related to blood flow, have been sparsely investigated in conscious rodents. 
Administration of zaprinast does not decrease mean arterial blood pressure at a dose of 2 
mg/kg (i.p.) in mice (Patil et al. 2004a) and 10 mg/kg (p.o.) in rats (Prickaerts et al. 1997). 
Yet, a decrease in blood pressure can be observed with zaprinast after systemic 
administration (i.v.) of doses higher than 10 mg/kg (Dundore et al. 1993). 
 One mg/kg sildenafil (i.p.) did not affect mean arterial blood pressure in mice up to six h 
after administration (Patil et al. 2004a). Yet sildenafil can decrease mean arterial blood 
pressure up to six h, but an oral dose of at least 10 mg/kg was needed in rats (Rehse et al. 
1999). Sildenafil has also been tested directly on cerebral blood flow as measured with 
laser-Doppler flowmetry, although rats need to be anesthetized for this technique (Zhang et 
al. 2002). Surprisingly, localized cerebral blood flow was increased after oral administration 
of 2 mg/kg sildenafil. 
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 Cerebral blood flow and glucose utilization have been investigated in mice with the 
[13N]ammonia uptake and [3H]2-deoxyglucose uptake technique (Ishikawa et al. 2002). It 
was found that within 5 min after 3 mg/kg rolipram (i.p.) administration, blood flow and 
glucose metabolism in the brain were both decreased by approximately 20 and 40%, 
respectively. At 30 min after administration glucose use was still decreased by 60%. 1 
mg/kg rolipram was also tested on central glucose use, which was found to be decreased by 
40% at 15 min after administration. Of note, these doses of rolipram are rather high and 
behaviourally effective doses are in general below 1 mg/kg (i.p.) (see Table 4). Increasing 
the dose of rolipram above 1 mg/kg will only result in sedation and locomotor depression. 
 Taken together, the PDE4-Is and PDE5-Is tested in rodents can have peripheral and 
central vascular and metabolic effects, but these effects occur after treatment with doses 
that are higher than required for cognition enhancement. Moreover, detailed inspection of 
the behavioral data already suggests that a uniform cerebrovascular effect is not sufficient to 
explain the differential effects on cognitive processes. For instance, administration of a 
cGMP analogue into the hippocampus improved early consolidation, whereas a comparable 
cAMP analogue had no effect (Bernabeu et al. 1996; Prickaerts et al. 2002a). Along similar 
lines, sildenafil improved early consolidation, whereas rolipram did not (Rutten et al. 2007b). 
On the other hand, late consolidation processes are improved by rolipram while sildenafil is 
ineffective. Once more, these findings indicate that it is not likely that cerebrovascular and 
metabolic effects explain the cognitive improvements as observed in rodents. 
 Sildenafil 100 mg has effects on the central nervous system of humans as evident from 
influenced evoked potential and reaction times (Grass et al. 2001; Schultheiss et al. 2001). 
The same dose of sildenafil has been shown to increase heart rate and decreased diastolic 
blood pressure in healthy subjects (Kruuse et al. 2002). However, sildenafil had no effect on 
bloodflow in the middle cerebral artery, just as there were no changes in radial and temporal 
artery diameters (Arnavaz et al. 2003; Kruuse et al. 2002). This indicates that effects on 
cognition after sildenafil administration are not likely to be related to cerebrovascular 
mechanisms in humans as well. 
 
Emotional arousal 
 
 Anecdotic report and case studies describe emotional arousal (anxiety, aggression) in 
men taking sildenafil (Milman and Arnold 2002). In rats it has been demonstrated that 
sildenafil (1-3 mg/kg) has an anxiogenic effect (Kurt et al. 2004). Effects on emotion and 
arousal are likely, since animal studies have shown that central cGMP is involved in 
sympathetic activation (Krukoff 1998). Concomitantly, anxiolytics including benzodiazepines 
reduced the stress-induced increase in central cGMP levels (Tang et al. 1997). cAMP levels 
were reduced as well after benzodiazepines administration, as found in vitro (Niles and 
Wang 1999); although increases in cAMP have also been observed (Cherry et al. 2001). In 
line with the latter observation the PDE4-I rolipram (0.1 mg/kg) had an anxiolytic effect in 
rats (Silvestre et al. 1999). Yet it has to be noted again that the dose of rolipram is still 
relatively high and decreased locomotor activity might have interfered with the behavioural 
response. Nevertheless, it is evident that the cyclic nucleotides cAMP and cGMP play a role 
in arousal and emotional processes. Emotional arousal, to a certain maximum, is necessary 
for an optimal cognitive performance (Prickaerts and Steckler 2005). Thus, effects of PDE-Is 
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on cognition can be influenced by or attributed to effects on processes of emotions and 
arousal. 
 
Long-term potentiation 
 
 Hippocampal LTP is the most established cellular model for the neuroplastic 
mechanisms that underlie learning and memory (Bliss and Collingridge 1993). LTP is 
described by the increase in the chemical strength of a synapse after tetanus stimulation 
that lasts for over an hour. Experimentally, a series of short, high frequency electric 
stimulations to a nerve cell synapse can strengthen, or potentiate, that synapse for several 
minutes to hours. Glutamate induces LTP via activation of the ionotropic NMDA receptor, 
after which calcium enters the cell triggering various pre- and postsynaptic changes. The 
mechanism of LTP and its relationship to learning and memory is quite complicated.  It 
depends on the fine-tuning of various components of the glutamatergic system including 
ionotropic and metabotropic glutamate receptors, other neurochemical systems, second 
messengers and signal transduction pathways. Hippocampal LTP can, depending on the 
induction paradigm, last for less than 3 h or longer. The former is called early-phase LTP (E-
LTP) and the later late-phase LTP (L-LTP). It has been suggested that E-LTP (or LTP1) can 
be transformed into L-LTP (LTP3), probably via an intermediate LTP2 form (Reymann and 
Frey 2007). Furthermore, it has been assumed that E-LTP is related to short-term memory 
and L-LTP to long-term memory, respectively (Izquierdo et al. 2002). 
 In general, both pre- and postsynaptic mechanisms are related to LTP and can involve 
the second messengers cAMP and cGMP. Figure 1 provides a schematic overview of the 
cellular processes related to LTP and second messenger signalling. More in detail, a 
postsynaptic cAMP/PKA/CREB pathway (Impey et al. 1996) and cGMP/PKG/CREB 
pathway (Lu et al. 1999) are involved in L-LTP. A postsynaptic calmodulin-dependent 
protein kinase II (CaMKII) pathway (Sweatt 1999) and presynaptic cGMP/PKG pathway 
(Arancio et al. 1995) have been implicated in E-LTP.  
 Since PDE-Is influence the levels of the second messengers cAMP and/or cGMP it can 
be argued that the procognitive effects of PDE-Is are related to the facilitation of LTP. Yet, 
only a limited number of studies have investigated the effects of PDE-Is on LTP. Most 
research has been aimed at the effects of PDE4 inhibition on LTP. The PDE4-I rolipram, 
when applied to hippocampal slices, has been shown to facilitate hippocampal LTP in rats 
and mice (Ahmed and Frey 2003; 2005; Gong et al. 2004; Navakkode et al. 2004; 2005). In 
addition, we recently demonstrated that the PDE9-I BAY 73-6691 amplified E-LTP elicited 
by weak tetanic stimulation in young Wistar rats (van der Staay et al. 2008). These findings 
are in line with observations of enhanced E-LTP after treatment with the PDE2-I BAY 60-
7550 in rats (Boess et al. 2004). Finally, chronic administration (1 mg/kg/day, i.p.), for 15 
days, of the PDE5-I sildenafil improved LTP in CA3-CA1 synapses of hippocampal slices in 
mice (Uthayathas et al. 2007). To our knowledge, no studies have investigated the effects of 
PDE10 inhibition on LTP. The few existing studies that investigated the effects of PDE-Is on 
LTP indicate that inhibition of PDEs may have a beneficial effect on synaptic plasticity.  
Since LTP is considered the underlying mechanism for learning and memory, it is relevant to 
evaluate the effects of PDE-Is on LTP in addition to and in parallel with behavioral studies. 
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Figure 1 Ca2+ entry through the postsynaptic ionotropic NMDA receptor triggers LTP induction. Ca2+ results 
in the activation of CaMKII (a specific form of CaMK). Activated CaMKII stimulates the insertion into the 
membrane of the ionotropic AMPA receptor, which is involved in regular signal transduction through the 
generation of excitatory postsynaptic potentials (EPSPs). In addition CaMKII activates AC resulting in the 
production of the second messenger cAMP. The latter activates PKA, which has a positive effect on the 
transcription factor CREB (via MAP kinases possibly). CREB activation is known to result in an increased gene 
expression, including the genes for AMPA receptors and thus future signal transduction is enhanced. Ca2+ is 
also known to activate the enzyme NOS, which produces NO. The latter can activate GC, which produces the 
second messenger cGMP. There are indications that postsynaptically cGMP has similar effects as cAMP, but 
via activation of PKG. NO is also known to act as a retrograde messenger and can thus stimulate presynaptic 
GC. It has been found that cGMP stimulates the synthesis and release of glutamate via PKG 
  
 The process opposed to LTP is long-term depression (LTD), which decreases, or 
depresses, the strength of a synapse for a certain amount of time as a result of either strong 
or persistent weak stimulation. Several studies have shown that PDE4-Is and PDE5-Is can 
induce or reinforce LTD in the hippocampus and the striatum among others (Bailey et al. 
2003; Calabresi et al. 1999; Navakkode et al. 2005). Recently it has been found that a deficit 
in LTD can result in memory impairment (Griffiths et al. 2008)  which is in line with the 
theoretical neural-network models that depend on bidirectional synaptic plasticity (LTP and 
LTD) to mediate learning and memory (Malenka 1994). Accordingly, it is now evident that 
besides excitatory strengthening mechanisms in LTP, stabilization or suppression 
mechanisms, e.g. LTD, are also crucial for the regulation of synaptic plasticity (Abel et al. 
1998). However, the exact underlying mechanisms remain elusive and the role of PDE-Is in 
these processes require further investigation.  
 
TIME WINDOWS IN MEMORY PROCESSES 
 
 PDE2, PDE4 and PDE9 inhibition improved both short-term memory (STM) and long-
term memory (LTM) (see Table 3, 4 and 6). PDE5 inhibition has only been investigated for 
LTM. Yet, based on the PDE9-I experiments (van der Staay et al. 2008), it might be 
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expected that PDE5 inhibition will result in STM improvements, though this needs to be 
confirmed in future studies. Taken together, treatment of rodents with different types of 
selective PDE-Is, which inhibit the degradation of the second messengers cAMP and/or 
cGMP, improved their STM as well as LTM. Furthermore, with respect to LTM it appears 
that for consolidation processes a distinction can be made between early consolidation (< 3 
h) and late consolidation (> 3 h) with cGMP being involved in the former and cAMP in the 
latter (Bernabeu et al. 1996; Izquierdo et al. 2006; Prickaerts et al. 2002a; Rutten et al. 
2007b). These findings suggest that different underlying mechanisms should explain 
consolidation processes. Or in more detail, are different forms of LTP involved in different 
phases of long-term memory consolidation?  
  Defining STM as not requiring protein synthesis may implicate that the time window of 
E-LTP corresponds with the duration of STM (1-3 h) , the definition often used in animal 
research (Izquierdo et al. 2002). Pre-synaptic cGMP is involved in E-LTP (LTP1) (Arancio et 
al. 1995), but cAMP is probably not (Nguyen and Woo 2003). Thus, it can be argued that 
rolipram should not improve STM. However, we found that rolipram can improve STM 
(Rutten et al. 2006). This effect might be explained by a general enhancement of synaptic 
transmission by increasing neurotransmitter availability, as rolipram has been found to 
activate the cognition-related cholinergic (Imanishi et al. 1997), but also noradrenergic and 
dopaminergic neurotransmitter systems (Schoffelmeer et al. 1985). 
 L-LTP (LTP2 and LTP3) is dependent on protein synthesis and last longer than 3 h 
(Reymann and Frey 2007). It can be assumed that L-LTP is related to LTM. Figure 2 
illustrates the inter relationship between STM and LTM, with intermediate memory (IM) in 
between STM and LTM. It might be speculated that LTP2 is representing early 
consolidation/IM and LTP3 represents late consolidation/LTM. These questions clearly 
warrant further investigations. 
 E-LTP can be converted into L-LTP (Pang et al. 2004). This is in line with the idea that 
information in the STM can be transferred into LTM (Baddeley 2003). As pre-synaptic cGMP 
plays a role in E-LTP, theoretically, inhibition of cGMP degradation with for instance a 
PDE9-I should therefore be able to influence L-LTP/LTM via E-LTP/STM as well. But cGMP 
as well as cAMP are involved in post-synaptic L-LTP processes resulting in phosphorylation 
of the transcription factor CREB eventually. However, as described above, both cyclic 
nucleotides have different effects on consolidation processes. This implies that the signal 
transduction pathways are far more complex than known thus far. It seems likely that 
additional modulators are involved in regulating and mediating the timed effect of the second 
messengers cGMP and cAMP on memory processes. 
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Figure 2 A schematic classification of memory identifying four distinct types of memory: sensory store, short-
term memory (STM)/working memory (WM), intermediate memory (IM) and long-term memory (LTM). In the 
sensory store, all the incoming information from the sensory organs is accumulated and depending on 
attention processes certain items can be transferred to STM/WM (Baddeley 2003). These stores generally 
have limited capacity and duration. Information can be stored for a longer period of time ranging from hours to 
years. It is suggested that there are two stages involved, that is IM and LTM (Kesner and Hopkins 2006). The 
time frames of the three stages of STM, IM and LTM are not clearly defined and depend on the definitions 
used by the researcher. Especially between animal and human research the definitions of the time windows 
tend to vary a lot (from seconds to hours). In addition, the exact role of different brain areas in this respect is 
not fully clear yet. But it is evident that the hippocampus plays a key role and is particularly involved in 
intermediate memory processes (Kesner and Hopkins 2006). We propose that information is processed from 
STM to IM via early consolidation and subsequently from IM to LTM via late consolidation. In addition, we 
assume that STM is supported by transient changes in neuronal transmission, not requiring gene expression 
and protein synthesis whereas IM and LTM are maintained by more stable and permanent neuronal changes 
that are dependent on protein synthesis (Izquierdo et al. 2002). cGMP-specific PDE-Is might be able to 
influence STM via enhanced LTP1. In addition, cAMP-specific PDE-Is influence STM probably via an 
increased neurotransmitter release directly. Furthermore, LTP2 might represent IM and should be specifically 
influenced by cGMP-specific PDE inhibition. Finally, LTM is likely represented by LTP3 which should be 
influenced by cAMP-specific PDE inhibition 
 
Targetting cognitive functioning 
 
 The application of PDE-Is in studies of animal cognition enhancement has been fruitful 
and these studies have extended our fundamental knowledge about the possible underlying 
cellular and molecular mechanisms of learning and memory and other cognitive functions. 
However, to predict which classes of PDE-Is are possibly the most effective cognition 
enhancers, in either preclinical or clinical studies, depends on various factors.  
 First, it is important to know the exact localization of specific PDE enzymes in the 
normal brain (see also Table 1). The localization of the enzymes might predict that certain 
cognitive functions that are primarily located in specific brain structures may be enhanced by 
some PDE-Is, but not by others. For example PDE10 is predominantly expressed in striatal 
areas (Schmidt et al. 2008) and is therefore a target for schizophrenia. In contrast, PDE4 is 
highly expressed in the hippocampus and cortex (Perez-Torres et al. 2000) and is therefore 
considered a better target for cognition enhancement. Of note, the development of a specific 
antibody against a selective PDE, preferentially of the level of isoform type, will more 
specifically target a PDE for a certain cognitive function (Fujita et al. 2007). 
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 Secondly, it must be taken into account that the constitution of the brain changes with 
age and the distribution of PDEs can be modified by the aging process As a consequence, a 
PDE-I can improve cognition in young subjects, but impair cognition in old subjects. 
Likewise, Ramos et al. (2003) demonstrated that rolipram had a positive effect on prefrontal 
cortex-dependent working memory in young rhesus monkeys, but negative effect on working 
memory in aged rhesus monkeys. However, rolipram improved performance in the passive 
avoidance task, a test of hippocampus-dependent memory, in both young and aged mice 
(Barad et al. 1998). With advancing age, opposite profiles between the function of PKA in 
the hippocampus and prefrontal cortex were suggested to explain the results of Ramos et al. 
(2003); i.e. the prefrontal cortex showed indices of increased PKA activity, while the 
hippocampus exhibited evidence of decreased PKA activity (Ramos et al. 2003). In addition, 
is has been shown that expression of PDE5 is strongly reduced in brains of Alzheimer’s 
disease patients (Reyes-Irisarri et al. 2007). However, PDE2 and PDE9 do not show this 
Alzheimer related reduction in expression patterns, but show the same distribution as in 
healthy age-matched controls (Reyes-Irisarri et al. 2007). Along similar lines, PDE5 
inhibition did not improve object memory in aged rats (Domek-Lopacinska and Strosznajder 
2008). Consequently, when developing a PDE-I for treatment of the cognitive decline 
resulting from Alzheimer’s disease, PDE2-Is and PDE9-Is may be a better target in this 
population than PDE5-Is.  
 Thirdly, since most PDEs are transcribed by several genes, which give rise to multiple 
PDE splice variants and isoforms, further investigation into possible isoform-specific effects 
of PDE-Is are a field of great interest. For example, four isoforms of PDE4 mRNA have been 
found; PDE4A, PDE4B, PDE4C and PDE4D. Indirect evidence suggests that PDE4A and 
PDE4B are involved in signaling pathways related to affective (Ye et al. 2000) and memory 
(Ahmed and Frey 2003) processes, respectively. Recently, the antidepressant potential of 
PDE4A in the hippocampus has been found to be related to specific splice variants of this 
PDE4 isoform (D'Sa et al. 2005). The same probably holds for PDE4B and memory (Ahmed 
and Frey 2005) or schizophrenia (Siuciak et al. 2008a). PDE4D KO mice have already been 
generated and these animals display both an antidepressant and pro-cognitive profile 
(Zhang et al. 2002).  Furthermore, it has been observed, that the expression of the majority 
of PDE4D isoforms (1-9) was reduced in the hippocampus of patients with Alzheimer’s 
disease compared to healthy adults. Interestingly, PDE4D1 and PDE4D2 were increased in 
the brains Alzheimer’s patients (McLachlan et al. 2007). These findings underscore the 
relevance of further investigations into the role of isoform specific PDEs in cognition 
enhancement. 
 Furthermore, the most widely used PDE4-I in behavioral studies, rolipram, produces 
severe dose-limiting emetic side effects including headache, gastric hyper secretion and 
severe emesis (e.g. nausea) in humans (Zhu et al. 2001). Novel PDE4-Is are thought to 
produce less emetic side effects, but thus far no human cognition studies have been 
reported using these second generation PDE4-Is. Thus far, only PDE5-Is can be prescribed 
to humans. However, particularly cardiovascular effects limit their usefulness as a general 
treatment for cognitive disorders, since patients with cardiovascular indications cannot be 
included. In addition, central effects including visual disturbances and headache, limits the 
use of PDE5-I such as sildenafil (Kruuse et al. 2002). Especially chronic treatment with 
SELECTIVE PDE-IS: A PROMISING TARGET FOR COGNITION ENHANCEMENT 
46 
these drugs could be disadvantageous. Again, an isoform specific PDE-I could circumvent 
the above mentioned side effects. 
 
FUTURE DIRECTIONS 
 
 In this review we summarized all recent available literature of the cognition enhancing 
effects of PDE-Is in preclinical studies. It has been shown that inhibitors of PDE2, PDE4, 
PDE5, PDE9 and PDE10 improve a wide range of cognitive processes, including 
information processing, attention, learning, executive functioning and response inhibition, in 
various behavioral models within different species. We argue that it is unlikely that blood 
flow is the mechanism underlying these procognitive effects. We feel that LTP appears to be 
a better substrate for the cognition enhancing properties of PDE-Is. 
Despite accumulating evidence for the procognitive effects of PDE-Is, further investigation is 
still required. First, more localization studies are required to obtain more knowledge about 
the localization of the specific PDE isoforms in different brain areas. In addition, the exact 
underlying working mechanisms of selective PDE-I have to be investigated by using central 
administration paradigms, blood flow measurements and parallel LTP experiments. Clearly, 
it is crucial to translate the procognitive findings in animals to human subjects. Since PDE5-I 
are already clinically accepted for the treatment of erectile dysfunction, these drugs can be 
readily tested in human subjects. Besides neuropsychological tasks to address cognitive 
functioning, imaging studies (EEG and fMRI) are necessary elucidate the central 
mechanisms underlying the cognition enhancing effects of PDE inhibition. 
 Taken together, PDE-Is offer a promising target for cognitive enhancement. Yet, the 
future for cognition enhancing PDE-Is lies in the development of isoform specific PDE-Is, 
that are present in the aged or Alzheimer diseased brain, and that have limited aversive side 
effect profiles within the effective dose range for cognition enhancement. Suitable 
candidates appear to be PDE2-Is or PDE9-Is, although little is known about their side effect 
profiles and isoform specificity.  
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ABSTRACT 
 
 A promising target for memory improvement is phosphodiesterase type 5 (PDE5), 
which selectively hydrolyzes cyclic guanosine monophosphate (cGMP). In rodents, PDE5 
inhibitors (PDE5-Is) have been shown to improve memory performance in many behavioural 
paradigms. However, it is questioned whether the positive effects in animal studies result 
from PDE5 inhibition in the central nervous system or the periphery. Therefore, we studied 
the effects of PDE5 inhibition on memory and determined whether compound penetration of 
the blood-brain barrier (BBB) is required for this activity. Two selective PDE5-Is, vardenafil 
and UK-343,664, were tested in the object recognition task (ORT) in both a MK-801- and 
scopolamine-induced memory deficit model, and a time-delay model without 
pharmacological intervention. Compounds were dosed 30 min before the learning trial of the 
task. To determine if the PDE5-Is crossed the BBB, their concentrations were determined in 
plasma and brain tissue collected 30 min after oral administration. Vardenafil improved 
object recognition memory in all three variants of the ORT. UK-343,664 was ineffective at 
either preventing MK-801-induced memory disruption or time-dependent memory decay. 
However, UK-343,664 attenuated the memory impairment of scopolamine. Vardenafil 
crossed the BBB whereas UK-343,664 did not. Further, co-administration of UK-343,664 
and scopolamine did not alter the brain partitioning of either molecule. This suggests that 
the positive effect of UK-343,664 on scopolamine-induced memory decay might arise from 
peripheral PDE5 inhibition. The results herein suggest that there may be multiple 
mechanisms that mediate the efficacy of PDE5 inhibition to improve memory performance in 
tasks such as the ORT and that these involve PDE5 located both within and outside of the 
brain. To further elucidate the underlying mechanisms, the cellular and subcellular 
localization of PDE5 needs to be determined. 
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INTRODUCTION  
 
 With the seminal findings of Barad et al. (1998) on the role of PDE4 in the regulation of 
long term potentiation (LTP) and learning and memory , there has grown a broad interest in 
the phosphodiesterases (PDE) as molecular targets to treat neuropsychiatric dysfunction 
(e.g. Halene and Siegel 2007; Menniti et al. 2006). PDEs are enzymes that inactivate the 
second messenger molecules cyclic adenosine monophosphate (cAMP) and cyclic 
guanosine monophosphate (cGMP). There are eleven families of PDEs, distinguished by 
molecular properties, substrate specificity, and regulation (Bender and Beavo 2006). These 
enzymes are expressed in unique and overlapping patterns throughout the body, and in 
particular in the CNS (Lakics et al. 2010). Both cAMP and cGMP play important roles in 
regulating processes of neuroplasticity, including LTP, that form the neurophysiological 
bases of learning and memory (Bliss and Collingridge 1993; Frey et al. 1993; Son et al. 
1998). Pharmacological inhibitors of different PDE families offer means to modulate discreet 
cyclic nucleotide signalling pathways involved in different aspects of learning and memory, 
possibly for therapeutic benefit. 
 A PDE family of particular interest with regard to pharmacological targeting is PDE type 
5 (PDE5). PDE5 inhibitors (PDE5-Is), including sildenafil, tadalafil, and vardenafil, are the 
first PDE-Is to achieve widespread clinical use, especially for the treatment of conditions 
caused by vascular dysfunction. PDE5 is specific for the metabolic inactivation of cGMP. 
The enzyme is expressed at high levels in smooth muscle of discreet vascular beds, where 
PDE5 inhibition causes increases in smooth muscle cGMP which results in vascular 
relaxation. Initially, PDE5-Is were of interest to reduce systemic blood pressure but were not 
sufficiently efficacious for commercial development. However, PDE5 is expressed at high 
levels in the vascular bed of the penis and these compounds found therapeutic utility and 
commercial success in the treatment of male erectile dysfunction.  PDE5 is also expressed 
at high levels in the lung, and PDE5-Is are now being used successfully to treat pulmonary 
hypertension. It has also been found that PDE5 inhibition regulates vascular tone in the 
prostate and there is growing interest in the use of PDE5-Is for treatment of benign prostatic 
hyperplasia. Thus, the success of PDE5-Is derives from the fundamental role of the enzyme 
in the regulation of vascular tone, with disease utility tied to enzyme localization in specific 
vascular beds (for a review see also Ghofrani et al. 2006; Puzzo et al. 2008).  
 cGMP signaling cascades are prominently represented in the control of neuronal 
function including the pre- and post-synaptic mediation of different forms of neuroplasticity 
(Kleppisch and Feil 2009; Son et al. 1998). Thus, it is of interest whether PDE5 is involved in 
the regulation of one or more such neuronal signalling cascades and whether PDE5-Is may 
impact cognitive function. In fact, there are now a number of reports of PDE5-Is improving 
learning and memory performance in animals. This includes improved memory for novel 
objects in the object recognition task (ORT) (Domek-Lopacinska and Strosznajder 2008; 
Prickaerts et al. 2005; Rutten et al. 2007b; Rutten et al. 2009; van Donkelaar et al. 2008), 
avoidance learning (Baek et al. 2011; Baratti and Boccia 1999; Boccia et al. 2011; Devan et 
al. 2004) and complex maze learning in rodents (Devan et al. 2004) (for an overview see 
Chapter 2). Particularly interesting is the finding that chronic treatment with a PDE5-I caused 
a long lasting improvement in memory function and reduced plaque load in a mouse model 
of the amyloid deposition of Alzheimer’s disease (AD) (Puzzo et al. 2009), although the 
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decrease in amyloid burden has not been replicated in a more recent study (Cuadrado-
Tejedor et al. 2011). However, PDE5 mRNA and protein is expressed at only low levels or 
not observed in forebrain regions thought to mediate learning and memory function in these 
types of tasks (see Discussion). This raises the question of localization of the PDE5 target 
and mechanism of action that accounts for the pro-cognitive effects of PDE5-Is. Previously, 
we reported that cognitive enhancing doses of PDE5-Is do not affect cerebral blood flow and 
glucose utilization, indicating that such vascular effects do not account for pro-cognitive 
efficacy (Rutten et al. 2009). In the present study, we take another approach to localize the 
PDE5 target involved in the pro-cognitive action of PDE5 inhibitors by investigating whether 
PDE5-Is must cross the blood-brain barrier (BBB) to improve memory for novel objects. 
 We examined the efficacy of UK-343,664, a PDE5-I that is assumed to only poorly 
cross the BBB (Abel et al. 2001; Walker et al. 2001), to improve memory in three variants of 
the ORT: a 24 h delay interval where memory degrades over time or a 1 h interval where 
memory is disrupted by administration of scopolamine or MK-801. The scopolamine-induced 
memory deficit model is a widely used cognitive impairment model (Klinkenberg and 
Blokland 2010). This anti-cholinergic agent has shown to impair memory in several 
behavioral tests including the ORT (e.g. Rutten et al. 2006; Schreiber et al. 2007). After 
scopolamine, the MK-801-induced memory deficit model is the second most commonly used 
deficit model for preclinical cognition research (van der Staay et al. 2011). MK-801 is an N-
methyl-D-aspartate (NMDA) receptor antagonist that disrupts in particular short-term 
memory (STM) and attention processes (e.g. Boess et al. 2004; van der Staay et al. 2008; 
Zhang et al. 2000), thereby causing cognitive deficits affiliated to schizophrenia (Kiss et al. 
2010; Moghaddam and Jackson 2003; Vardigan et al. 2010). Therefore one has to be aware 
that the effects of MK-801 on a memory performance cannot be seen separately from STM 
and attention processes. The dose of MK-801 used in the present study is known to impair 
memory in rodents, but without causing sensorimotor impairments, motivational effects 
and/or signs of intoxication (van der Staay et al. 2011). We compare the efficacy of UK-
343,664 in these assays to that of vardenafil, which is assumed to more readily cross the 
BBB (Prickaerts et al. 2004b) and which has previously been reported to be efficacious in 
the ORT (Prickaerts et al. 2004b; Rutten et al. 2007b; Rutten et al. 2009; van Donkelaar et 
al. 2008). These results are discussed with regard to the localization of the PDE5 target(s) 
for these compounds and the role of central and peripheral mechanisms in modulating 
object recognition memory.     
 
METHODS AND MATERIALS 
 
Animals 
 
 All behavioural and related treatment were approved by the local ethical committee for 
animal experiments of Maastricht University and met governmental guidelines. Five batches 
of twenty-four 4-month-old male Wistar rats (Harlan, The Netherlands) were used with 
average body weights of 351 g (± 2.67, batch 1 vardenafil 1 h interval MK-801), 498 g (± 
4.80, batch 2 vardenafil 1h interval scopolamine), 364 g (± 3.93, batch 3 UK-343,664 1 h 
interval MK-801), 409 g (± 4.23, batch 4 UK-343,664 interval scopolamine) and 406 g (± 
5.86, batch 5 UK-343,664 24 h interval with vardenafil as a positive control). The animals 
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were housed individually in standard cages on sawdust bedding in an air-conditioned room 
(about 20°C). They were kept on a 12/12-hour reversed light/dark cycle (lights on from 19.00 
to 7.00 h) and had free access to food and water. The rats were housed in the same room 
as where they were tested. A radio, which was playing softly, provided background noise in 
the room. All testing was done between 9.00 and 18.00 h. 
 Neuropharmacokinetics studies were conducted at BioDuro, Pharmaceutical Product 
Development Inc. (Beijing, PRC) in accordance with the Guide for the Care and Use of 
Laboratory Animals (Institute of Laboratory Animal Resources, 1996).  Male Wistar Han rats 
(250–300 g, 2.5-months old; Vital River Laboratories, Beijing, PRC) were maintained on a 
12 h light-dark cycle in a temperature- and humidity-controlled environment with free access 
to food and water throughout the studies. 
 
Treatment 
 
 MK-801 and scopolamine were prepared daily and dissolved in saline. Based on 
previous results (data not shown), a dose of 0.125 mg/kg was selected for MK-801 and a 
dose of 0.1 mg/kg for scopolamine, since these doses impaired recognition memory without 
affecting exploratory activity. Administration (1 ml/kg) was intraperitoneal (i.p.) (30 min 
before T1). 
 Vardenafil and UK-343,664 were first dissolved in 1.5 ml ethanol with 2% Tween 80. 
After extraction of ethanol via vaporization under N2 gas, the end volume of 0.5% 
methylcellulose was added. Both compounds (2 ml/kg) were given by oral gavage (p.o.). For 
vardenafil, the doses tested are 0.3 - 3 mg/kg in the 1 h interval and 3 mg/kg in the 24 h 
interval. For the latter, vardenafil was used as a positive control and the dose of 3 mg/kg 
was based on previous findings (Prickaerts et al. 2005; Prickaerts et al. 2002). For UK-
343,664 the doses tested were 1-30 mg/kg in the MK-801 deficit model and 3-30 mg/kg in 
the scopolamine deficit model and 24 h interval. All compounds were administered 30 min 
before T1. Vardenafil was kindly donated by BAYER (Wuppertal, Germany) and UK-343,664 
was a gift from Pfizer Inc (Groton, CT, USA). The experimenter was blind to the compounds 
and doses tested. Sixteen animals were used for each condition in the vardenafil 1 h interval 
studies; twelve for the UK-343,664 1 h interval studies and the 24 h interval study. Of note, 
control conditions (vehicle, saline and MK-801) were always tested in 24 animals, as part of 
the training protocol (see below).       
 For neuropharmacokinetics studies, all drugs were tested alone or in behaviourally 
tested combinations of MK-801 (0.125 mg/kg, i.p.), scopolamine (0.1 mg/kg, i.p.), vardenafil 
(3 mg/kg, p.o.) and/or UK-343,664 (30 mg/kg, p.o.).  Three animals were dosed per 
treatment regimen. 
 
Object recognition memory 
 
 The ORT was performed as described elsewhere (Prickaerts et al. 1997). The 
apparatus consisted of a circular arena, 83 cm in diameter. Half of the 40 cm high wall was 
made of gray polyvinyl chloride, the other half of transparent polyvinyl chloride. Two objects 
were placed in a symmetrical position about 10 cm away from the gray wall. Each object 
was available in triplicate. We used four different objects: 1) a cone consisting of a gray 
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polyvinyl chloride base (maximal diameter 18 cm) with a collar on top made of brass (total 
height 16 cm), 2) a standard 1 l transparent glass bottle (diameter 10 cm, height 22 cm) 
filled with water, 3) a massive metal cube (10.0 x 5.0 x 7.5 cm) with two holes (diameter 1.9 
cm), and 4) a massive aluminium cube with a tapering top (13.0 x 8.0 x 8.0 cm). These 
objects are presented in a semi-random manner to prevent the same objects being used in 
two consecutive test sessions. As a result, the time between presentations of similar objects 
to a certain animals is at least one week. Rats could not displace the objects. Fluorescent 
red tubes and a light bulb provided a constant illumination of about 8 lux on the floor of the 
apparatus and light intensity was equal throughout the apparatus.           
 A testing session comprised two trials. The duration of each trial was 3 min. During the 
first trial (T1) the apparatus contained two identical objects (samples). A rat was always 
placed in the apparatus facing the wall at the middle of the front (transparent) segment. After 
the first exploration period the rat was placed back in its home cage. Subsequently, after a 
predetermined delay interval, the rat was returned to the apparatus for the second trial (T2), 
but now with two dissimilar objects, a familiar one (the sample) and a new one. The times 
spent in exploring each object during T1 and T2 were recorded manually with a personal 
computer. 
 Exploration was defined as follows: directing the nose to the object at a distance of no 
more than 2 cm and/or touching the object with the nose. Sitting on the object was not 
considered exploratory behaviour. In order to avoid the presence of olfactory trails the 
objects were always thoroughly cleaned with 70% ethanol. All combinations and locations of 
objects were used in a balanced manner to reduce potential biases due to preferences for 
particular locations or objects. 
 In previous studies we have found that rodents show a good object memory 
performance with a 1 h delay interposed between T1 and T2 (Rutten et al. 2007a; van 
Donkelaar et al. 2008). However, when a 24 h delay interval is used, the animals do not 
discriminate between the novel and familiar object in T2, indicating that they do not 
remember the object that was presented in T1 (Prickaerts et al. 2004b; Rutten et al. 2007b). 
Using a 4 h delay, the discrimination performance is intermediate between the performance 
of 1 h and 24 h delay, suggesting a delay-dependent forgetting in this task (Sik et al. 2003). 
Based on this experience, in the present study we used a 1 h interval to test the memory 
enhancing effects of PDE-Is in the MK-801 as well as the scopolamine deficit model and a 
24 h interval to test the effects of UK-343,664 without an additional pharmacological 
intervention.    
 In the first week, the animals were handled daily and adapted to the procedure in two 
days, i.e. they were allowed to explore the apparatus (without any objects) twice for 3 min 
each day. Next, the rats were adapted to the testing and p.o. (2 ml/kg) and i.p. (1 ml/kg) 
administration procedures by a saline injection 30 min before T1 until they showed a stable 
discrimination performance, i.e. a good discrimination at 1 h interval and no discrimination at 
24 h interval (after about 1 week). After this, testing of the control conditions began. The 
animals used for the 1 h delay interval experiments were all treated with saline or MK-
801/scopolamine together with the vehicle of the PDE5-Is, 30 min before T1. More 
specifically, batch 1 and 3 were treated with MK-801 (0.125 mg/kg, i.p.), batch 2 and 4 with 
scopolamine (0.1 mg/kg, i.p.). The rats used in the 24 h delay interval, batch 5, were only 
treated with the vehicle (p.o.) 30 min before T1. Subsequently, the PDE5-Is were tested: 
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vardenafil (0.3-3 mg/kg, p.o.) in combination with MK-801 in batch 1 and with scopolamine 
in batch 2, UK-343,664 (1-30 mg/kg, p.o. in MK-801 deficit model; 3-30 mg/kg in 
scopolamine deficit model) in combination with MK-801 in batch 3 and in combination with 
scopolamine in batch 4, and UK-343,664 (3-30 mg/kg, p.o.) in a 24 h interval with vardenafil 
(3 mg/kg, p.o.) as a positive control in batch 5. In total, each animal in each batch was 
tested 6-7 times and did not show any decline in performance or exploratory behaviour. 
Doses/vehicle per compound were tested randomly with a wash-out period of at least one 
day in between test sessions. 
 
Determination of vardenafil, UK-343,664, MK-801 and scopolamine concentrations in 
plasma and brain samples 
 
 Following the sequential administration (2 ml/kg for p.o. doses, 1 ml/kg for i.p. doses) of 
compounds (i.e. PDE5-I/vehicle (p.o.) followed immediately by scopolamine/MK-801/saline 
(i.p.)), each rat was placed under isoflurane anesthesia at 0.5 h post-dose. Blood samples 
were obtained by cardiac puncture and collected into EDTA-containing tubes, which were 
stored on wet ice until plasma isolation.  Subsequently, the whole brain was extracted, 
rinsed of excess blood with ice-cold saline, placed into a tared vial, weighed and frozen on 
dry ice. All plasma and brain tissue were stored at -20 °C until processing for bioanalysis. 
 Compound quantification within collected plasma and brain was performed at BioDuro, 
Pharmaceutical Product Development Inc. For bioanalytical sample preparation, plasma 
was used as is, while brain samples were first homogenized in a 4-fold volume (w/v) of 
saline.  Both matrices were processed for the quantification of dosed compound using liquid-
liquid extraction methodology followed by a characterized liquid chromatography-tandem 
mass spectrometry (LC-MS/MS) assay. Individual standard curves were prepared in 
respective control matrices, an appropriate dynamic range was achieved for each 
compound, and instrument settings and potentials were adjusted to optimize the MS signal 
for each analyte.  Raw data were processed using Analyst Software version 1.4.2 (AB Sciex 
Inc., Ontario, Canada). The lower limit of quantification (LLOQ) for all compounds was 1 
nanogram per millilitre (ng/ml) for plasma and 2.5 nanogram per gram (ng/g) for brain. 
 
Statistical analysis 
 
 The basic measures in the ORT were the times spent exploring an object during T1 and 
T2. Table 1 depicts how these measures of the ORT (e1, e2 and d2) were calculated. e1 
and e2 are measures of the total exploration time of both objects during T1 and T2 
respectively. d2 is considered as index measure of discrimination between the new and the 
familiar objects. In fact, d2 is a relative measure of discrimination that corrects for 
exploration activity (e2). Thus, there should be no differences in d2 indices between 
experiments with similar treatments at similar intervals.  
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Table 1 Measures involved in the object recognition test. e1 is the measure of the time spent in exploring both 
identical objects (a1 and a2) in the T1, and e2 is the measure of the time spent in exploring both the familiar 
(a) and new object (b) in the T2; d2 is the measure of discrimination between the new and familiar objects 
Exploration Discrimination 
e1 = a1 + a2  
e2  = a + b d2 = (b – a) / e2 
 
 One-sample t-statistics were performed in order to assess whether d2 differed from 
zero per treatment condition (within comparison). Effects between the different conditions 
were assessed by a one-way ANOVA (between comparisons). In case of a statistically 
reliable dose effect, comparisons between means of the different doses were analyzed in 
more detail using post hoc Bonferroni t-tests (P < 0.05).  
 If the plasma or brain sample of a compound was below the quantification limit (BQL), 
but one or more of the other samples in the same (compound) group had measurable 
values, the BQL was treated as zero. The levels of vardenafil, UK-343,664, MK-801 and 
scopolamine in plasma and brain samples as well as the brain/plasma ratio were analysed 
with a non-parametric Kruskal Wallis test because of the low number of subjects per group, 
i.e. 3. In case of a statistically reliable condition effect, comparisons between means of the 
different treatments were analyzed in further detail using pairwise non-paramatric Mann-
Whitneys tests with adjusted p-values for the number of tests. 
 
RESULTS 
 
Effects of vardenafil on MK-801-induced memory deficits 
 
 The results of vardenafil treatment, 30 min before T1 in combination with MK-801, are 
summarized in Table 2. There were no differences between treatment conditions in the level 
of exploration in T1 (e1: F(4,95) =  1.07, n.s.) and in T2 (e2: F(4,95) = 2.47, n.s.).  
 
Table 2 Results of treatment with vardenafil on exploration time; drug administration (p.o.) was 30 min before 
T1. The delay interval between T1 and T2 was 1 h. Mean values (± SEM) of total exploration time (s) during 
the T1 (e1) and T2 (e2). n = 24 per vehicle condition; n = 16 per experimental condition. MK = MK-801, var = 
vardenafil 
PO vehicle vehicle 0.3 mg/kg var 1 mg/kg var 3 mg/kg var 
IP saline 0.125 mg/kg MK 0.125 mg/kg MK 0.125 mg/kg MK 0.125 mg/kg MK 
e1 15.35 (1.17) 17.18 (1.27) 18.61 (1.48) 19.84 (1.39) 18.88 (1.67) 
e2 17.94 (0.92) 19.08 (1.14) 20.38 (1.55) 24.13 (2.02) 20.88 (2.06) 
 
 The effects of vardenafil on the relative discrimination index d2 are presented in Figure 
1. One sample t-tests showed that the d2 value of the vehicle/saline and 1 mg/kg vardenafil 
conditions differed from zero, in contrast to the vehicle/MK-801 and vardenafil 0.3 mg/kg 
and 3 mg/kg conditions. When comparing between groups, differences were found for the 
d2 index (F(4,95) = 8.42, P < 0.001). Post hoc Bonferroni comparisons revealed that the d2 
values were higher in the vehicle/saline and 1 mg/kg vardenafil conditions than in the 
vehicle/MK-801 condition (see Figure 1). In addition, the d2 was higher in vehicle/saline than 
in the vardenafil 0.3 mg/kg condition. 
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Figure 1 Effects of vardenafil on discrimination performance (d2) in the ORT (mean ± SEM). All drugs were 
given 30 min before T1. Interval was 1 h. 1 mg/kg vardenafil completely reversed the MK-801-induced memory 
deficit. A difference from the MK-801 condition is depicted with asterisks (Bonferroni t-tests, ***: P < 0.001). A 
difference from zero is depicted with # (One sample t-tests, ###: P < 0.001) 
 
Effects of vardenafil on scopolamine-induced memory deficits 
 
 The results of the vardenafil treatment, 30 min before T1, are summarized in Table 3. 
There were no differences found between treatment conditions in the level of exploration in 
T1 (e1: F (4,95) = 0.95, n.s.). In T2, there were no differences between treatment conditions 
in the level of exploration either (e2: F(4,95) = 1.53, n.s.).  
 
Table 3 Results of treatment with vardenafil on exploration time; drug administration (p.o.) was 30 min before 
T1. The delay interval between T1 and T2 was 1 h. Mean values (± SEM) of total exploration time (s) during 
the T1 (e1) and T2 (e2). n=24 per vehicle condition; n = 16 per experimental condition. Scop = scopolamine, 
var = vardenafil 
PO vehicle vehicle 0.3 mg/kg var 1 mg/kg var 3 mg/kg var 
IP saline 0.1 mg/kg scop 0.1 mg/kg scop 0.1 mg/kg scop 0.1 mg/kg scop 
e1 18.94 (1.25) 16.76 (1.32) 18.39 (1.51) 17.48 (1.99) 20.83 (2.03) 
e2 22.36 (1.59) 20.34 (2.57) 18.13 (1.03) 19.15 (1.98) 25.54 (3.03) 
 
 The effects of vardenafil treatment on the relative discrimination index d2 are 
graphically presented in Figure 2. One sample t-tests showed that d2 values of vardenafil 1 
mg/kg, 3 mg/kg and vehicle/saline condition differed from zero (see Figure 2). In contrast, 
the vehicle/scopolamine and 0.3 mg/kg vardenafil conditions showed no differences from 
zero. When comparing between groups, differences were found for the d2 index (F(4,95) = 
9.47, P < 0.001). The d2 values were higher for the vardenafil 1 mg/kg, 3 mg/kg and 
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vehicle/saline conditions than for the vehicle/scopolamine and vardenafil 0.3 mg/kg 
conditions (Bonferroni t-tests; see Figure 2). 
 
 
Figure 2 Effects of vardenafil on the discrimination performance (d2) in the ORT (mean ± SEM). All drugs 
were given 30 min before T1. Interval was 1 h. 1 and 3 mg/kg vardenafil completely reversed the scopolamine-
induced memory deficit. A difference from the scopolamine condition is depicted with asterisks (Bonferroni t-
tests, **: P < 0.01; ***: P < 0.001). A difference from zero is depicted with # (One sample t-tests, ###: P < 
0.001) 
 
Effects of UK-343,664 on MK-801-induced memory deficits 
 
 The results of UK-343,664 treatment, 30 min before T1, are summarized in Table 4. No 
differences were found between treatment conditions in the level of exploration in T1 (e1: F 
(5,94) = 0.41, n.s.). In T2, there were also no differences between treatment conditions in 
the level of exploration either (e2: F(5,94) = 1.69, n.s.).  
   
Table 4 Results of treatment with UK-343,664 on exploration time; drug administration (p.o.) was 30 min 
before T1. The delay interval between T1 and T2 was 1 h. Mean values (± SEM) of total exploration time (s) 
during the T1 (e1) and T2 (e2). n = 24 per vehicle condition; n = 12 per experimental condition. MK = MK-801, 
UK = UK-343,664 
PO vehicle vehicle 1 mg/kg UK 3 mg/kg UK 10 mg/kg UK 30 mg/kg UK 
IP saline 0.125 mg/kg 
MK 
0.125 mg/kg 
MK 
0.125 mg/kg 
MK 
0.125 mg/kg MK 0.125 mg/kg MK 
e1 19.70 (1.35) 20.04 (0.98) 20.48 (1.83) 19.36 (1.57) 19.86 (1.68) 22.17 (1.15) 
e2 20.86 (1.11) 20.07 (1.47) 18.59 (1.63) 23.13 (1.69) 22.76 (1.64) 17.56 (1.28) 
 
 One sample t-tests showed that d2 values of the vehicle/saline condition differed from 
zero. In contrast, the other conditions showed no differences from zero. The effects of UK-
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343,664 treatment on the d2 are presented in Figure 3. When comparing between groups, 
differences were found for the d2 index (F(5,94) = 9.28, P < 0.001). The d2 values were 
higher for the vehicle/saline condition than for the other conditions (see Figure 3) (Bonferroni 
t-tests). 
 
 
Figure 3 Effects of UK-343,664 on the discrimination performance (d2) in the ORT (mean ± SEM). All drugs 
were given 30 min before T1. Interval was 1 h. UK-343,664 did not reverse the MK-801-induced memory 
deficit. A difference from the MK-801 condition is depicted with asterisks (Bonferroni t-tests, ***: P < 0.001). A 
difference from zero is depicted with # (One sample t-tests, ###: P < 0.001) 
 
Effects of UK-343,664 on scopolamine-induced memory deficits 
 
 The results of the UK-343,664 treatment, 30 min before T1, are summarized in Table 5. 
There were no differences found between treatment conditions in the level of exploration in 
T1 (e1: F (4,83) = 0.90, n.s.). In T2, there were no differences between treatment conditions 
in the level of exploration either (e2: F(4,83) = 0.69, n.s.).  
 
Table 5 Results of treatment with UK-343,664 on exploration time; drug administration (p.o.) was 30 min 
before T1. The delay interval between T1 and T2 was 1 h. Mean values (± SEM) of total exploration time (s) 
during the T1 (e1) and T2 (e2). n=24 per vehicle condition; n = 12 per experimental condition. Scop = 
scopolamine, UK = UK-343,664 
PO 
IP 
vehicle 
saline 
vehicle 
0.1 mg/kg scop 
3 mg/kg UK 
0.1 mg/kg scop 
10 mg/kg UK 
0.1 mg/kg scop 
30 mg/kg UK 
0.1 mg/kg scop 
e1 18.73 (0.94) 18.28 (1.10) 16.07 (1.34) 17.46 (1.78) 20.08 (2.16) 
e2 22.74 (1.09) 21.14 (1.23) 23.26 (2.73) 19.31 (1.48) 21.38 (2.76) 
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 The effects of UK-343,664 treatment on the relative discrimination index d2 are 
graphically presented in Figure 4. One sample t-tests showed that d2 values of UK-343,664 
10 mg/kg, 30 mg/kg and vehicle/saline condition differed from zero (see Figure 4). In 
contrast, the vehicle/scopolamine and 3 mg/kg UK-343,664 conditions showed no 
differences from zero. When comparing between groups, differences were found for the d2 
index (F(4,83) = 6.48, P < 0.001). The d2 values were higher for the UK-343,664 30 mg/kg 
and vehicle/saline conditions than for the vehicle/scopolamine and UK-343,664 3 mg/kg 
conditions (Bonferroni t-tests; see Figure 4). 
 
 
Figure 4 Effects of UK-343,664 on the discrimination performance (d2) in the ORT (mean ± SEM). All drugs 
were given 30 min before T1. Interval was 1 h. 30 mg/kg UK-343,664 completely reversed the scopolamine-
induced memory deficit, whereas 10 mg/kg had an intermediate effect. A difference from the scopolamine 
condition is depicted with asterisks (Bonferroni t-tests, **: P < 0.01). A difference from zero is depicted with # 
(One sample t-tests, #: P < 0.05; ##: P < 0.01; ###: P < 0.001) 
 
Effects of UK-343,664 or vardenafil on memory performance in a 24 h interval 
 
 The results of PDE5-I treatment, 30 min before T1, are summarized in Table 6. There 
were no differences between treatment conditions in the level of exploration in T1 (e1: 
F(4,71) =  1.56, n.s.) nor in T2 (e2: F(4,71) = 0.27, n.s.).  
 The effects of PDE5 inhibition on the relative discrimination index d2 in a 24 h interval 
are presented in Figure 5. One sample t-tests showed that the d2 value of the vardenafil (3 
mg/kg) condition differed from zero, in contrast to the vehicle and UK-343,664 conditions. 
When comparing between groups, differences were found for the d2 index (F(4,71) = 3.26, 
P < 0.05). Bonferroni post hoc t-tests (P < 0.05) comparisons revealed that the d2 values 
only differed between the vardenafil and the 3 mg/kg UK-343,664 condition (see Figure 5). 
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Table 6 Results of treatment with UK-343,663 or vardenafill on exploration time; drug administration (p.o.) was 
30 min before T1. The delay interval between T1 and T2 was 24 h. Mean values (± SEM) of total exploration 
time (s) during the T1 (e1) and T2 (e2). n = 24 per vehicle condition; n = 12 per experimental condition. UK  = 
UK-343,664, var = vardenafil 
PO vehicle 3 mg/kg UK 10 mg/kg UK 30 mg/kg UK 3 mg/kg var 
e1 19.37 (1.64) 19.01 (2.10) 20.67 (1.46) 17.11 (2.23) 14.43 (1.16) 
e2 20.88 (1.19) 22.07 (2.55) 20.90 (1.03) 19.84 (2.07) 22.50 (2.78) 
 
 
Figure 5 Effects of PDE5 inhibition on the discrimination performance (d2) in the ORT (mean ± SEM). All drugs 
were given 30 min before T1. Interval was 24 h. Vardenafil had an intermediate effect on memory. A difference 
from zero is depicted with # (One sample t-tests, #: P < 0.05) 
 
Plasma and brain concentrations of vardenafil, UK-343,664, MK-801 and scopolamine  
 
 Total plasma (Cp) and total brain (Cb) compound concentrations, as well as brain-to-
plasma ratios (Cb:Cp), of vardenafil and UK-343,664 30 min after administration are 
summarized in Table 7. Paralleling the behavioural experiments, both molecules’ Cp and Cb 
were determined in combination with saline, MK-801 (0.125 mg/kg, i.p.) or scopolamine (0.1 
mg/kg, i.p.). For vardenafil, mean Cp and Cb were > LLOQ in all conditions; Cp, Cb and Cb:Cp 
did not differ between groups (respectively χ2  = 5.96, n.s; χ2 = 3.31, n.s; χ2 = 1.56, n.s.). 
For UK-343,664, mean Cp was > LLOQ in all groups and no difference between these 
groups was found (χ2 = 4.39, n.s.). However, UK-343,664 Cb was > LLOQ in only one of 
three animals in the MK-801 condition. 
 For both MK-801 and scopolamine, Cp, Cb and Cb:Cp were determined 30 min after their 
administration (Table 8). Paralleling the behavioural experiments, both molecules’ Cp and Cb 
were determined in combination with vehicle, vardenafil (3 mg/kg, p.o.) or UK-343,664 (30 
mg/kg, p.o.); both were evaluated twice in combination with vehicle (i.e. in both the 
vardenafil and the UK-343,664 paradigm). For MK-801, mean Cp and Cb were > LLOQ in all 
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conditions. No differences in Cp (χ2 = 4.54, n.s.) or Cb:Cp (χ2  = 1.70) were observed 
between groups, whereas one was detected for Cb (χ2  = 6.27, P < 0.05). However, non-
parametric adjusted pairwise comparisons revealed no detailed effects on Cb between 
separate MK-801-dosed groups. Additionally, scopolamine mean Cp and Cb were > LLOQ in 
all conditions, but no differences between groups were found (plasma χ2  = 2.68, n.s.; brain 
χ2  = 3.46, n.s.; ratio χ2  = 0.55, n.s.).  
 
Table 7 Mean (±SEM) neuropharmacokinetics (N=3/condition) of vardenafil and UK-343,664 30 min after PO 
administration (3 mg/kg and 30 mg/kg, respectively) concomitant with saline, MK-801 (0.125 mg/kg, i.p.) or 
scopolamine (0.1 mg/kg, i.p.). For both compounds, the LLOQ for plasma and brain were 1 ng/ml and 2.5 ng/g, 
respectively. n.a.: not applicable; BQL: below quantification limit 
 Saline MK-801 
(0.125 mg/kg) 
Scopolamine 
(0.1 mg/kg) 
Vardenafil (3 mg/kg) 
 
Cp (ng/ml) 38.3 (2.1) 22.1 (5.3) 10.2 (8.0) 
Cb (ng/g) 4.3 (0.2) 2.7 (1.5) 1.2 (1.2) 
Cb:Cp 0.11 (0.01) 0.15 (0.04) 0.14 (n.a.) 
 
UK-343,664 (30 mg/kg) 
 
Cp (ng/ml) 47.3 (7.1) 50.1 (17.1) 5.8 (5.8) 
Cb (ng/g) BQL 1.1 (1.1) BQL 
Cb:Cp n.a. 0.05 (n.a.) n.a. 
 
Table 8 Mean (±SEM) neuropharmacokinetics (N=3/condition except for vehicle (N=6/condition)) of MK-801 
and scopolamine 30 min after i.p. administration (0.125 mg/kg and 0.1 mg/kg, respectively) concomitant with 
vehicle, vardenafil (3 mg/kg, p.o.) or UK-343,664 (30 mg/kg, p.o.). For both compounds, the LLOQ for plasma 
and brain were 1 ng/mL and 2.5 ng/g, respectively. n.a.: not applicable 
 Vehicle  Vardenafil 
(3 mg/kg)  
UK-343,664  
(30 mg/kg) 
MK-801 (0.125 mg/kg) 
 
Cp (ng/ml) 6.0 (1.3) 6.4 (3.6) 15.1 (2.3) 
Cb (ng/g) 48.2 (5.2) 50.6 (8.2) 85.4 (5.3) 
Cb:Cp 9.4 (1.5) 12.6 (4.7) 5.8 (0.5) 
 
Scopolamine (0.1 mg/kg) 
 
Cp (ng/ml) 4.5 (0.8) 3.9 (0.8) 2.7 (0.4) 
Cb (ng/g) 16.8 (1.3) 16.3 (3.9) 12.0 (0.5) 
Cb:Cp 4.2 (0.7) 4.1 (0.2) 4.7 (0.8) 
 
DISCUSSION 
 
 The ORT is a one trial learning and memory task tapping an intrinsic drive to explore 
and remember aspects of novelty in the environment (Ennaceur 2010; Ennaceur and 
Delacour 1988). The tasks require discrimination between novel and familiar objects.  A 
number of lines of evidence indicate that the core circuitry that computes this discrimination 
resides within the perirhinal cortex and is involved in ORT performance (Brown and 
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Aggleton 2001; Winters and Bussey 2005). Hippocampal processing is additionally involved 
in object recollection (Mumby 2001). Studies with pharmacological agents reveal a large 
number of diverse molecular targets that impact object recognition and memory (e.g. de 
Bruin et al. 2011; Ennaceur et al. 1989; Prickaerts et al. 2005; Prickaerts et al. 2012). 
Mapping the effects of these pharmacological agents to circuitry and signaling mechanisms 
increase our understanding of the molecular underpinnings of object recognition and 
memory.  Furthermore, the ability of these compounds to improve ORT performance 
suggests that such agents may be of therapeutic value to treat cognitive dysfunction in 
humans. The key to realizing this potential therapeutic value is mapping these molecular 
mechanisms to relevant disease mechanisms. There are a number of reports of PDE5-Is 
improving performance in the ORT (Domek-Lopacinska and Strosznajder 2008; Prickaerts 
et al. 2005; Rutten et al. 2007b; Rutten et al. 2009; van Donkelaar et al. 2008). However, 
PDE5 expression is limited in the CNS, particularly in forebrain regions at the core of 
processing object recognition and memory. Therefore, we asked the provocative question: 
does the PDE5 target for the action of the inhibitors in the ORT lie solely within the brain? 
 In the present study, we compared the effects of two PDE5-Is in several ORT variants. 
One compound, vardenafil, was assumed to cross the BBB (Prickaerts et al. 2004a). In the 
present study we confirmed this assumption, finding that vardenafil had a brain-to-plasma 
ratio (Cb:Cp) of 0.11 30 min after its oral administration. The other PDE5-I, UK-343,664, was 
predicted to poorly permeate the BBB because of its physiochemical properties and P-
glycoprotein-mediated efflux liability (Abel et al. 2001; Walker et al. 2001). In fact, UK-
343,664 (30 mg/kg, p.o.) resulted in easily quantifiable total plasma concentrations, whereas 
total brain concentrations were below the LLOQ resulting in a Cb:Cp < 0.05. The 
approximate cerebral blood volume relative to total unperfused brain volume is 0.04 
(Hitchcock and Pennington 2006), thus a Cb:Cp >0.04 determined in this study if a PDE5-I 
was indeed brain penetrant. Collectively, these data confirm the brain penetration of 
vardenafil and strongly imply the lack of brain partitioning by UK-343,664. 
 In the behavioural studies, vardenafil improved object recognition memory in three ORT 
variants, namely, where memory degrades as a function of time or where memory is 
disrupted by the muscarinic antagonist scopolamine or the NMDA antagonist MK-801. UK-
343,664, was not effective in preventing delay-dependent memory decay or memory 
disruption by MK-801. These results suggest that there is PDE5 within the brain that 
mediates the effects of such inhibitors on object recognition and memory in these 
paradigms. Along similar lines, a recent study of Puzzo et al. (2009) indicated that 
penetration of the BBB is crucial for the beneficial effects of PDE5-Is in a transgenic 
APP/PS1 mouse model of Alzheimer’s disease. It was shown that chronic sildenafil 
treatment improved spatial working memory in a radial arm maze and contextual fear 
conditioning, whereas treatment with tadalafil, which is assumed to not cross the BBB, did 
not improve memory in these tasks (Puzzo et al. 2009).  
 However, we found that both vardenafil and UK-343,664 ameliorated the disruptive 
effect of scopolamine. Co-administration of scopolamine with vardenafil or UK-343,664 did 
not alter the Cb:Cp of the PDE5-Is, consistent with no evidence in the literature suggesting 
scopolamine compromises BBB integrity. Co-administration of either vardenafil or UK-
343,664 with scopolamine also had no effect on scopolamine neuropharmacokinetics. Thus, 
the parsimonious conclusion is that the effect of UK-343,664 in the scopolamine model is 
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mediated by systemic PDE5. Therefore, the question remains why the effective dose of UK-
343,664 (30 mg/kg, p.o.) in the scopolamine test is not effective in a delay-dependent 
memory decay test (i.e. natural forgetting), while vardenafil (3 mg/kg, p.o.) is effective in 
both tests. The memory enhancing effect of UK-343,664 is therefore likely related to its 
combination with central and/or possible peripheral effects of scopolamine. Interactions of 
UK-343,664 or vardenafil with MK-801 can be ruled out based on the behavioral and 
neuropharmacokinetic data. 
 The behavioural results with vardenafil can be considered in terms of data on the 
localization of PDE5 in the rat brain. In the first analysis using in situ hybridization in rat, 
Kotera et al. (1997) reported robust expression of PDE5A mRNA in Purkinje cells of the 
cerebellum, but in no other brain region. Van Staveren et al. (2003) subsequently confirmed 
PDE5 mRNA expression in Purkinje cells. In addition, PDE5 mRNA was observed in 
scattered cells in the hippocampus, dentate gyrus, and cortex. However, PDE5 mRNA was 
not detected in these brain regions of Alzheimer’s disease patients and healthy age-
matched controls (Reyes-Irisarri et al. 2007). Immunohistochemical analysis by several 
groups using different PDE5 antibodies observed robust expression of PDE5 protein in 
rodent Purkinje cells (Giordano et al. 2001; Kotera et al. 2000; Menniti et al. 2009; Shimizu-
Albergine et al. 2003). PDE5 protein expression has also been detected in spinal cord motor 
neurons (Menniti et al. 2009; Nakamizo et al. 2003) and in the cell bodies of midbrain 
mesencephalic 5 neurons (Kruse et al. 2006; Menniti et al. 2009). Rare PDE5-expressing 
cells in cortical areas in rats have also been reported (Menniti et al. 2009). Thus, PDE5 
expression in Purkinje neurons is amply confirmed and PDE5 protein is also consistently 
observed in identified brain stem and spinal cord neurons. In contrast, PDE5 expression in 
forebrain, particularly in those regions most directly implicated in object recognition and 
memory, is uncertain; PDE5 mRNA and protein expression in forebrain is not detected in 
some studies and, when detected, is restricted to scattered cells of unknown phenotype 
(Menniti et al. 2009). There is, however, biochemical evidence of PDE5 activity in the 
hippocampus. In rat hippocampal slices, incubation with a PDE5-I and a nitric oxide donor 
elevated cGMP detected by immunocytochemistry. The increase in cGMP was localized to 
astrocytes in the CA1, varicose neuronal fibers in the CA2/CA3 region and in some fibers in 
the CA1 and dentate gyrus (Prickaerts et al. 2002). In slices from mouse hippocampus, 
cGMP increases were observed in astrocytes and CA3 varicosities (Rutten et al. 2005).  
 The biochemical/functional effects of PDE5-Is in the hippocampus links PDE5 to 
circuitry implicated in object discrimination. However, further study is needed to reconcile 
these functional effects of PDE5 inhibition with the apparently very limited forebrain PDE5 
expression. The sparse cellular expression pattern suggests the possibility that the enzyme 
is localized to one or more neuronal interneuron population. PDE5-expressing interneurons, 
even if numerically small, could exert powerful, differential effects on network-level signal 
processing that could contribute to the efficacy of PDE5-Is in the ORT. Further confirmation 
of expression and identification of the sparse cell types that putatively express the enzyme 
in forebrain, including object memory-related rhinal and hippocampal areas, is needed as a 
step towards evaluating this possibility.  
 The unexpected finding that UK-343,664 ameliorated the effect of scopolamine on ORT 
performance suggests that for the scopolamine paradigm, inhibition of a PDE5 target 
outside the BBB also impacts object recognition and memory. PDE5 is highly expressed in 
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discreet vascular beds throughout the body, including some cerebrovascular beds (Kruuse 
et al. 2003; Kruuse et al. 2002; Menniti et al. 2009). Thus, it is reasonable to speculate that 
a locus for the peripheral effect of PDE5 inhibition in the ORT resides in the 
cerebrovasculature. Our previous studies indicate no effect of vardenafil on local cerebral 
glucose utilization and cerebral blood flow in the hippocampus and perirhinal areas that 
might account for an effect in ORT (Rutten et al. 2009). Kruuse and colleagues (2009) also 
reported lack of effects of PDE5-Is on cerebrovascular responsiveness in humans. Thus, if 
cerebrovascular PDE5 is the target of the inhibitors in the ORT, the mechanism does not 
appear to be hemodynamic.  
 In summary, the results of the present study suggest that there may be multiple 
mechanisms that mediate the efficacy of PDE5 inhibition to improve performance in 
cognitive tasks such as the ORT and that these involve enzyme located both within and 
outside of the brain.  In many respects, these results are surprising. That one locus of action 
is in inside the brain is surprising, given the sparse (or absent) expression of the enzyme in 
forebrain regions most significantly involved in object recognition and memory. That the 
other locus could be outside the brain is simply astonishing. PDE5-Is are widely used 
clinically to treat vascular disorders, where these compounds have been safe and well-
tolerated. However, initial studies of such compounds in humans have not enhanced 
cognitive function (Goff et al. 2009; Schultheiss et al. 2001), although a recent study 
investigating the effects of PDE5 inhibition in patients with erectile dysfunction revealed a 
positive effect on several cognitive tasks (Shim et al. 2011). Further preclinical research is 
clearly needed to better identify the enzyme targets and mechanisms that account for 
activity in nootropic tasks such as the ORT and this may guide future clinical studies into 
cognitive function, ideally as a step towards realizing a new therapeutic use of PDE5-Is. 
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ABSTRACT  
 
 The objective of this study was to assess the effects of phosphodiesterase type 2 
(PDE2) and type 10 (PDE10) inhibition on memory function in the object recognition task 
using the scopolamine- and MK-801-induced memory deficit model. The effects of the PDE2 
inhibitor BAY 60-7550 and the PDE10 inhibitor PQ-10 on object recognition performance 
were investigated in the scopolamine (0.1 mg/kg, i.p.) or MK-801 (0.125 mg/kg, i.p.) model. 
BAY 60-7550 was tested at a dose of 0.3 - 3 mg/kg (p.o.) in both models; PQ-10 was tested 
at doses of 0.1 – 1 mg/kg (p.o.) in the scopolamine model and 0.3 – 3 mg/kg in the MK-801 
model. All compounds were injected 30 min before the learning trial. Both BAY 60-7550 (1 
mg/kg) and PQ-10 (0.3 mg/kg) attenuated the scopolamine-induced memory deficit. The 
MK-801-induced memory deficit was reversed after treatment with each PDE inhibitor at a 
dose of 1 mg/kg or higher. PQ-10 was highly brain penetrant, whereas 60-7550 levels in the 
brain were very low after oral treatment. We concluded that since BAY 60-7550 and PQ-10 
reversed both scopolamine- and MK-801-induced memory deficits, this supports the notion 
that dual substrate PDE inhibitors might be suitable candidates for cognition enhancement.   
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INTRODUCTION 
 
 Recently, phosphodiesterase inhibitors (PDE-Is) have gained increased attention as a 
possible cognition enhancer (for review see Blokland et al. 2006 and Chapter 2). So far, 
eleven subclasses of phosphodiesterases (PDEs) are identified and depending on the 
subclass they belong to, these enzymes hydrolyze cyclic adenosine monophosphate 
(cAMP) and/or cyclic guanosine monophosphate (cGMP). cAMP and cGMP are second 
messengers which play an important role in glutamatergic signal transduction, including 
processes underlying long term potentiation (LTP) (Bailey et al. 1996; Chien et al. 2003; 
Frey et al. 1993; Son et al. 1998), which is the proposed neurophysiological correlate of 
memory (Bliss and Collingridge 1993). Indeed, several PDE-Is have been found to increase 
e.g. neuronal excitability (Threlfell et al. 2009) and facilitate LTP (Boess et al. 2004). 
Furthermore, cAMP and cGMP are assumed to directly affect neurotransmitter release, 
including acetylcholine (Imanishi et al. 1997). It has indeed been shown that central 
application of analogues of these second messengers can have memory enhancing effects 
in rodents (e.g. Bernabeu et al. 1996; Matsumoto et al. 2006; Prickaerts et al. 2002). 
Therefore, PDE-Is may modulate learning and memory processes, as they are supposed to 
enhance second messenger signaling in the brain. 
 The pro-cognitive effects of novel compounds on memory processes are often 
assessed by means of pharmacological deficit models, which temporarily impair memory 
performance. A widely used model to study the effects of drug administration before the 
learning trial is the scopolamine model (for review see Klinkenberg and Blokland 2010). This 
anti-cholinergic agent has shown to impair memory in several behavioural tests including the 
object recognition task (ORT, e.g. Rutten et al. 2006; Schreiber et al. 2007). The ORT, also 
known as the novel object recognition (NOR) task, is a one trial learning test (Akkerman et 
al. 2012). In a previous study we have shown that the cAMP-selective PDE4-I rolipram 
reversed a scopolamine-induced memory deficit in the ORT in rats (Rutten et al. 2006). In 
addition, rolipram was shown to reverse the effects of scopolamine in several other 
behavioural tests (Egawa et al. 1997; Ghelardini et al. 2002; Imanishi et al. 1997; Zhang et 
al. 2000). In comparison to PDE4 inhibition, the literature on effects of dual substrate, i.e. 
both cAMP and cGMP, PDE-Is including those for PDE2 and PDE10 on memory processes 
in deficit models in the ORT are very limited. To our knowledge, only Van Donkelaar et al. 
(van Donkelaar et al. 2008) reported that the PDE2-I BAY 60-7550 given 30 min before T1 
can reverse a memory deficit caused by acute tryptophan depletion (ATD), which causes a 
temporal lowering of serotonin in the brain (e.g. van Donkelaar et al. 2008).  
 After scopolamine, the MK-801 induced memory deficit model is the second most 
commonly used deficit model used in preclinical cognition research (van der Staay et al. 
2011). MK-801 is an N-methyl-D-aspartic acid (NMDA) antagonist which impairs among 
others memory function and attention processes (e.g. Boess et al. 2004; van der Staay et al. 
2008; Zhang et al. 2000) and is therefore assumed to be more affiliated to cognitive deficits 
related to schizophrenia. Therefore, the MK-801 model (for review see van der Staay et al. 
2011) would be a useful addition to the scopolamine model, since recent studies (e.g. 
Grauer et al. 2009; Schmidt et al. 2008) have focused on PDE10 inhibition as a treatment 
for positive, negative and cognitive symptoms of schizophrenia. In addition, previous studies 
have demonstrated that PDE2-I, PDE4-Is and PDE9-I reverse MK-801 induced working 
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memory, social odor recognition or avoidance learning deficits in a variety of behavioural 
tasks in rodents (Boess et al. 2004; Grauer et al. 2009; van der Staay et al. 2008; Zhang et 
al. 2000; Zhang et al. 2005).  
 The aim of the present study was to further characterize the effects of PDE2-I and 
PDE10-I on memory function. Therefore, we investigated the effects of the PDE2-I BAY 60-
7550 and the PDE10-I PQ-10 on object recognition memory in scopolamine- and MK-801-
induced deficit models. PQ-10 belongs to the same class as the PDE10 inhibitor 
papaverine, but IC50 literature suggests that is about 5 times more potent then papaverine, 
yet still about 10 times less potent the known PDE10 inhibitors TP-10 and MP-10 (Alderton 
et al. 2009; Siuciak 2008). To our knowledge the PQ-10 inhibitor has not been tested before 
on cognitive behaviour. We also determined the amount of BAY 60-7550 and PQ-10 in the 
blood plasma and brain tissue after treatment to gain insight into their brain penetration 
properties. We hypothesized that both PDE-Is could reverse the effects of scopolamine and 
MK-801 in the ORT. To our knowledge, this is the first time effects of these two different 
putative cognition enhancing drugs are assessed in deficit models related to dementia and 
schizophrenia. 
 
METHODS AND MATERIALS 
 
Animals 
 
 All experimental procedures were approved by the local ethical committees for animal 
experiments of the Maastricht University or biocrea and met governmental guidelines. For 
the behavioural experiments, 24 four-month-old male Wistar rats (Harlan, Horst, The 
Netherlands) were used with average body weights of 498 g (± 5 (standard error of mean, 
SEM), batch 1) and 351 g (± 3 (SEM), batch 2) for respectively the scopolamine and the 
MK-801 experiments. The animals were housed individually in standard Makrolon cages on 
sawdust bedding in an air-conditioned room (about 20°C). They were kept on a 12/12-h 
reversed light/dark cycle (lights on from 19.00 to 7.00 h) and had free access to food and 
water. The rats were housed in the same room as where they were tested. A radio, which 
was playing softly, provided background noise in the room. All testing was done between 
9.00 and 18.00 h. Six animals were chosen randomly for the determination of BAY 60-7550 
and PQ-10 levels in blood plasma and brain. For the additional BAY 60-7550 experiment 
performed at biocrea, 9 two-month-old female Wistar rats (Charles River, Sulzfeld, 
Germany) were used with an average body weight of 200-300 g. The animals had free 
access to food and water. 
 
Treatment 
 
 Scopolamine hydrobromide and MK-801 hydrogen maleate (Sigma Aldrich, 
Zwijndrecht, The Netherlands) were prepared daily and dissolved in saline. Based on 
previous results (data not shown), a dose of 0.125 mg/kg was selected for MK-801 and a 
dose of 0.1 mg/kg for scopolamine, since these doses impaired recognition memory without 
affecting exploratory activity. Furthermore, these specific doses of scopolamine and MK-801 
are generally accepted as memory impairer in rodents, without causing sensorimotor 
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impairments or motivational effect (Klinkenberg and Blokland 2010; 2011; van der Staay et 
al. 2011), although possible additional effects on attention cannot be ruled out completely. 
Administration (1 ml/kg) was intraperitoneal (i.p.) (30 min before T1).   
 BAY 60-7550 and PQ-10 were first dissolved in 1.5 ml 100% ethanol with 2% Tween 
80. After extraction of ethanol via vaporization under N2 gas, the compounds were dissolved 
in 0.5% methylcellulose. BAY 60-7550 was tested at the doses of 0.3 - 3 mg/kg, PQ-10 was 
tested at the doses of 0.1 - 1 mg/kg in the scopolamine and 0.3 - 3 mg/kg in the MK-801 
model, respectively. Both compounds were given by oral gavage (p.o.) 30 min before T1 in 
an injection volume of 2 ml/kg. BAY 60-7550 was a kind gift from BAYER (Wuppertal, 
Germany) and PQ-10 was kindly donated by Johnson & Johnson (Beerse, Belgium). The 
experimenter was blind to the compounds and doses tested. Twenty-four animals (batch 1) 
were used for each condition in the scopolamine study; sixteen (batch 2) for the MK-801 
study. Of note, control conditions (saline, MK-801 and scopolamine) were always tested in 
24 animals as part of the training protocol (see below). Visual inspection of the rats following 
drug administration indicated no gross side effects (e.g. sensorimotor effects or sedation) 
following drug administration. 
 
Object recognition memory 
 
 The ORT was performed as described elsewhere (Ennaceur et al. 1997; Prickaerts et 
al. 1997). The apparatus consisted of a circular arena, 83 cm in diameter. Half of the 40 cm 
high wall was made of gray polyvinyl chloride, the other half of transparent polyvinyl 
chloride. Two objects were placed in a symmetrical position about 10 cm away from the gray 
wall. We used four different sets of objects: 1) a cone consisting of a gray polyvinyl chloride 
base (maximal diameter 18 cm) with a collar on top made of brass (total height 16 cm), 2) a 
standard 1 l transparent glass bottle (diameter 10 cm, height 22 cm) filled with water, 3) a 
solid metal cube (10.0 x 5.0 x 7.5 cm) with two holes (diameter 1.9 cm), and 4) a solid 
aluminium cube with a tapering top (13.0 x 8.0 x 8.0 cm). A rat could not displace the 
objects. Fluorescent red tubes and a light bulb provided a constant illumination of about 8 
lux on the floor of the apparatus and the light intensity was equal in the different parts of the 
apparatus. 
 A testing session comprised two trials. The duration of each trial was 3 min. During T1 
the apparatus contained two identical objects (samples). A rat was always placed in the 
apparatus facing the wall at the middle of the front (transparent) segment. After the first 
exploration period the rat was put back in its home cage. Subsequently, after a 
predetermined delay interval, the rat was put back in the apparatus for T2, but now with two 
dissimilar objects, a familiar one (the sample) and a new one. The times spent in exploring 
each object during T1 and T2 were recorded manually with a personal computer. 
 Exploration was defined as follows: directing the nose to the object at a distance of no 
more than 2 cm and/or touching the object with the nose. Sitting on the object was not 
considered as exploratory behaviour. In order to avoid the presence of olfactory trails the 
objects were always thoroughly cleaned with 70% ethanol. All combinations and locations of 
objects were used in a balanced manner to reduce potential biases due to preferences for 
particular locations or objects. 
INHIBITION OF PDE2 OR PDE10 REVERSES OBJECT MEMORY DEFICITS 
84 
 In several studies we have demonstrated that rodents show good object memory 
performance when a 1 h delay is interposed between T1 and T2 (Rutten et al. 2007a; van 
Donkelaar et al. 2008). However, when a 24 h delay interval is used, animals did not 
discriminate between the novel and familiar object in T2, indicating that they did not 
remember the object that was presented in T1 (Prickaerts et al. 2004; Rutten et al. 2007b). 
Using a 4 h delay, the discrimination performance was between the performance of the 1 h 
and 24 h delay, suggesting a delay-dependent forgetting in this task (Sik et al. 2003). In the 
present study a 1 h interval was used to test the memory enhancing effects of PDE-Is in the 
scopolamine and MK-801 deficit model.  
 In the first week, the animals were handled daily and adapted to the procedure in two 
days, i.e. they were allowed to explore the apparatus (without any objects) twice for 3 
minutes each day. Next, they were adapted to the testing and p.o. and i.p. administration 
procedures by a saline injection (2 ml/kg p.o., 1 ml/kg i.p.) 30 min before T1 until a stable 
discrimination performance was observed, i.e. a good discrimination at 1 h interval and no 
discrimination at 24 h interval (all animals performed as expected). After this, testing of the 
control conditions began, i.e. animals were treated with saline, scopolamine (0.1 mg/kg, i.p.) 
or MK-801 (0.125 mg/kg, i.p.) together with the vehicle of the PDE-Is (p.o.), 30 min before 
T1. Subsequently, BAY 60-7550 (0.3-3 mg/kg, p.o.) and PQ-10 (0.1-1 mg/kg p.o. in the 
scopolamine, 0.3-3 mg/kg p.o. in the MK-801 model) were tested in both deficit models. A 
wash-out period of at least one day was applied between testing session. The control 
conditions (saline, scopolamine and MK-801) were tested in 24 animals. In addition, each 
PDE-I was tested in 24 (scopolamine study, batch 1) or 16 (MK-801 study, batch 2) animals.  
 
Determination of BAY-60-7550 and PQ-10 levels in plasma and brain samples 
 
 BAY 60-7550 (1 mg/kg) and PQ-10 (1 mg/kg) were administered p.o. 30 min before 
blood collection (300 µl) from the saphenous vein into a heparinized tube (microcuvette 
CB300, Sarstedt, Germany). Sampled blood was centrifuged at 3000g for 10 min at 4 °C. 
After blood sampling, rats were killed by decapitation and the heads were immerged in liquid 
nitrogen for 5 s. Subsequently, the brain was removed and rinsed with distilled water. 
Plasma and brains were stored at -80 °C until compound determination took place.   
 Plasma and brain levels of BAY 60-7550 and PQ-10 were determined using a qualified 
research UPLC-MS/MS method. After solubilisation (with methanol) and protein precipitation 
(with acetonitrile), plasma and brain samples were quantified on a reversed phase UPLC-
column (Acquity UPLC C18 1.7 µ BEH, 50x2.1mm; Waters, Milford, US).  Mobile phases 
consisted of 0.1 % FA (solvent A) and acetonitrile (solvent B). Chromatographic separation 
was obtained by gradient elution (90 % solvent A; 10 % solvent B starting conditions to 10 % 
solvent A; 90 % solvent B in 1 min) at a flow rate of 0.8 ml/min. Total run time was 1.7 min. 
 UPLC-MS/MS analysis was carried out on a API-4000 MS/MS (Applied Biosystems, 
Toronto, Canada), which was coupled to an UPLC-system (Waters, Milford, US). The 
MS/MS, operated in the positive ion mode using the TurboIonSpray-interface (electrospray 
ionization), was optimized for the quantification of the compounds (MRM transition for BAY 
60-7550 was 477.2 > 459. MRM transition for PQ-10 was 404.2 > 258). The limit of 
quantification was determined for each compound separately; for BAY 60-7550 the limits 
were 0.2 ng/ml for plasma samples and 1 ng/g for brain samples; for PQ-10 the limits were 1 
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ng/ml and 10 ng/g respectively. The intra batch accuracy from independent QC samples 
was about 20% for plasma and brain samples. Brain samples were homogenized in milliQ-
water (1/10 w/w). 
 For the additional determination of the levels of the PDE2-I BAY 60-7550 in blood 
plasma and brain tissue, BAY 60-7550 (10 mg/kg) was dissolved in vehicle solution (5% 
ethanol 10% solutol in water) and was administered p.o. 30, 60 and 240 min before blood 
(200 µl) collection by puncture of the ophthalmic venous plexus into Brand-micro-
haematocrit-tubes applying a slight isoflurane anesthesia. Collected blood samples were 
centrifuged at 2000g for 10 min at 4 °C. After blood sampling, rats were killed by 
decapitation. The brain was removed, washed with cooled PBS buffer at 4 °C, dried with a 
paper towel and immerged into liquid nitrogen for 5-10 s. Plasma and brains stored at -80 °C 
until compound determination took place.   
 Plasma and brain levels of BAY 60-7550 were determined using a LC-ESI-MS/MS 
method. After solubilisation (with methanol) and protein precipitation (with acetonitrile), 
plasma and brain samples were quantified on a reversed phase HPLC-column (Luna C18, 
50x2 mm, 3 µm; Phenomenex, Germany). The mobile phases consisted of 1 mM 
ammonium acetate with 5% acetonitril (solvent A) and acetonitrile (solvent B). 
Chromatographic separation was obtained by gradient elution (90 % solvent A; 10 % solvent 
B starting conditions to 0 % solvent A; 100 % solvent B in 3 min) at a flow rate of 0.6 ml/min. 
 The LC-ESI-MS/MS analysis for BAY 60-7550 was carried out on a API-3000 triple 
quad mass spectrometer (Applied Biosystems, Toronto, Canada) with Turbo ion spray 
interface working in positive ion mode. The MS/MS system was coupled to a binary pump 
LC-system HP Agilent 1100 (Agilent Technologies, Santa Clara, US) and optimized for the 
quantification of the test compound BAY 60-7550 (MRM transition was 477.3 > 459.3). MRM 
transition for PQ-10 was 404.2 > 258). The determined limit of quantification for BAY 60-
7550 was 0.64 ng/ml and 0.64 ng/g for plasma and brain samples, respectively. 
 
Statistical analysis 
 
 The basic measures in the ORT were the times spent exploring an object during T1 and 
T2. Table 1 depicts how these measures of the ORT (e1, e2 and d2) were calculated. e1 
and e2 are measures of the total exploration time of both objects during T1 and T2 
respectively. d2 is considered as index measure of discrimination between the new and the 
familiar objects. In fact, d2 is a relative measure of discrimination that corrects for 
exploration activity (e2). Thus, there should be no differences in d2 indices between 
experiments with similar treatments at similar intervals.  
 
Table 1 Measures involved in the object recognition test. e1 is the measure of the time spent in exploring both 
identical objects (a1 and a2) in the first trial, and e2 is the measure of the time spent in exploring both the 
familiar (a) and new object (b) in the second trial; d2 is the measure of discrimination between the new and 
familiar objects 
Exploration Discrimination 
e1 = a1 + a2  
e2  = a + b d2 = (b – a) / e2 
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 One-sample t-statistics were performed in order to assess whether d2 differed from 
zero per treatment condition (within comparison). Effects between the different conditions 
were assessed by one-way ANOVA (between comparisons). In case of a statistically reliable 
dose effect, comparisons between means of the different doses were analyzed in more 
detail using post hoc Bonferroni t-tests. 
 
RESULTS 
 
Effects of BAY 60-7550 and PQ-10 on scopolamine-induced memory deficits 
 
 The results of the BAY 60-7550 and PQ-10 treatment, 30 min before T1, are 
summarized in Table 2. No differences were observed between treatment conditions in the 
level of exploration in T1 (e1: F (7,191) = 1.41, n.s.) or T2 (e2: F(7,191) = 0.15, n.s.).  
 
Table 2 Effects of treatment with BAY 60-7550 and PQ-10 in the scopolamine-induced memory deficit model 
on exploration time. Drug administration (p.o.) was 30 min before T1. The delay interval between T1 and T2 
was 1 h. Mean values (± SEM) of total exploration time (s) during T1 (e1) and T2 (e2).  n = 24 per condition. 
BAY = BAY 60-7550, PQ = PQ-10, scop = scopolamine; all in mg/kg. No differences from the scopolamine 
condition were found 
PO vehicle vehicle BAY 0.3 BAY 1 BAY 3 PQ 0.1 PQ 0.3 PQ 1 
IP saline scop scop 0.1 scop 0.1 scop 0.1 scop 0.1 scop 0.1 scop 0.1 
e1 17.15 
(1.26) 
16.76 
(1.32) 
18.98 
(1.32) 
18.62 
(1.27) 
19.22 
(1.27) 
17.83 
(0.91) 
19.60 
(1.22) 
21.15 
(1.16) 
e2 20.15 
(9.00) 
20.34 
(2.57) 
21.06 
(1.53) 
19.16 
(1.03) 
19.83 
(1.44) 
19.88 
(1.18) 
19.50 
(1.41) 
19.70 
(1.11) 
 
 The effects of BAY 60-7550 and PQ-10 treatment on the relative discrimination index 
d2 are presented in Figure 1. One sample t-tests showed that d2 values of the saline, 1 - 3 
mg/kg BAY 60-7550 and 0.3 - 1 mg/kg PQ-10 conditions differed from zero. In contrast, the 
scopolamine, 0.3 mg/kg BAY 60-7550 and 0.1 mg/kg PQ-10 conditions showed no 
differences from zero. When comparing between groups, differences were found for the d2 
index (F(7,191) = 18.87, P < 0.001). Accordingly, the d2 values for the saline, 1 – 3 mg/kg 
BAY 60-7550 and 0.3 – 1 mg/kg PQ-10 conditions were higher than for the scopolamine, 0.3 
mg/kg BAY-60-7550 and 0.1 mg/kg PQ-10 conditions (Bonferroni t-tests, see Figure 1). 
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Figure 1 Effects of BAY 60-7550 and PQ-10 on discrimination performance (d2) the ORT (means ± SEM). All 
drugs were given 30 min before T1. Interval was 1h. BAY 60-7550 as well as PQ-10 completely reversed the 
scopolamine-induced memory deficit. A difference from the scopolamine condition is depicted with asterisks 
(Bonferroni t-tests, **: P < 0.01; ***: P < 0.001). A difference from zero is depicted with # (one sample t-tests, 
###: P < 0.001). n=24 per condition 
 
Effects of BAY 60-7550 and PQ-10 on MK-801-induced memory deficits 
 
 The results of the BAY 60-7550 or PQ-10 treatment, 30 min before T1 in combination 
with MK-801, are summarized in Table 3. Differences between treatment were observed in 
the level of exploration in T1 (e1: F(7,143) =  5.49, P < 0.001.). When comparing between 
groups with a post hoc analysis (Bonferroni t-tests, P < 0.05), the level of exploration in T1 
in the 0.3 and 1 mg/kg PQ-10 condition was higher than in the saline condition. Also, the 
level of exploration in T1 was higher in the 3 mg/kg PQ-10 than in the other conditions, 
except for 0.3 and 1 mg/kg PQ-10. In T2, no differences were observed between treatment 
conditions in the level of exploration (e2: F(7,143) = 1.90, n.s.).  
 The effects of BAY 60-7550 and PQ-10 (injected 30 min before T1) on the relative 
discrimination index d2 are presented in Figure 2. One sample t-tests showed that the d2 
value of the saline, BAY 60-7550 1-3mg/kg and PQ-10 1-3 mg/kg condition differed from 
zero, in contrast to the MK-801, BAY 60-7550 0.3 mg/kg and PQ-10 0.3 mg/kg conditions. 
Accordingly, when comparing between groups, differences were found for the d2 index 
(F(7,143) = 9.05, P < 0.001). Bonferroni post hoc t-tests (P < 0.05) comparisons revealed 
that the d2 values were higher in the saline, BAY 60-7550 1 - 3 mg/kg and PQ-10 1-3 mg/kg 
conditions than in the MK-801 and PQ-10 0.3 mg/kg conditions. In addition, the d2 was 
higher in saline than in the BAY 60-7550 0.3 mg/kg condition. 
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Table 3 Effects of treatment with BAY 60-7550 and PQ-10 in the MK-801-induced memory deficit model on 
exploration time. Drug administration (p.o.) was 30 min before T1. The delay interval between T1 and T2 was 1 
h. n = 24 per vehicle condition, n = 16 per experimental condition. Mean values (± SEM) of total exploration 
time (s) during T1 (e1) and T2 (e2). BAY = BAY 60-7550, PQ = PQ-10, MK = MK-801; all in mg/kg. A 
difference from the MK-801 condition is depicted with asterisks (Bonferroni t-tests, **: P < 0.01) 
PO vehicle vehicle BAY 0.3 BAY 1 BAY 3 PQ 0.3 PQ 1 PQ 3 
IP saline MK MK 
0.125 
MK 
0.125 
MK 
0.125 
MK 
0.125 
MK 
0.125 
MK 
0.125 
e1 15.35 
(1.17) 
17.18 
(1.27) 
18.06 
(1.60) 
18.64 
(1.66) 
18.42 
(1.38) 
23.18 
(1.80) 
23.03 
(1.78) 
26.38 
(2.38)** 
e2 17.94 
(0.92) 
19.08 
(1.14) 
19.24 
(1.28) 
22.44 
(2.13) 
20.99 
(2.20) 
22.00 
(1.88) 
22.28 
(1.79) 
24.25 
(1.63) 
 
 
Figure 2 Effects of BAY 60-7550 and PQ-10 on discrimination performance (d2) in the ORT (means ± SEM). 
All drugs were given 30 min before T1; interval was 1h. BAY 60-7550 and PQ-10 completely reversed the MK-
801-induced memory deficit. A difference from the vehicle/MK-801 condition is depicted with asterisks 
(Bonferroni t-tests, *: P < 0.05; **: P < 0.01; ***: P < 0.001). A difference from zero is depicted with # (one 
sample t-tests, ###: P < 0.001). n=24 per vehicle condition, n=16 per experimental condition 
 
Determination of BAY-60-7550 and PQ-10 levels in plasma and brain samples 
 
 The concentrations of BAY 60-7550 or PQ-10 in plasma and brain tissue, 30 min after 
oral treatment, are summarized in Table 4. BAY 60-7550 concentrations were 0.9 ng/ml in 
plasma, but were undetectable in brain tissue. PQ-10 concentrations were 77.7 ng/ml in 
plasma and 51.3 ng/g in the brain. Since the dosage of BAY 60-7550 used in our 
behavioural experiments (1 mg/kg) resulted in a concentration that was below quantification 
limit in the brain tissue, we performed an additional experiment with a higher dose of BAY 
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60-7550 (10 mg/kg) administered at various time intervals (30 min, 60 min and 240 min 
before sampling) to check whether BAY 60-7550 was able to penetrate the blood-brain 
barrier (BBB) at all (see Table 5).  
 
Table 4 Concentration of BAY 60-7750 or PQ-10 in plasma or brain tissue. Effects of BAY 60-7550 (1 mg/kg, 
p.o.) or PQ-10 (1 mg/kg, p.o.) treatment on their concentrations in plasma or brain tissue 30 min after 
administration (means ± SEM). n = 3 per condition. BQL = below quantification limit 
Compound Plasma (ng/ml) Brain (ng/g) 
BAY 60-7550 0.9 (0.1) BQL 
PQ-10 77.7(23.8) 51.3 (9.0) 
 
Table 5 Concentration of BAY 60-7750 in plasma or brain tissue. Effects of BAY 60-7550 (10 mg/kg, p.o.) 
treatment on its concentrations in plasma or brain tissue at different time points (30, 60 and 240 min) after 
administration (means + SEM). n = 3 per condition 
Compound Plasma (ng/ml) Brain (ng/g) 
BAY 60-7550   
t=30 min 72.9 (28.6) 3.6 (1.6) 
t=60 min 61.4 (25.5) 3.5 (1.4) 
t=240 min 7.5 (2.0) 0.3 (0.3) 
 
DISCUSSION 
 
 It was demonstrated that after a 1 h interval, rats in the saline condition still 
remembered the familiar object whereas scopolamine (0.1 mg/kg) and MK-801 (0.125 
mg/kg) conditions disrupted object memory. Furthermore, the scopolamine-induced object 
memory deficit was reversed by oral co-treatment with either the PDE2-I BAY 60-7550 or 
the PDE10-I PQ-10, at a minimal effective dose (MED) of 1 and 0.3 mg/kg, respectively. In 
addition, the MK-801-induced deficit was reversed by both PDE2-I and PDE10-I at a MED of 
1 mg/kg. At present, we have no valid explanation why PQ-10 appears to be more potent in 
the scopolamine model as compared to the MK-801 model. 
 Scopolamine, MK-801 and BAY 60-7550 had no effect on exploratory activity of the 
animals whereas PQ-10 increased object exploration time in T1 in the MK-801 model. In 
general, PDE10-Is are known to have either no effect on exploratory activity, decrease 
locomotor activity or induce catalepsy (Grauer et al. 2009; Schmidt et al. 2008; Siuciak et al. 
2006a). However, MK-801 is known to affect locomotor activity (e.g. Andine et al. 1999; 
Brosnan-Watters et al. 1996), so the effect on exploratory activity in our study could partly 
be explained by a possible interaction between MK-801 and PQ-10. Of note, since the d2 
index is a relative measure of discrimination that corrects for exploration activity, these 
changes in exploration will not affect the object recognition index.  
 It was shown that the behaviourally active dose of 1 mg/kg PQ-10 was present in blood 
plasma and brain tissue 30 min after oral administration, unlike the corresponding dose of 1 
mg/kg BAY 60-7550 that was only detectable in the blood. Increasing the dose of BAY 60-
7550 up to 10 mg/kg resulted in a brain concentration of 3.6 ng/g. Based on the brain-
plasma concentration ratio of 0.05 calculated after administration of 10 mg/kg BAY 60-7550 
it can be estimated that the brain concentration 30 min after administration of 1 mg/kg BAY 
60-7550 would be 0.045 ng/g. This is below the detection limit of 1 ng/g of our quantification 
for BAY 60-7550. Of note, the approximate cerebral blood volume relative to total 
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unperfused brain volume is 0.04 (Hitchcock and Pennington 2006). Considering the 
averaged brain-plasma concentration of 0.05, this raises the question whether BAY 60-7550 
enters the brain substantially. PQ-10 is clearly brain penetrant with a brain-plasma ratio of 
0.66. Yet, it can be taken into consideration that PDE2 is the type of PDE with the highest 
mRNA expression in brain structures implicated in objection recognition memory (Lakics et 
al. 2010) (see also below), thus probably low brain concentrations could probably be 
sufficient to have a biological effect. Furthermore, BAY 60-7550 could affect cyclic 
nucleotide signal cascades by increasing the levels of cAMP and cGMP, which do not 
necessarily need high levels at the beginning, but may eventually cause biological 
responses because of signal amplification in the cascades. Nevertheless, the lack of a clear 
penetration of BAY 60-7550 into the brain raises the question whether an additional or 
alternative mechanism might be causing the memory improvements after PDE2-I treatment. 
It might be speculated that an active metabolite penetrates the BBB. In addition, it might be 
argued that PDE2 inhibition exerts a peripheral (e.g. cardiovascular) effect which improves 
memory function.    
 Only a limited number of studies have investigated the effects of PDE2 inhibition on 
memory. Boess et al. (2004) demonstrated that administration of 3 mg/kg BAY 60-7550 
(p.o.) 30 min before the test session reversed a MK-801-induced working memory deficit in 
the T-maze in mice. Our findings that BAY 60-7550 improved memory processes is in line 
with previous findings in which the compound was given before the learning trial (Domek-
Lopacinska and Strosznajder 2008; van Donkelaar et al. 2008). As such, Domek-
Lopacinska and Strosznajder (2008) demonstrated that 0.3 mg/kg BAY 60-7550 (1 h before 
T1, s.c.) enhanced object memory in 3- and 12-month old rats using a 2 h delay interval 
after which the animals did not remember the objects presented in T1. Furthermore, Van 
Donkelaar et al. (2008) showed that administration of this PDE2-I 30 min before T1 (3 
mg/kg, p.o.) reversed an ATD-induced STM deficit in the ORT.  
 The role of PDE10 in learning and memory has been investigated by means of PDE10 
knock-out (KO) as well as PDE10-I treated control animals in a variety of tasks. Siuciak and 
co-workers (2006b; 2008) found that learning and memory in the passive avoidance and 
water escape task were unaffected in PDE10A KO mice on a DBA1LacJ background. 
Furthermore, these animals displayed the same conditioned avoidance response as wild-
type (WT) mice although they required more training (Siuciak et al. 2006b; Siuciak et al. 
2008). However, PDE10A KO mice on a C57BL/6N background were unable to reach the 
level of performance of the WT animals (Siuciak et al. 2008). Hebb et al. (2008) 
demonstrated that chronic treatment with the PDE10-I papaverine impaired learning and 
memory in the water escape task in WT mice and discussed that this could be explained by 
increased perseveration and impaired locomotor activity. This in contrast to acute treatment 
with PDE10-Is papaverine (10 and 30 mg/kg, p.o.) and MP-10 (3 mg/kg, p.o.) immediately 
after training which reversed a MK-801 induced memory deficit (0.1 mg/kg, i.p.) in social 
odor recognition in CF-1 mice (Grauer et al. 2009). Furthermore, it was shown that 
papaverine (10 - 30 mg/kg, i.p.) improved memory in the ORT if given 30 min before training 
in a 48 h delay interval in rats and MP-10 was also effective, though only a strong trend 
toward significance at the lowest dose tested (0.1 mg/kg, i.p.) (Grauer et al. 2009). These 
positive findings are supported by our PQ-10 data in the ORT. 
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 The brain regions involved in object recognition are the hippocampus and the rhinal 
cortices. Although there is some debate about the exact roles of each brain region, the 
hippocampus is considered as the site where object information from the perirhinal cortex is 
integrated with contextual information from the parahippocampal (or postrhinal in rats) 
cortex, thus underlying the formation of episodic memory (e.g. Aggleton and Brown 2006; 
Eichenbaum et al. 2007; Melichercik et al. 2012; Mumby 2001; Winters and Bussey 2005; 
Wixted and Squire 2010). It was demonstrated that the levels of PDE2 protein expression 
are highest in the hippocampus, cortical areas, basal ganglia, substantia nigra, amygdale, 
interpeduncular nucleus and medial habenula in rats (Stephenson et al. 2009). Furthermore, 
Van Staveren et al. (2004; 2003) showed that PDE2 mRNA was distributed widely 
throughout the brain, including the hippocampus, cortex, striatum, amygdale and medial 
habenula in rodents. In addition, it was demonstrated that incubation of hippocampal slices 
with PDE2-Is resulted in a dose-dependent increase of cAMP and cGMP (Boess et al. 2004; 
van Staveren et al. 2001). In addition, PDE2 protein distribution in human, primate, dog and 
mouse cortex was shown to be similar to that in the rat cortex (Sadhu et al. 1999; 
Stephenson et al. 2009). In line with these findings, PDE2 mRNA expression was observed 
in the cortex, hippocampus, caudate, putamen, nucleus accumbens and claustrum to a 
similar extend in healthy adults, patients with Alzheimer’s disease and age matched controls 
(Lakics et al. 2010; Reyes-Irisarri et al. 2007). The positive effects of PDE2 inhibition on 
memory performance combined with the protein and mRNA expression data, suggests that 
it might be a suitable target for cognition enhancement for Alzheimer’s disease patients. 
Additionally, treatment of cognitive deficits in schizophrenia could also be considered since 
BAY 60-7550 was effective in our glutamatergic MK-801 memory deficit model. 
 PDE10A localization showed some overlap with the localization of PDE2 although 
PDE10A is much more pronouncedly expressed in the striatum. Immunohistochemistry 
showed that PDE10A is expressed predominantly in the nucleus accumbens, caudate 
nucleus, globus pallidus and substantia nigra, and to a lower extent in the CA regions of the 
hippocampus, dendate gyrus, cortex, thalamus and cerebellar granule cell layer in 
macaques, dogs and rodents (Coskran et al. 2006; Seeger et al. 2003). Studies 
investigating PDE10A mRNA expression in rodents and humans demonstrated similar 
results (Fujishige et al. 1999; Lakics et al. 2010; Loughney et al. 1999; Soderling et al. 1999) 
except for the globus pallidus and substantia nigra where PDE10A was barely detected 
(Seeger et al. 2003). In addition, it was found that administration of PDE10-Is MP-10 and 
TP-10 dose-dependently increased cAMP and cGMP in the striatum (other brain regions 
were not investigated) (Grauer et al. 2009; Schmidt et al. 2008), whereas the results for the 
less selective PDE10-I papaverine vary (Schmidt et al. 2008; Siuciak et al. 2006a). 
Recently, PDE10 has become a target for treating the positive, negative and cognitive 
symptoms of schizophrenia. It has been demonstrated that the positive effects of PDE10-Is 
are not limited to learning and memory, but also includes prepulse inhibition and auditory 
sensory gating (Grauer et al. 2009; Schmidt et al. 2008), and executive functioning (Rodefer 
et al. 2005; Rodefer et al. 2012) as well. Furthermore, PDE10 inhibition disrupted 
conditioned avoidance responding, which is a preclinical model predictive of antipsychotic 
activity, improved social approach/social avoidance performance and showed less 
susceptibility to extrapyramidal side effects in rodents (Grauer et al. 2009; Schmidt et al. 
2008; Siuciak et al. 2006a). In addition, PQ-10 was effective in a low dose in our cholinergic 
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scopolamine memory deficit model. This would suggest that PDE10 inhibition could be 
considered as treatment of cognitive deficits in Alzheimer’s disease. Further research using 
transgenic mouse models of Alzheimer’s disease would be needed to confirm this. 
 Based on the present findings, we conclude that BAY-60-7550 and PQ-10 completely 
reversed the scopolamine-induced object memory deficit at a dose of 1 – 3 mg/kg and 0.3 - 
1 mg/kg, respectively. In addition, both compounds completely reversed the MK-801-
induced object memory deficit at a dose of 1 mg/kg onward. It can be argued that increased 
levels of cAMP and cGMP in the brain underlie the observed object memory improvement 
after treatment with BAY 60-7550 or PQ-10, although it has to be noted that brain 
penetration of BAY 60-7550 is poor. Taken together, our findings support the notion that 
PDE2 and PDE10 inhibition might offer a promising therapeutic tool for memory 
enhancement in Alzheimer’s disease and schizophrenia, respectively.  
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ABSTRACT 
  
 Sensory gating is an adaptive mechanism of the brain to prevent overstimulation. 
Patients suffering from clinical disorders such as Alzheimer’s disease or schizophrenia 
exhibit a deficit in gating, which indicates an impairment in basic information processing that 
might contribute to the cognitive problems seen in these patients. Phosphodiesterase type 5 
inhibitors (PDE5-Is) have been shown to improve cognition in rodents in various behavioural 
tasks and might consequently be an interesting target for cognition enhancement. However, 
the effects of PDE5-Is on sensory gating are not known yet. Our objective was to study the 
effects of PDE5 inhibition on auditory sensory gating in rats and humans. In the rat study 
vehicle or 0.3-3 mg/kg of the PDE5-I vardenafil was given orally 30 min before testing and 
electrode locations were the vertex, hippocampus and the striatum. The human subjects 
received placebo, 10-20 mg vardenafil 85 min before testing and sensory gating was 
measured at the cortex (Fz, FCz and Cz) electrodes. Significant gating was only found for 
the N1 component in rats, while all three peaks P1, N1 and P2 showed gating in humans, 
i.e. the response to the second sound click was decreased as compared to the first for these 
deflections. Administration of vardenafil did neither have an effect on sensory gating in rats 
nor in humans. These findings imply that positive effects of PDE5 inhibition on cognition are 
not mediated by more early phases of information processing. 
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INTRODUCTION 
 
 Sensory gating is an automatic process involved in information processing. More 
specifically it is an adaptive mechanism of the central nervous system that prevents 
overstimulation of higher cortical areas and helps filtering sensory information (e.g 
(Cromwell et al. 2008)). The standard paradigm assessing this mechanism consists of two 
identical auditory stimuli that are presented with an inter-stimulus interval (ISI) between 0.5-
2 s and an inter-trial interval (ITI) of at least 8 s (Cromwell et al. 2008; Hajos 2006). In 
healthy individuals – humans as well as animals - the response to the second stimulus (S2) 
will be smaller than the response to the first stimulus (S1). Of note, the duration of the ISI is 
crucial; if it is shorter than 0.5 s or longer than 2 s, sensory gating will not be elicited. 
Extensive research has shown that the process of sensory gating is disrupted in patients 
suffering from clinical disorders including schizophrenia and Alzheimer’s disease (e.g. Adler 
et al. 1982; Ally et al. 2006; Javitt 2009; Jessen et al. 2001). 
 The responses evoked by this auditory sensory gating paradigm can be assessed using 
electroencephalographic (EEG) and event-related potential (ERP) measurements. In 
humans, the P50, also known as P1, is considered to be the main ERP component related 
to sensory gating (e.g. Chang et al. 2011; Dalecki et al. 2011). In addition, the N100 (N1) 
and P200 (P2) might also be affected (e.g. Boutros et al. 2009; Lijffijt et al. 2009). There is 
still a debate about which ERP component in rats is possibly the functional equivalent of the 
P50 in humans. Some researchers suggest that the P13 (P1) (e.g. Miyazato et al. 1999) is 
the most suitable candidate, whereas others assume it is the N40 (N1) or P60 (P2) (e.g. 
Mears et al. 2006; Zhou et al. 2008). It has also been suggested that the entire P1-N1-P2 
complex is involved in the auditory sensory gating paradigm in rats just as in humans (e.g. 
Broberg et al. 2010; Mears et al. 2009). 
 Recently, phosphodiesterases (PDEs) gained increased attention as a promising target 
for cognition enhancement. Depending on the enzyme subclass they selectively hydrolyze 
the second messengers cyclic adenosine monophosphate (cAMP) and/or cyclic guanosine 
monophosphate (cGMP) (Bender and Beavo 2006). It has been shown that drugs that 
prevent the breakdown of these PDEs, the so-called PDE inhibitors (PDE-Is), improve 
cognition in animals in a wide range of behavioural tasks (for review see Chapter 2). Since 
the cyclic guanosine monophosphate (cGMP) specific phosphodiesterase type 5 inhibitors 
(PDE5-Is) are clinically approved for treatment of erectile dysfunction, they can be tested in 
animals as well as humans, which makes them particularly interesting from a translational 
perspective. It has already been shown that PDE5 inhibition has a positive effect on a 
variety of cognitive processes in animals, including learning (e.g. Devan et al. 2006; Devan 
et al. 2007), memory (e.g. Chapter 3 and Prickaerts et al. 2002b; Rutten et al. 2007; van 
Donkelaar et al. 2008), executive functioning and response inhibition (Rutten et al. 2008). In 
contrast, only a limited number of studies investigated the effects of PDE5-Is on cognition in 
humans. Three of those studies did not show any effects of PDE5 inhibition on cognitive 
performance in healthy adults (Grass et al. 2001; Schultheiss et al. 2001) and patients with 
schizophrenia (Goff et al. 2009) respectively. Yet, EEG measurements in healthy adults 
indicated that there might be an effect of treatment with the PDE5-I sildenafil on attention 
(Schultheiss et al. 2001). Interestingly, it has recently been demonstrated that repeated 
dosing of the PDE5-I Udenafil improves the cognitive performance of patients suffering from 
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a erectile dysfunction on a modified version of the mini-mental state examination and an 
assessment battery addressing frontal executive functioning (Shim et al. 2011).  
 In our present study, we investigated the effects of PDE5 inhibition on sensory gating in 
rats and humans. Rats were included because of the extensive learning and memory 
enhancing effects that have already been reported in rodents while to our knowledge basic 
auditory information processing has not been studied yet after PDE5 inhibition. Likewise, the 
effects on sensory gating in humans were studied to gain further insight into the effects of 
PDE5 inhibition on information processing in humans, but also to see whether the drug 
effects found in rodents can be translated to the human situation and vice versa. It has 
indeed been shown that the ERPs of humans and rats show a substantial amount of 
similarities (e.g. Sambeth et al. 2003). Based on these findings we expect that the effects of 
drugs on these ERPs are comparable between humans and animals (Maxwell et al. 2004). 
First, we tested whether our paradigm elicited sensory gating. Next, the effects of the PDE5-
I vardenafil on sensory gating were investigated. It was chosen to test 0.3-3 mg/kg 
vardenafil in rats since this dose range is mostly used in a wide array of behavioural tasks 
(e.g. Chapter 3 and Prickaerts et al. 2004; Prickaerts et al. 2002b; Rutten et al. 2007; Rutten 
et al. 2009). We included the vertex, hippocampus and striatum as electrode locations 
because of their involvement in sensory gating. The vertex was chosen to represent the 
cortex since the EEG signal at this location is relatively comparable to that at a similar 
location in humans. We recorded EEG from the Fz, FCz and Cz (vertex) locations in 
humans (see (Jasper 1958)) and used 10 mg and 20 mg because these are the dosages 
commonly used in humans.  
 
METHODS AND MATERIALS  
 
Animal study 
 
Animals 
 
 All experimental procedures were approved by the local ethical committee for animal 
experiments of Maastricht University and met governmental guidelines. Thirteen 3-month-
old male Wistar rats (Harlan, The Netherlands) were used with average body weights of 385 
g (± 12.50). The animals were housed individually in standard Makrolon cages on sawdust 
bedding in an air-conditioned room (about 20°C). They were kept on a 12/12-h reversed 
light/dark cycle (lights on from 19.00 to 7.00 h) and had free access to food and water. The 
rats were housed in the same room as where they were tested. All testing was done 
between 9.00 and 18.00 h in a shielded Skinnerbox. 
 
Surgery and EEG recordings 
 
 The animals received 0.1 ml/kg Temgesic (Schering-Plough B.V., Utrecht, The 
Netherlands) subcutaneously 30 min before surgery as analgesia. Forene isoflurane (Abbott 
B.V., Hoofddorp, The Netherlands) was used as a general inhalation anesthetic. After the 
animal was placed into the stereotactic apparatus and an incision was made to expose the 
skull, lidocaine was applied as additional local anesthesia. Next, bregma was identified and 
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the electrodes were placed in the striatum (AP 0.48, ML -3.0, DV -5.0), dorsal hippocampus 
(AP -2.8, ML -1.8, DV -2.6) and vertex (AP -3.5, ML -1.0, DV -1.0) (Paxinos and Watson 
1998). The reference and ground electrodes were both placed in the cerebellum. The 
electrodes and the connector were fixed to the skull by using three screws and Paladur 
denture acrylic (Heraeus Kulzer, Hanau, Germany). The animals were given at least two 
weeks to recover from the surgery. 
 In the first week after recovery, the animals were handled daily and adapted to the 
procedure, i.e. they were connected to the EEG set-up and allowed to explore the 
Skinnerbox in which the recording would take place. In addition the rats were adapted to 
p.o. administration procedures by saline injections (2 ml/kg). Next, the control condition was 
tested, i.e. animals were treated with placebo; this was tested twice and averaged for the 
statistical analysis. Subsequently three doses of the PDE5-I vardenafil were randomly tested 
(0.3, 1, 3 mg/kg, p.o.). The sensory gating paradigm consisted of 70 pairs of auditory stimuli 
which were presented with stimulus duration of 10 ms, ISI of 500 ms and ITI 6-10 s. The 
EEG signal was sampled at 1000 Hz, filtered between 1 - 133.5 Hz and stored on a 
personal computer. The stimuli were 2500 Hz clicks with a sound intensity of 80 dB. Since 
the animals were tested in a sound attenuated room with a maximal background noise level 
of 20 dB, the level of our stimulus salience was approximately 60 dB. After the study was 
finished, the animals were killed by decapitation and the brains were taken out. The brains 
were stored in 4% formaldehyde at 4-6 ºC until electrode localization took place. 
 
Treatment 
 
 Vardenafil was first dissolved in 1.5 ml ethanol with 2% Tween 80. After extraction of 
ethanol via vaporization under N2 gas, the compounds were dissolved in 0.5% 
methylcellulose. The compound was tested at a dose of 0.3-3 mg/kg and administered by 
oral gavage (2 ml/kg) 30 min before testing. Vardenafil was kindly donated by BAYER 
(Wuppertal, Germany). The experimenter was blind to the compound and doses tested. All 
animals were treated with each condition once, except for the control condition (placebo), 
which was tested twice as part of the training.  
 
Electrode localization 
 
 In order to verify the localization of the striatal and hippocampal electrode, coronal 
slices (50 µm) were made with a vibratome and put on glass slides. Next, a hematoxyline 
and eosine (HE) staining was applied and the slices were inspected under a microscope. If 
the localization of the hippocampal or striatal electrode could not be verified and/or the raw 
data did not show the typical delta and theta waves in the hippocampal EEG, the animal 
was excluded for that part of the analyses (number of animals mentioned in the results 
section). Since the vertex electrode measures the EEG signal at the cortical surface, there 
was no need for localization. 
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Statistical analysis 
 
 Segments between 100ms before until 500ms after stimulus onset were made for each 
stimulus type (S1 and S2) separately, using the last 100 ms before onset as baseline. High 
pass (1Hz) and low pass (30 Hz) filters were applied. The segments were visually checked 
and removed from the data set if a movement artefact occurred within 500 ms after stimulus 
presentation. Both the grand average (all animals) and the individual data (single animal) 
were used to determine the auditory evoked potential (AEP) components. In general, P1 
was defined as most positive value between 20 and 50 ms after stimulus onset. N1 was the 
most negative value between 50 – 80 ms for the vertex and between 40 – 70 ms for the 
striatum and hippocampus. Finally, P2 was defined as most positive value between 65 - 105 
ms for the vertex and between 55 – 90 ms for the striatum and hippocampus.  
 General linear models (GLM) repeated measures were used to analyze the amplitudes 
of the components. First, the responses to the S1 and S2 were compared for the vehicle 
condition to see whether sensory gating occurred. Next, the responses to the PDE-Is 
conditions were compared to placebo condition for each stimulus (treatment) separately as 
well as for both stimuli together (treatment x stimulus). In case of a statistically reliable 
effect, comparisons between means of the conditions were analyzed in more detail using 
post hoc Bonferroni t-tests (P < 0.05). Two animals were excluded from the analysis of the 
vertex and the striatum electrodes because of no reliable EEG signal. 
 
Human study 
 
Participants 
 
 All experimental procedures were approved by the independent Ethics Committee of 
Maastricht University and the Academic Hospital Maastricht (The Netherlands). Eighteen 
participants (21 ± 0.7 years old, 5 males) were recruited through advertisements at 
Maastricht University. They had to be willing to sign an informed consent and were paid for 
their participation.  
 The subjects’ physical and mental health was checked by a physician by means of a 
standard medical questionnaire and a medical examination.  Subjects were excluded if they 
suffered from or had a history of cardiac, hepatic, renal, pulmonary, neurological, 
gastrointestinal, haematological or psychiatric illness. Other exclusion criteria were 
excessive drinking ( > 20 glasses of alcohol containing beverages a week), pregnancy or 
lactation, use of medication other than oral contraceptives, use of recreational drugs from 2 
weeks before until the end of the experiment, and any sensory or motor deficit which could 
reasonably be expected to affect test performance. In addition, subjects who had a first-
degree relative with (history of) a psychiatric disorder were excluded as well. The 
participants could leave the study at any given time without any consequence.  
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EEG recordings 
 
 An EEG cap was used to place a set of 32 EEG electrodes according to the 
international 10-20 system (Jasper 1958). Only the Fz, FCz and Cz locations were used in 
the current study since it has been demonstrated previously that midline electrodes show 
better P50 sensory gating than left/right hemispheric sites, especially the Cz (vertex) and 
FCz electrodes (Wan et al. 2006). In addition, the Fz electrode has been demonstrated to 
show a similar amount of P200 gating and was therefore included as well (Wan et al. 2007). 
A reference and a ground were placed at the linked mastoids and at the forehead, 
respectively. Eye movements were detected by horizontal and vertical electro-oculogram 
(EOG) recordings. Before electrode attachment, the positions were cleaned with alcohol and 
slightly scrubbed with a gel in order to provide a good measurement. Both EEG and EOG 
were filtered between 0.01 and 100 Hz and sampled at 1000 Hz. 
 The sensory gating paradigm consisted of 60 pairs of identical auditory stimuli with a 
duration of 3 ms and intensity of 80 dB. Since testing took place in a sound attenuated room 
with a maximal background noise level of 20 dB, the stimulus salience was approximately 
60 dB. The interval between the first (S1) and the second (S2) stimulus was 500 ms; the 
interval between pairs was randomized between 6 – 10 s. The subjects were familiarized 
with this test during a training session. 
    
Design and treatment 
 
 The study was conducted according to a double-blind, placebo-controlled, 3-way cross-
over design. Order of treatments was balanced over three test days and separated by a 
washout period of at least 7 days. The balancing of the treatment order was be 
accomplished by counterbalancing.  
 Treatment consisted of a placebo, 10 mg vardenafil HCl (Levitra), or 20 mg vardenafil 
HCl (Levitra) and was within the range of dosages (5-20 mg) approved for human use 
(EMEA 2008). Previous studies have shown that peak plasma levels of vardenafil were 
reached 30-120 minutes (median 60 min) after a single dose of 20 mg vardenafil; the 
terminal half-life was around 4-5 hours (EMEA 2008). Since this study was part of a larger 
experiment consisting of multiple tasks, our sensory gating paradigm was tested 85 minutes 
after drug treatment. The drugs were ingested orally and combined with a low-fat breakfast, 
because fatty food might affect the absorption of vardenafil. The experimenter and subjects 
were blind to the compound and doses tested.  
 
Medical questionnaire 
 
 A medical questionnaire was presented to the subjects twice each testing day: directly 
before ingesting the compound/placebo (baseline) and approximately 100 minutes later 
(during a short break) (treatment). This questionnaire addressed 31 physical complaints, 
including headache, nausea, dry mouth, blurred vision and dizziness. Participants could 
indicate on a four point scale to what extent these items applied to their physical well-being 
(0 = not present; 3 = extremely present). The difference between the baseline and treatment 
scores were analysed by using GLM repeated measures. 
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Statistical analysis 
 
 Segments between 100ms before until 500ms after stimulus onset were made for each 
stimulus type (S1 and S2) separately, using the last 100 ms before onset as baseline. High 
pass (1Hz) and low pass (30 Hz) filters were applied. The segments were visually checked 
for EOG activity and other artefacts, and removed from the data set if an artefact occurred 
during the first 500 ms after stimulus presentation. The grand average was used to 
determine the AEP components. P1 was defined as most positive value between 60 and 90 
ms after stimulus onset, N1 as most negative value between 85 and 150 ms, P2 as most 
positive value between 140 and 250 ms. 
 GLM repeated measures were used to analyze the amplitudes of the AEP components 
at the Fz, FCz and Cz locations (channel). First, the responses to the S1 and S2 were 
compared for the placebo condition to see whether sensory gating occurred. Next, the 
responses to the vardenafil conditions were compared to placebo condition for each 
stimulus separately (treatment x channel) as well as for both stimuli (treatment x stimulus x 
channel). In case of a statistically reliable effect, comparisons between means of the 
conditions were analyzed in more detail using post hoc Bonferroni t-tests (P < 0.05). One 
subject was excluded from the analyses because of an incomplete data set. 
 
RESULTS 
 
Animal study 
 
Effects of placebo on sensory gating in rats 
 
 The effects of placebo treatment on sensory gating are depicted in Figure 1. GLM 
repeated measures showed that the N1 peak is less negative in response to S2 than S1 at 
the vertex (F(1, 10) = 11.39, P < 0.01). In the hippocampus, the N1 peak was also less 
negative after the presentation of S2 than S1 (F(1, 12) = 6.20, P < 0.05).  
 
Effects of PDE5 inhibition on information processing in rats 
 
 No effects of vardenafil treatment (0.3-3 mg/kg, p.o. 30 min before testing) on the P1, 
N1 and P2 were found in the hippocampus and striatum as well as for the P1 and P2 in the 
vertex. Vardenafil seemed to affect the N1 in the vertex (F(2, 24) = 3.31, P < 0.05), but 
further post-hoc analysis revealed no difference between treatment conditions. This is 
illustrated in Figure 2 showing the results of vardenafil treatment on the peaks and locations 
that showed sensory gating in the placebo condition (see Figure 1) (N1 vertex: 
condition*stimulus (F(1, 14) = 0.33, n.s.); hippocampus: condition*stimulus (F(2, 23) = 0.39, 
n.s.), condition (F(2, 24) = 1.87, n.s.) ). 
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Figure 1 Effects of placebo (vehicle) (p.o. 30 min before testing) on grand average ERPs (P1, N1 and P2 
component) after the presentation of S1 and S2; effects on gating are depicted with asterisks (*: P < 0.05). 
Latencies are shown on the x-axis in milliseconds (ms), amplitudes on the y-axis in microvolts (μV). nvertex = 
11; nstriatum = 11; nhippocampus = 13 
 
 
 
 
Figure 2 No effects of treatment with the PDE5-I vardenafil on the mean amplitude (±SEM) of N1 in the vertex 
and N1 in the hippocampus were found (GLM repeated measures). Drugs were given 30 min before testing. 
Compounds/doses are shown on the x-axis, amplitudes are presented on the y-axis in μV. Nvertex = 11, 
nhippocampus = 13 
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Human study 
 
Effects of placebo on sensory gating in humans 
 
 The effects of placebo treatment on sensory gating are depicted in Figure 3. GLM 
repeated measures showed that there is an interaction between stimulus and channel for 
the P1 (F(1, 17) = 4.60, P < 0.05), N1 (F(1, 19) = 15.25, P < 0.001) and P2 (F(1, 19) = 
24.61, P < 0.001) peaks. Further analyses for the three channels separately showed that the 
P1 was less positive after S2 than S1 at the FCz (F(1, 16) = 5.69, P < 0.05), and Cz (F(1, 
16) = 7.13, P < 0.05). In addition, the N1 was less negative and the P2 less positive after the 
S2 than S1 at the Fz (N1: F(1, 16) = 59.55, P < 0.001; P2: F(1, 16) = 34.94, P < 0.001), FCz 
(N1: F(1, 16) = 56.32, P < 0.001; P2: F(1, 16) = 50.08, P < 0.001) and Cz (N1: F(1, 16) = 
49.48, P < 0.001; P2: F(1, 16) = 52.73, P < 0.001). 
 
  
 
Figure 3 Effects of placebo treatment (orally 85 min before testing) on grand average ERPs (P1, N1 and P2 
component) after the presentation of S1 and S2; effects on gating are depicted with asterisks (n = 17). 
Latencies are shown on the x-axis in milliseconds (ms), amplitudes on the y-axis in microvolts (μV) 
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Effects of PDE5 inhibition on information processing in humans  
 
 The effects of vardenafil (10-20 mg, p.o. 85 min before testing) administration on the 
ERP components in the placebo condition (see Figure 3) are shown in Figure 4. An 
interaction effect for the P1 was found for stimulus*treatment*channel (F(2, 35) = 3.72, P < 
0.05). Additional analyses of the differences between S1 and S2 showed an interaction 
between treatment condition and channel (F(2, 35) = 3.72, P < 0.05). Post-hoc analyses of 
each channel separately revealed no further effects. Furthermore, an interaction was 
detected for the N1 for stimulus*condition (F(1, 23) = 3.98, P < 0.05); however, Bonferonni 
post-hoc analysis of the difference between S1 and S2 showed no effect between treatment 
conditions. No effects of PDE5 inhibition on the P2 peak were found. 
 
a) 
   
b) 
   
c) 
   
Figure 4 No effects of treatment with the PDE5-I vardenafil on the mean amplitude (±SEM) of a) P1, b) N1 and 
c) P2 after the presentation of S1 and S2 were found (GLM repeated measures). Drugs were given 85 min 
before testing; n = 17. Compounds/doses are shown on the x-axis, amplitudes are presented on the y-axis in 
μV 
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Medical questionnaire  
 
 An effect of treatment was found on the report of headache (F(2, 28) = 6.34, P < 0.01) 
and feeling weak (F(2, 26) = 7.43, P < 0.01). Bonferroni post-hoc analysis revealed that 
there was an increase after administration of both vardenafil 10 mg and 20 mg compared to 
the placebo condition. 
 
DISCUSSION 
 
 The aim of this study was to test the effects of PDE5 inhibition on auditory sensory 
gating in rats and humans. It was demonstrated that after treatment with placebo the N1 in 
the vertex and the hippocampus was more negative after S1 than S2 in rats. Additionally, 
the response to the S2 was smaller than to the S1 at the P1, N1 and P2 peak in humans in 
the placebo condition. This indicates that our paradigm elicited sensory gating in the rats as 
well as in the human subjects. However, neither in rats nor in humans an effect of PDE5 
inhibition with vardenafil was found on sensory gating.  
 In Chapter 3 we showed that vardenafil treatment reversed an MK-801- as well as a 
scopolamine-induced memory deficit in the object recognition task in rats at a dose of 1 
mg/kg and 1-3 mg/kg respectively. Vardenafil was administered orally 30 minutes before 
testing, similar to our present sensory gating study. To verify the assumption that vardenafil 
crosses the blood-brain barrier (BBB) in these animals, blood plasma and brain tissue 
concentration of 3 mg/kg vardenafil were determined 30 min after oral treatment. It was 
found that vardenafil had a brain-to-plasma ratio (Cb:Cp) of 0.11. The approximate cerebral 
blood volume relative to total unperfused brain volume is 0.04 (Hitchcock and Pennington 
2006), thus a Cb:Cp >0.04 indicated that vardenafil was brain penetrant. In addition, to 
determine whether there was enough vardenafil present in the brain to be biologically active, 
we calculated the free brain concentration to meaningfully compare this data to the IC50 
value of the compound (0.1 nM). The free brain concentration was calculated using 
vardenafil’s molecular weight and its free fraction in plasma and brain homogenate. The free 
brain concentration of 3 mg/kg vardenafil was 0.4 nM, which is 4 times its IC50 value. This 
suggests that the 1 and 3 mg/kg doses of vardenafil used in the present study have 
sufficient biological activity, i.e. PDE5 inhibition. The dose of 0.3 mg/kg vardenafil would 
have a relatively low biological activity of 0.4 times the IC50, but apparently still enough to 
be biologically active and to improve memory function as previously found in the object 
recognition task (Prickaerts et al. 2002a). It may thus be concluded that the doses of 
vardenafil we used in this study should have been expected to be active under the 
conditions tested. 
 As mentioned before, it has been shown that PDE5-Is improve cognition in a variety of 
behavioural tasks in rodents and monkeys (for overview see Chapter 2). Yet, although the 
effects of PDE5 inhibition on cognition (especially learning and memory) have been widely 
investigated in rodents, little is known about the effects on EEG measurements, including 
ERPs. However, the results of our current study indicate that the positive effects of PDE5-Is 
in healthy adult rats might be mediated by affecting higher cognitive processes instead of 
early basic processes such as sensory gating.   
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 Grass et al. (2001) studied the effects of sildenafil treatment on seven different 
psychophysical tasks measuring among others short term memory and divided attention in 
healthy human subjects. Although PDE5 inhibition showed some effects in reaction time 
tests, no effects on the cognitive tasks were found. Interestingly, in a recent study of Shim et 
al. (2011) repeated dosing of the PDE5-I udenafil improved performance on the Korean 
version of the mini-mental state examination and an assessment battery addressing frontal 
executive functioning in patients suffering from erectile dysfunction. However, another study 
(Goff et al. 2009) investigating the effects of sildenafil administration in patients with 
schizophrenia did not show an effect on cognitive performance. The effects of sildenafil on 
positive and negative symptoms of schizophrenia were also investigated, but no changes in 
symptoms were found. In contrast, Akhandzadeh et al. (2011) demonstrated that sildenafil 
when combined with the atypical antipsychotic risperidone increased the latter’s 
effectiveness in reducing the negative symptoms in patients with schizophrenia. 
Furthermore, it was shown in healthy subjects that although sildenafil treatment did not 
improve the behavioural response in attention and word recognition tasks, it did have an 
effect on EEG measurements (Schultheiss et al. 2001). During the auditory selective 
attention task, sildenafil elicited EEG responses indicative for an improvement of attention. 
No effects on ERP measurements related to word recognition were found, although a 
reduction in negativity of these measurements between 150 and 250 ms after stimulus 
presentation was found in the word recognition task. The role of this negative deflection in 
word recognition is not clear, but the authors suggest that ‘there is an effect of sildenafil on 
cerebral information processing’. In our current study, we did not find an effect of PDE5 
inhibition on a more specific part of information processing, namely sensory gating. 
However, the participants did report an increase in headache, which is one of the most 
commonly reported side effects (≥ 10% of the subjects participating in clinical trials) after 
vardenafil treatment (EMEA 2008), and feeling weak after the administration of 10 – 20 mg 
vardenafil compared to the placebo condition on a questionnaire about medical complaints. 
This indicates that vardenafil is at least bioactive at the dosages and time frame used in our 
sensory gating study. This would also be confirmed by previous pharmacokinetic data 
(EMEA 2008) which showed that the maximum plasma concentrations of vardenafil after 
oral dosing are reached within 30 – 120 minutes (median 60 min.); our time point of testing 
after 85 min is well within this period when also side effects were reported. Additionally, 
when we take into account the body surface area and the body weight to extrapolate the 
animal dose to the human dose using the formula of Reagan-Shaw et al. (2008), the doses 
of 0.3 - 3 mg/kg in rats should be equivalent to 3 - 31 mg in our human participants. This 
indicates that the 10 mg and 20 mg dosages of vardenafil used in our human experiment 
are equivalent to the doses, i.e. higher than 1 mg/kg, which have been shown to exert 
positive effects on cognition in previous animal studies (e.g. Chapter 3 and Prickaerts et al. 
2002b) and which we also used in the present animal experiment. Thus, although we did not 
find an effect of vardenafil on sensory gating, the compound can be assumed to be 
bioactive. So, the effects of PDE5-Is on EEG measures seem to be task dependent and 
might affect different parts of information processing as we used a sensory gating paradigm 
to measure the effects on basic auditory information processing, whereas Schultheiss et al 
(2001) found the effect in a word recognition task after treatment with 100 mg sildenafil. It 
can not be ruled out completely that stimulus salience might have had an effect on the ability 
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to detect drug effects as well, since there are sensory gating studies in which the stimuli did 
not exceed 15 – 20 dB above background noise levels in animals (Halene and Siegel 2008) 
and humans (Cadenhead et al. 2005). However, based on previous experiments in our lab 
(e.g. Sambeth et al. 2007) and a wide variety of sensory gating studies in animals (e.g. 
Mears et al. 2006; Sambeth et al. 2003; Zhou et al. 2008) as well as humans (Dalecki et al. 
2011; Jessen et al. 2001; Lijffijt et al. 2009) which used stimulus parameters similar to ours, 
it is unlikely that stimulus salience affected our results. 
 To summarize, the PDE5-I vardenafil did not affect basic auditory information 
processing tested in a sensory gating paradigm in rats or humans. These findings imply that 
the positive effects of PDE5 inhibition previously found in both species are possibly the 
result of positive effects on higher cognitive functions specifically (e.g. memory or attention) 
instead of on more basic processes involved in a variety of cognitive domains (e.g. basic 
auditory processing). To further elucidate the effects of PDE5 inhibition on cognition, 
identical deficit models in animals and humans (e.g. scopolamine or ketamine) should be 
used in a translational setting. In addition, testing the effects of PDE5-Is on cognitive 
performance and EEG measurements in a patient population suffering from cognitive 
dysfunction (e.g. patients with schizophrenia and patients suffering from dementia) is likely 
to provide further insight into the cognition enhancing potential of PDE5 inhibition.  
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ABSTRACT  
 
 Phosphodiesterase type 2 (PDE2), type 10 (PDE10), and type 5 (PDE5) have been 
considered as relevant targets for cognition enhancement. Although it is well established 
that PDE inhibitors improve memory functions in animals, the effects on auditory information 
processing are less clear. The aim of this study was to test the effects of PDE2 (BAY 60-
7550), PDE5 (vardenafil) and PDE10 (PQ-10) inhibition on sensory gating in rats. EEG was 
recorded from the hippocampus, striatum, and vertex. Sensory gating was found for the N1 
in the vertex and hippocampus, as revealed by diminished amplitudes to S2 compared to 
S1. Administration of PDE-Is did not affect sensory gating. However, PDE2 inhibition 
increased the P1 peak after presentation of S1 at the vertex and PQ-10 increased the N1 
peak in general compared to vehicle treatment at the hippocampus. To summarize, PDE2 
and PDE10 inhibition affect auditory information processing in general, whereas PDE5 
inhibition has no effect. These findings suggest that the positive effects of PDE5 inhibition 
on cognition previously found in animals are possibly the results of an effect on higher 
cognitive functioning specifically whereas the cognition enhancing effects of PDE2 and 
PDE10 inhibition might also be influenced by effects on earlier stages of information 
processing.  
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INTRODUCTION 
 
 Phosphodiesterases (PDEs) are enzymes that selectively hydrolyze the second 
messengers cyclic guanosine monophosphate (cGMP) and/or cyclic adenosine 
monophosphate (cAMP) by breaking their phosphodiester bond. It has been shown that 
compounds that inhibit these PDEs, so-called PDE inhibitors (PDE-Is), improve cognitive 
functioning in a wide variety of behavioural paradigms (for a review see Blokland et al. 2012 
and Chapter 2). This has lead to an increased attention for PDEs as a promising target for 
cognition enhancement. In recent studies we have shown that the cGMP selective PDE5-I 
vardenafil completely reversed object recognition short-term memory and/or acquisition 
memory deficits induced by the NMDA antagonist MK-801 or acute tryptophan depletion 
(Chapter 3 and van Donkelaar et al. 2008). In addition, the PDE2-I BAY 60-7550 and 
PDE10-I PQ-10, which elevate both cGMP and cAMP, were able to reverse memory 
impairments caused by MK-801, as well as by the muscarinic antagonist scopolamine 
(Chapter 4).  
 Localization studies demonstrated that mRNA expression of PDE2 (Lakics et al. 2010; 
Stephenson et al. 2012; van Staveren et al. 2004; Van Staveren et al. 2003), PDE5 (Lakics 
et al. 2010; Loughney et al. 1998; van Staveren et al. 2004) and PDE10 (Fujishige et al. 
1999; Lakics et al. 2010; Loughney et al. 1999; Soderling et al. 1999) can all be detected in 
the cortex and hippocampus of mammals with PDE2 mRNA expression being highest and 
PDE5 mRNA expression being lowest. In addition, in the striatum predominantly PDE10 and 
– to a lesser extent – PDE2 mRNA expression was demonstrated as well. Combining the 
behavioural data in the memory deficit models with these localization data support the 
notion that these PDE-Is might be a suitable tool to treat memory deficits (Chapter 2 and 
Blokland et al. 2012; Xu et al. 2011) 
 Interestingly, the PDE10-I TP-10 was able to reverse d-amphetamine induced deficits in 
a sensory gating paradigm which assesses basic information processing (Schmidt et al. 
2008). A study by Grauer et al. (2009) indicated that PDE10 inhibition has a positive effect 
on prepulse inhibition (PPI), which also addresses information processing, in rats and mice. 
This implies that the therapeutic use of a PDE-I and in particular a PDE10-I might not be 
limited to memory dysfunction, but also extend to early stages of (auditory) information 
processing. 
 In the present study we therefore specifically investigated the effects of PDE inhibition 
on information processing, in particular sensory gating in rats. Sensory gating is an adaptive 
mechanism that helps to prevent overstimulation of higher cortical areas with sensory 
information (for review see e.g. Cromwell et al. 2008). This mechanism can be assessed by 
using a paradigm in which two identical, auditory stimuli are presented with an inter-stimulus 
interval (ISI) of 500 ms and an inter-trial interval (ITI) of at least 6 s. Normally, the response 
to the first auditory stimulus (S1) is significantly larger than the response to the second 
stimulus (S2) reflecting sensory gating. However, this mechanism can be disrupted by e.g. 
pharmalogical intervention with d-amphetamine (Halene and Siegel 2008; Schmidt et al. 
2008) or clinical disorders such as Alzheimer’s disease or schizophrenia (Adler et al. 1982; 
Javitt 2009; Jessen et al. 2001). 
 In human subjects, the P50 (also known as P1) component of the event-related 
potential (ERP) is regarded to be the main component in the sensory gating paradigm, 
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although the N100 (N1) and P200 (P2) seem to be involved as well (e.g. Boutros et al. 2009; 
Chang et al. 2011; Dalecki et al. 2011; Lijffijt et al. 2009). There is still a debate about which 
ERP component in rats is possibly the functional equivalent of the P50 in humans. It has 
been suggested that the P13 (P1), N40 (N1) or even P60 (P2) might be the functional 
equivalent of the P50 in humans, while it has also been suggested that the entire P1-N1-P2 
complex is the most suitable candidate (e.g. Broberg et al. 2010; Mears et al. 2009; Mears 
et al. 2006; Miyazato et al. 1999; Zhou et al. 2008). 
 We previously demonstrated that PDE5 inhibition with vardenafil does not affect 
sensory gating in rats at doses which are normally able to improve memory (Chapter 3 and 
5). This led us to conclude that the positive effects of PDE5 inhibition on cognition are 
mediated by higher cognitive processes and not by more early stages of information 
processing. In the current study we investigated the effects of a PDE2-I (BAY 60-7550) and 
PDE10-I (PQ-10) at the dosage that was previously found to improve memory function as 
well (e.g. Boess et al. 2007 and Chapter 4). For the EEG measurements we included the 
vertex, hippocampus and striatum as electrode locations. These three locations were 
included because of their involvement in sensory gating (e.g. Bickford-Wimer et al. 1990; 
Cromwell et al. 2007; Cromwell et al. 2008). The vertex was also chosen to represent the 
cortex since the EEG signal at this location can also be measured in humans, thus offering a 
possible translation of our results to humans. We expected that the cGMP-specific PDE5-I 
vardenafil would not affect sensory gating as demonstrated previously (Chapter 5). 
Contrarily, the dual substrate PDE-Is BAY 60-7550 and PQ-10 were expected to have an 
effect on sensory gating, since it was shown that PDE10 inhibition was able to reverse an 
amphetamine induced sensory gating impairment (Schmidt et al. 2008). 
 
METHODS AND MATERIALS 
 
Animals 
 
 All experimental procedures were approved by the local ethical committee for animal 
experiments of Maastricht University and met governmental guidelines. Fourteen 3-month-
old male Wistar rats (Harlan, The Netherlands) were used with average body weights of 386 
g (± 11.66). The animals were housed individually in standard Makrolon cages on sawdust 
bedding in an air-conditioned room (about 20°C). They were kept on a 12/12-h reversed 
light/dark cycle (lights on from 19.00 to 7.00 h) and had free access to food and water. The 
rats were housed in the same room as where they were tested. A radio, which was playing 
softly, provided background noise in the room. All testing was done between 9.00 and 18.00 
h in a shielded Skinnerbox. 
 
Surgery and EEG recordings 
 
 The animals received 0.1 ml/kg Temgesic (Schering-Plough B.V., Utrecht, The 
Netherlands) subcutaneously 30 min before surgery as analgesia. Forene isoflurane (Abbott 
B.V., Hoofddorp, The Netherlands) was used as a general inhalation anesthetic. After the 
animal was placed into the stereotactic apparatus and an incision was made to expose the 
skull, lidocaine was applied as additional local anesthesia. Next, bregma was identified and 
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the electrodes were unilaterally placed in the striatum (AP 0.48, ML -3.0, DV -5.0), dorsal 
hippocampus (AP -2.8, ML -1.8, DV -2.6) and at the vertex (AP -3.5, ML -1.0, DV -1.0) 
(Paxinos and Watson 1998). The reference and ground electrodes were both placed on the 
cerebellum. The electrodes and the connector were fixed to the skull by using three screws 
and Paladur denture acrylic (Heraeus Kulzer, Hanau, Germany). The animals were given at 
least two weeks to recover from the surgery. 
 In the first week after recovery, the animals were handled daily and adapted to the 
procedure, i.e. they were connected to the EEG set-up and allowed to explore the 
Skinnerbox in which the recording would take place. In addition the rats were adapted to 
p.o. administration procedures by saline injections (2 ml/kg). Next, the control condition was 
tested, i.e. animals were treated with vehicle; this was tested twice and averaged for the 
statistical analysis. Subsequently three doses of the PDE5-I vardenafil were randomly tested 
(0.3, 1, 3 mg/kg, p.o.). The results of this experiment were described in Chapter 5 including 
only the animals whose dataset was complete and electrode localization was validated for 
the vehicle treatment and all PDE5-I conditions. Additionally, we randomly tested the PDE2-I 
BAY 60-7550 and the PDE10-I PQ-10 (both 1 mg/kg p.o.). The sensory gating paradigm 
consisted of 70 pairs of auditory stimuli which were presented with stimulus duration of 10 
ms, ISI of 500 ms and ITI 6-10 s. The EEG signal was sampled at 1000 Hz, filtered between 
1 - 133.5 Hz and stored on a personal computer. The stimuli were 2500 Hz clicks with a 
sound intensity of 80 dB and duration of 10 ms. After the study was finished, the animals 
were killed by decapitation and the brains were taken out. The brains were stored in 4% 
formaldehyde at 4-6 ºC until electrode localization took place, which was done as described 
previously (Chapter 5). 
 
Treatment 
   
 BAY 60-7550, vardenafil, and PQ-10 were first dissolved in 1.5 ml ethanol with 2% 
Tween 80. After extraction of ethanol via vaporization under N2 gas, the compounds were 
dissolved in 0.5% methylcellulose. It was chosen to test the previously found most effective 
dose (1 mg/kg, p.o.) of each PDE-I in improving memory in an object recognition task. All 
compounds were administered by oral gavage (2 ml/kg) 30 min before testing. BAY 60-7550 
and vardenafil were a gift from BAYER (Wuppertal, Germany); PQ-10 was kindly donated by 
Johnson & Johnson (Beerse, Belgium). All animals were treated with each condition once, 
except for the control condition (vehicle), which was tested twice as part of the training.  
 
Statistical analysis 
   
 Segments between 100ms before until 500ms after stimulus onset were made for each 
stimulus type (S1 and S2) separately, using the last 100 ms before onset as baseline. High 
pass (1Hz) and low pass (30 Hz) filters were applied. The segments were visually checked 
and removed from the data set if a movement artefact occurred within 500 ms after stimulus 
presentation. Both the grand average (all animals) and the individual data (single animal) 
were used to determine the auditory evoked potential (AEP) components. In general, P1 
was defined as the most positive value between 20 and 55 ms after stimulus onset, N1 as 
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the most negative value between 35 and 75 ms, P2 as the most positive value between 55 
and 100 ms.   
 General linear models (GLM) repeated measures were used to analyze the amplitudes 
of the components. First, the responses to the S1 and S2 were compared for the vehicle 
condition to see whether sensory gating occurred. Next, the responses to the PDE-Is 
conditions were compared to placebo condition for each stimulus (treatment: vehicle and 
PDE-I) separately as well as for both stimuli together (Treatment x Stimulus). One animal 
was excluded from the vertex and two animals from the striatum electrodes because of no 
reliable EEG signal at the corresponding electrode.  
 
RESULTS 
 
Effects of vehicle on sensory gating 
 
 The effects of vehicle treatment on sensory gating are depicted in Figure 1. GLM 
repeated measures showed that the N1 peak was less negative after S2 than S1 in the 
vehicle condition (F(1, 12) = 6.12, P < 0.05) at the vertex and hippocampus (F(1, 13) = 6.20, 
P < 0.05), whereas no effects on the P1 and P2 were found. In the striatum, no effects were 
found (F < 4.36). Thus, sensory gating was generally found in the hippocampus and the 
vertex. 
 
  
 
Figure 1 Effects of vehicle on grand average ERPs after the presentation of S1 and S2. Nvertex = 13; 
Nhippocampus = 14; Nstriatum = 12. Effects on gating are depicted with asterisks in the saline condition (*: P < 0.05)   
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Effects of PDE inhibition on information processing 
 
Vertex 
 
 The PDE2-I BAY 60-7550 did not have an effect on the ERP components of the S2 or 
sensory gating. However, GLM repeated measures showed that the P1 peak of the S1 was 
more positive after BAY 60-7550 than vehicle treatment (F(1, 10) = 7.59, P < 0.05) (see 
Figure 2). No other effects of PDE2 inhibition were found. In addition, treatment with the 
PDE5-I vardenafil or the PDE10-I PQ-10 did not affect S1, S2 or sensory gating (data not 
shown, F < 2.84).  
 
   
Figure 2 Effects of treatment with a PDE2-I (BAY 60-7550), PDE5-I (vardenafil) or PDE10-I (PQ-10) on the 
mean amplitude (±SEM) of the P1 in the vertex after the presentation of S1 and S2. NPDE2 = 11; NPDE5 = 11; 
NPDE10 = 12 
 
Hippocampus 
 
 No effects of PDE2 or PDE5 inhibition on the ERP components of the S1, S2 or 
sensory gating were found (data not shown, F < 2.69). The PDE10-I PQ-10 did not affect S1 
or S2 separately either. Yet, the GLM repeated measures with treatment as well as stimulus 
as a within subject variable showed that PQ-10 treatment increased the overall N1 
compared to vehicle treatment (F(1, 13) = 4.71, P < 0.05). This is also illustrated in Figure 3 
showing the effects of all PDE-Is on their hippocampal N1 peaks that showed sensory 
gating in the placebo condition (see Figure 1). 
 
   
Figure 3 Effects of treatment with a PDE2-I (BAY 60-7550), PDE5-I (vardenafil) or PDE10-I (PQ-10) on the 
mean amplitude (±SEM) of the N1 in the hippocampus after the presentation of S1 and S2. NPDE2 = 13; NPDE5 = 
14; NPDE10 = 14 
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Striatum 
 
 GLM repeated measures demonstrated no effects of PDE2 (n=11), PDE5 (n=11) or 
PDE10 (n=12) inhibition on the ERP components of S1, S2 or sensory gating (data not 
shown, F < 2.98). 
 
DISCUSSION 
 
 The present study showed that after treatment with vehicle the N1 in the vertex and 
hippocampus was less negative after S2 than after S1 indicating sensory gating in both 
electrode locations. However, in the striatum, no sensory gating was found. None of the 
PDE-Is affected sensory gating directly as no Stimulus x Treatment interaction was found. 
Yet, it was demonstrated that the PDE2-I BAY 60-7550 increased the P1 peak after S1 
compared to vehicle in the vertex. In addition, the PDE10-I PQ-10 affected the N1 in 
general, with this peak being more negative after PQ-10 than vehicle treatment in the 
hippocampus.  
 Administration of the PDE5-I vardenafil did not have an effect on sensory gating as we 
already recently showed in rats and humans (Chapter 5). Although the effect of PDE5 
inhibition on learning and memory has been widely investigated (for review see e.g. Chapter 
2 and Prickaerts et al. 2004), little is known about the effects on ERPs. A study by 
Schultheiss et al (2001) investigated the effects of PDE5 inhibition on ERPs in humans. 
They showed that sildenafil (100 mg p.o., 1 h before testing) reduced N150/250 and 
increased P300 activity related to the improvement in attention in healthy human adults. 
Additionally, to our knowledge only one study has thus far examined the effects of PDE5 
inhibition on ERPs and information processing in animals (Chapter 5). Our results indicate 
that the effects of PDE5 inhibition during memory tasks using the same dosage range 
(Chapter 3 and Baratti and Boccia 1999; Devan et al. 2006; Devan et al. 2007; Devan et al. 
2004; Singh and Parle 2003) are predominantly mediated by effects on higher cognitive 
processes and not on early stages of information processing, since the early ERP 
components were not affected by PDE5 inhibition. 
 The PDE2-I BAY 60-7550 and PDE10-I PQ-10 did not affect sensory gating either. 
Schmidt et al (2008) previously showed that the PDE10-I TP-10 (3 mg/kg) reversed sensory 
gating deficits in the hippocampus induced by d-amphetamine. However, this study was 
performed in anesthetized rats while we used freely moving animals in the present study. In 
addition, we did not use a deficit model here, which clearly could explain the difference 
between both studies. Furthermore, based on the IC50 values it could be argued that PQ-10 
is about 10 times less potent than TP-10 (Siuciak 2008), yet we tested PQ-10 at a dose (1 
mg/kg) known to improve memory processes (Chapter 4). Finally, the routes of 
administration differed between both studies (intravenously versus orally), which might also 
have an effect. In contrast to auditory sensory gating, the TP-10 compound did not have an 
effect on sensorimotor gating in PPI paradigms (Schmidt et al. 2008). However, the PDE10-
Is papaverine and MP-10, approximately 5 times less potent and 10 times more potent than 
PQ-10 respectively (Alderton et al. 2009; Siuciak 2008), reversed MK-801 induced PPI 
deficits in rats and improved PPI-linked sensorimotor gating in healthy mice (Grauer et al. 
2009). This suggests that it would be interesting to test PQ-10 in a PPI paradigm as well. 
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Nevertheless, although we presently did not find a direct effect of PDE10 inhibition with PQ-
10 nor of PDE2 inhibition with BAY 60-7550 on auditory sensory gating, PQ-10 as well as 
BAY 60-7550 showed effects on information processing. Administration of BAY 60-7550 
increased the P1 peak after presentation of S1 at the vertex, which might indicate an 
arousal effect, and PQ-10 increased the N1 peak at the hippocampus in general compared 
to vehicle treatment, which might point to a general enhancing effect on auditory information 
processing. However, it has to be noted that the SEM and the number of statistical tests 
were quite large in our study, which might have led to a false positive and should be 
investigated further in future research. 
 Interestingly, the PDE-Is that have an effect on information processing both affect 
cGMP and cAMP, whereas PDE5 is cGMP specific (e.g. Bender and Beavo 2006). The fact 
that we only found an effect of the dual substrate PDE-Is suggests that information 
processing might be influenced by cAMP. This would also be in line with previous findings of 
Maxwell et al. (2004) who demonstrated that the cAMP-specific phosphodiesterase type 4 
inhibitor (PDE4-I) rolipram enhanced the amplitude of the P20 (P1) and N40 (N1) peaks 
after S1 in the hippocampus in non-anesthetized mice in a sensory gating paradigm. In 
addition, this compound reversed an amphetamine-induced deficit at these peaks after S1. 
However, no effects on sensory gating were found for the P20 and N40. Another study 
(Halene and Siegel 2008) showed that the PDE4-I Ro-20-1724 increased the response to 
S1 at the P20 (P1) and N40 (N1) peaks in the hippocampus in mice in a sensory gating 
paradigm as well. In addition, they found that this PDE4-I reversed a decreased N40 after 
S1 and a N40 gating deficit induced by d-amphetamine. Interestingly, they did not find an 
effect of PDE4 inhibition on a d-amphetamine induced PPI deficit in mice. These results 
imply that dual substrate as well as cAMP specific PDE-Is are able to affect auditory 
information processing in a sensory gating paradigm, but that the results differ when it 
comes to other paradigms such as PPI. 
 To summarize, the PDE5-I vardenafil did not have an effect on basic auditory 
information processing examined in a sensory gating paradigm. This in contrast to 
administration of the PDE2-I BAY 60-7550 or PDE10-I PQ-10 which affected auditory 
information processing in general. These results imply that the positive effects of PDE5 
inhibition on cognition previously found in animals are possibly the results of an effect on 
higher cognitive functioning specifically whereas the cognition enhancing effects of PDE2 
and PDE10 inhibition might also be influenced by effects on earlier cognitive processes such 
as information processing. To further elucidate the effects of PDE inhibition on information 
processing deficit models (e.g. d-amphetamine) and other paradigms (e.g. PPI) could be 
employed. 
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ABSTRACT 
 
 Phosphodiesterase type 5 inhibitors (PDE5-Is) improve cognitive performance of 
rodents, but the few human studies investigating their effects did not systematically 
investigate cognitive effects and the results have been quite contradictory. Therefore, we 
examined whether the PDE5-I vardenafil improves memory and executive functioning and 
affect EEG in healthy young adults. Participants were selected out of a group of volunteers, 
based on their performance on a memory screening and they were orally treated with 
vardenafil (10-20 mg or placebo). Memory- and executive functioning were tested while 
EEG activity was recorded. Additionally, a simple reaction time task and questionnaires 
addressing various complaints were presented. No prominent effects of vardenafil on 
cognition were found; participants only made more mistakes on a reaction time task after 20 
mg vardenafil. During encoding of words, the P300 was generally smaller after vardenafil 
treatment. Furthermore, the N400 was larger after vardenafil 10 mg than placebo treatment 
in a spatial memory task at Fz. Finally, headache and feeling weak were reported more after 
vardenafil treatment. Vardenafil did not affect cognitive performance of healthy adults and 
showed only some incidental effects on ERPs. These findings in humans do not corroborate 
the cognition enhancing effects of PDE5-Is in healthy animals. 
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INTRODUCTION 
 
 Phosphodiesterase type 5 inhibitors (PDE5-Is) such as sildenafil (also known as 
Viagra), tadalafil (Cialis) and vardenafil (Levitra) are often used drug-treatments for erectile 
dysfunction (ED) (Langtry and Markham 1999; Setter et al. 2005). This is accomplished by 
the selective inhibition of phosphodiesterase type 5 (PDE5), an enzyme that inactivates 
cyclic guanosine monophosphate (cGMP) (Bender and Beavo 2006). Because of the 
presence of PDE5 in the brain it is not inconceivable that when a PDE5 inhibitor enters the 
brain it could have cognitive effects as well (Lakics et al. 2010). It has indeed been 
demonstrated that these drugs can enhance cognition in a variety of behavioural tasks in 
animals (for review see Chapter 2). For example, PDE5 inhibition did not only improve 
learning and memory performance in healthy rodents (e.g. Baratti and Boccia 1999; 
Prickaerts et al. 1997; Prickaerts et al. 2002; Rutten et al. 2005), but also enhanced 
executive functioning (Rodefer et al. 2012) and memory performance in animals impaired by 
age (Domek-Lopacinska and Strosznajder 2008), pharmacological intervention (Chapter 3 
and Devan et al. 2007) or a model of the amyloid deposition of Alzheimer’s disease (Puzzo 
et al. 2009). In addition, treatment with the PDE5-I sildenafil increased response inhibition 
and executive functioning in healthy cynomolgus macaque monkeys (Rutten et al. 2008).  
 In contrast to the extensive report of the positive effects of PDE5 inhibition on cognition 
in animals, relatively little is known about the effects in humans. Schultheiss and colleagues 
(2001) showed that sildenafil treatment did not affect the behavioural response of healthy 
adults, but appeared to have a positive influence on event-related potential (ERP) 
measurements related to selective attention. Another study by Grass et al. (2001) 
demonstrated that sildenafil decreased motor reaction time and showed a weak tendency of 
psychomotor improvement, but also failed to find a positive effect of PDE5 inhibition on 
cognition in healthy volunteers. In a recent study using the PDE5-I vardenafil we did not 
observe any effect on information processing as measured with sensory gating (Chapter 5). 
It has also been shown that sildenafil treatment did not affect cognition in patients with 
schizophrenia (Goff et al. 2009). However, another study investigating the effects of 
repeated dosing of the PDE5-I udenafil in patients suffering from ED, demonstrated that this 
treatment improved performance of these patients on the Korean version of the mini-mental 
state examination (MMSE) and on an assessment battery measuring frontal executive 
function (Shim et al. 2011).  
 In general, the results of the animal and human studies seem to be rather contradictory 
and we therefore examined the influence of PDE5-Is more specifically on memory 
functioning, since it has already been established extensively that PDE5 inhibition has 
memory enhancing effects in animals in a variety of behavioural models (e.g. Chapter 3 and 
Domek-Lopacinska and Strosznajder 2008; Patil et al. 2004; Prickaerts et al. 2002; Rutten 
et al. 2007; Rutten et al. 2005; van Donkelaar et al. 2008). Therefore, we included multiple 
memory tasks in our study. Furthermore, since sildenafil improved executive functioning in 
rodents (Rodefer et al. 2012) and monkeys (Rutten et al. 2008), we incorporated executive 
functioning tasks as well. In addition, instead of the PDE5-I sildenafil, which was used in 
most human cognition studies so far, we used vardenafil, because we previously found that 
compared to sildenafil a lower dose of vardenafil is needed to obtain memory improving 
effects in rats (Prickaerts et al. 2002). Thus, vardenafil appears to be more potent. Given the 
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fact that sildenafil appeared to affect ERPs during attention-related tasks (Schultheiss et al. 
2001), we decided to include electroencephalography (EEG) in the present study as well of 
which the sensory gating data has already been reported in Chapter 5. 
 The aim of this study was to examine the effects of vardenafil on cognition, in particular 
memory, but also executive function and attention, and the electrophysiological correlates, 
i.e. ERPs, of information processing in healthy volunteers. Cognitive performances were 
assessed while simultaneously recording brain activity. The results will provide further 
information on the potential of vardenafil as cognitive enhancer and will increase our 
knowledge on the role of PDE5 in human cognition in general.  
 
METHODS AND MATERIALS 
 
Participants  
 
 All experimental procedures were approved by the independent Ethics Committee of 
Maastricht University and the Academic Hospital Maastricht (The Netherlands). The study 
was conducted according to the code of ethics on human experimentation established by 
the declaration of Helsinki (1964) and amended in Edinburgh (2000) and in accordance with 
the Medical Research Involving Human Subjects Act (WMO). The participants were 
recruited through advertisements at Maastricht University. They had to be willing to sign an 
informed consent and were paid for their participation. 
 The present study started with a screening of 40 university students in which they were 
asked to complete the memory tasks used in our main study. Based on their performance 
we invited the volunteers within the 25th and 75th percentile to participate in our study. The 
reason for this distinction was as follows. Participants with the highest scores were not likely 
to benefit from the treatment (ceiling effect). However, participants with the lowest scores 
are 1) likely to show better performance on the test the next time (regression to the mean) 
and 2) may have scored not very high because of motivation problems. 
 Based on this screening, 18 out of the 40 participants were included in our study, 
because we needed a multiple of six for our randomization conditions. The volunteers (21 ± 
0.7 years old, 5 males) were screened by a physician by means of a standard medical 
questionnaire and a medical examination. Participants were excluded if they suffered from 
or had a history of cardiac, hepatic, renal, pulmonary, neurological, gastrointestinal, 
haematological or psychiatric illness. Other exclusion criteria were excessive drinking ( > 20 
glasses of alcohol containing beverages a week), pregnancy or lactation, use of medication 
other than oral contraceptives, use of recreational drugs from 2 weeks before until the end 
of the experiment, and any sensory or motor deficit which could reasonably be expected to 
affect test performance. In addition, participants who had a first-degree relative with (history 
of) a psychiatric disorder were excluded as well. The participants could leave the study at 
any given time without any consequence. 
 
Design and Treatment 
  
 The study was conducted according to a double-blind, placebo-controlled, 3-way cross-
over design. Order of treatments was balanced over three test days and separated by a 
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washout period of at least 7 days. The balancing of the treatment order was accomplished 
by counterbalancing.  
 Treatment consisted of a placebo, 10 mg vardenafil HCl (Levitra), or 20 mg vardenafil 
HCl (Levitra) and was within the range of dosages (5-20 mg) approved for human use 
(EMEA 2008). Previous studies have shown that peak plasma levels of vardenafil were 
reached 30-120 minutes (median 60 min) after a single dose of 20 mg vardenafil; the 
terminal half-life was around 4-5 hours (EMEA 2008). Therefore, we started the 
measurement 45 minutes after drug intake. The drugs were ingested orally and combined 
with a low-fat breakfast, because fatty food might affect the absorption of vardenafil. The 
experimenter and participants were blind to the compound and doses tested.  
 
Assessments  
 
 After enrolment in the study, the participants first underwent a training session. During 
this session, all tests were practiced to familiarize the participants with the study procedures 
and minimize procedural learning effects.  
     Each test day started with assessing the general status of the participants and filling in 
questionnaires. Next, they received the capsules either containing vardenafil (10 or 20 mg) 
or a placebo. Forty five minutes later the test battery started with the immediate recall of a 
verbal learning task (VLT), followed by the continuous recognition memory task (CRMT), the 
immediate recognition of a spatial memory task (SMT) and sensory gating, of which the 
latter has already been reported as part of a translational study (Chapter 5). Next the 
participants had a short break during which they filled in the questionnaires and had a glass 
of water if they wanted. After 5-10 minutes we started testing again; first they performed the 
tower of London (TOL), then the Stroop task, a reaction time (RT) task, the delayed recall 
and recognition of the VLT, and finally the delayed recognition of the SMT.  
 
Questionnaires 
 
Profile of Mood States (POMS)  
 
 The POMS (McNair et al. 1971) is a self-evaluation scale for short, alternating states. It 
consists of 64 adjectives comprising five bipolar mood factors (depression, anger, fatigue, 
vigor and tension) paired at 32 visual analogue scales (100 mm). In this way, the participant 
could indicate to what extent these items are appropriate to his/her mood.  
  
Bond & Lader visual analogue scale (VAS)  
  
 Subjective evaluations of alertness were assessed by using an adjusted series of 9 
visual analogue scales (100 mm), which provided summary scores for alertness (Bond and 
Lader 1974).  
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Questionnaire medical complaints  
  
 This questionnaire addressed 31 potential physical complaints, including headache, 
nausea, dry mouth, blurred vision and dizziness. Next to each complaint was a four-point 
scale. In this way, the participant could indicate to what extent these items are appropriate 
to his/her physical well being (0 = not present; 3 = extremely present). 
 
VLT 
 
 The VLT is an adapted version of the Rey auditory verbal learning test (Lezak 1995), 
which assesses immediate and delayed memory for verbal information. This task, modified 
by Riedel et al. (1999), was developed to maximize the possibility of measuring 
enhancement rather than impairment only, by prolonging the list words to be learned. The 
list consisted of 30 monosyllabic words (18 nouns and 12 adjectives) in Dutch. The words 
were shown on a computer screen for 1 second; the total inter-trial interval (ITI) was 3 
seconds. Three trials with the same item sequence were presented. Each trial ended with a 
free recall of the words (immediate recall). Eighty minutes after the third trial, the participant 
was asked to recall as many words as possible without the words being presented (delayed 
recall). Subsequently, a recognition test was presented, consisting of 15 familiar words and 
15 new but comparable words (distracters). The words were shown on a computer screen 
for 2 seconds (total ITI of 3 seconds) and participants were asked to rate whether they were 
presented in the learning trials by a ‘yes/no’ response. Different versions of this test were 
balanced over test days. For immediate and delayed recall, the total words correct, incorrect 
and double were calculated for the analyses, for the recognition test reaction times and 
correct responses were used. For the EEG analysis, the ERPs of the three encoding trials 
were averaged.  
 
CRMT 
 
 This task assessed recognition memory and was used as an immediate recognition test 
(based on a task used by e.g. Curran et al. 1998; Van Strien et al. 2007). A series of 
pictures (black and white line drawings) was presented on a computer screen with an ITI of 
3 seconds. Five pictures were presented five times at the beginning of the task and occurred 
randomly in the series as fillers. Sixty pictures were only repeated once in the series 1, 3 or 
10 stimuli after they were presented the first time (20 pictures in each condition). The 
participants had to rate each of the pictures as ‘old’ (I have seen it before) or ‘new’ (I have 
not seen it before). Different versions of this test were balanced over test days. The 
variables used for the analyses were the reaction time and the number of correct responses 
in general. In addition, these variables were calculated for the ‘old’ pictures presented 1, 3 or 
10 stimuli after they were presented for the first time.  
 
SMT  
 
 The SMT is a spatial memory task (based on the object relocation test (Kessels et al. 
1999; Sambeth et al. 2009)) that consisted of two parts; immediate and delayed recognition. 
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The immediate recognition comprises 6 trials in which ten pictures (total of 60 pictures) were 
presented one by one on a computer screen (encoding phase) with an ITI of 3 seconds. The 
participants had to remember the location of the pictures. After each trial, the objects 
disappeared from the screen and reappeared one by one in the middle of the screen 
(repetition phase), followed by the presentation of a ‘1’ and a ‘2’ in different locations 
(relocation phase). The participants had to determine whether the picture had been 
presented on the location indicated by 1 or 2 consecutively for each picture. During the 
delayed recognition procedure 60 min after the initial presentation of the pictures, the 
subject had to decide again what the location of the pictures had been. Different versions of 
this test were balanced over test days. The measures used are the reaction time and the 
number of correct responses. 
 
TOL 
 
 The TOL is used to assess executive functioning, including frontal planning abilities 
(Schmitt et al. 2005). This comprises the ability to think ahead and to evaluate the 
consequences of ones actions. The original version of the TOL consisted of three colored 
balls, which had to be arranged on three sticks to match the target configuration on a picture 
while only one ball could be moved at a time (Shallice 1982). In our study, we used a 
digitalized version that consisted of computer-generated images of the begin- and end-
arrangements of the balls. The subject had to decide as fast as possible, whether the end-
arrangement could be accomplished in 2, 3, 4, 5 or 6 steps from the begin arrangement by 
pushing the corresponding number coded button (the arrangement with 6 steps was 
excluded from the analysis). Each condition was randomly presented 10 times, expect for 
the 6 steps condition which only occurred 4 times. Different versions of this test were 
balanced over test days. Reaction times and correct responses were the main performance 
measures.  
  
Stroop 
 
 The Stroop task is well known for its ability to induce interference, and assesses 
response inhibition and focused attention. In this task, colour names (in Dutch) were printed 
in coloured ink and presented with an ITI between 2.5-3.5 seconds; in the congruent 
category, the colour name and the colour of the ink were the same, in the incongruent 
category they were not. The participants had to name the colour of the ink, not the words 
themselves. Because of the urge to read the printed words (even if one is asked to ignore 
them) interference occurs. Since the printed words and ink colour differed in the incongruent 
category, interference was stronger in this category than in the congruent category; this is 
called the ‘Stroop effect’ and is known to remain even after extended practice (Gazzaniga et 
al. 2002). The colours used in this task were blue, red, green and yellow. The colour of the 
ink had to be named by pressing one out of four buttons, which each represented one of the 
colours. Each colour was randomly presented 20 times in the congruent as well as the 
incongruent condition which brings the total amount of stimuli in the congruent as well as the 
incongruent condition at 80. The main performance measures were the reaction times and 
the number of correct responses.  
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RT task 
 
 The RT task (modified version of the CANTAB® choice reaction task (e.g. 
Dassanayake et al. 2012)) assessed motor speed and it was used to assess whether the 
drugs administered in the current experiment impair vigilance. Participants were presented 
with an arrow that was either pointing to the left or right side of the screen. Depending on 
whether the arrow pointed to the left or the right, the subject had to push the left or right 
button respectively. Dependent variables are the reaction time and number of correct 
responses. 
 
EEG recordings 
 
 An EEG cap was used to place a set of 32 EEG electrodes according to the 
international 10-20 system (Jasper 1958), but only the midline electrodes (Fz, FCz, Cz, CPz, 
Pz) were used in the statistical analysis. A reference and a ground were placed at the linked 
mastoids and at the forehead, respectively. Eye movements were detected by horizontal 
and vertical electro-oculogram (EOG) recordings. Before electrode attachment, the positions 
were cleaned with alcohol and slightly scrubbed with a gel in order to provide a good 
measurement. Both EEG and EOG were filtered between 0.01 and 100 Hz and sampled at 
1000 Hz. The EEG responses were recorded during the VLT, CRMT, SMT and Stroop task.  
 The EEG data was analysed using Vision Analyzer 2 (Brain Products, Gilching, 
Germany) software. Epoch files were made from 100ms before stimulus onset until 1000ms 
after onset, using the last 100 ms before stimulus onset as baseline. High pass (1Hz) and 
low pass (30 Hz) filters were applied offline. The segments were checked for EOG activity 
(visually and by using the Gratton and Coles method in Vision Analyzer) and other artifacts 
and excluded if an artifact occurred during the first 1000 ms after stimulus presentation. 
Next, averages were calculated for each stimulus type and treatment. The grand average 
was used to determine the ERP components. Although the time windows for peak detection 
varied for each task, generally taken the N100 (not detected for the SMT) was defined as 
most negative value between 70 and 140 ms after stimulus onset, P150 as most positive 
value between 130 and 210, N200 as most negative value between 140-310 ms, P300 as 
most positive value between 255 and 380 ms, N400 as most negative value between 365 
and 520 ms (not detected in the CRMT and Stroop) and P600 (not detected in the SMT 
encoding phase) as most positive value between 380 and 700 ms. 
  
Statistical analysis 
 
 General linear model (GLM) repeated measures were used to analyse the effects of 
vardenafil treatment on the outcome variables of the cognitive tasks, the subjective mood 
scales, and the peak amplitudes of the ERP measurements. The results from the 
questionnaires during the baseline measurement (directly before ingesting the 
compound/placebo) were subtracted from the treatment measurement (approximately 100 
minutes later) for further analysis. Treatment (three levels: placebo, vardenafil 10 mg, 
vardenafil 20 mg) was used as a within subject factor, as were the different stimulus and/or 
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response types within a task if applicable (type). In the analyses of the ERP components, 
the factor channel (five levels: Fz, FCz, Cz, CPz, Pz) was included as well. In case of a 
statistically reliable effect, comparisons between means of the different conditions were 
analysed in more detail using post hoc t-tests (P < 0.05) with Bonferroni correction. One 
participant was excluded from the entire analysis and another one from the analysis of the 
behavioural response to the Stroop and the RT task all because of an incomplete data set. 
Additionally, one subject had to be excluded from the analyses of the P300 peak of the 
CRMT, based on the results on the outlier test. 
 
RESULTS 
 
 A wide variety of channel effects was found for the ERP components across the tasks. 
It is beyond the scope of this paper to report all of them separately, but in general the N200 
was less negative at the parietal compared to the frontal part of the midline, whereas the 
P300 and the P600 grew more positive across the midline from the frontal to the parietal 
area. These are common effects.  
  
VLT-behaviour 
 
 Immediate recall No effects of vardenafil treatment were found with regard to words 
recalled correctly (F(2, 32) = 0.38, n.s.), incorrectly (F(2, 32) = 0.05, n.s.) or mentioned twice 
(F(2, 32) = 1.13, n.s.) (see also Table 1). 
 Delayed recall With regards to the delayed recall, no effects of vardenafil were 
found for the words correctly recalled (F(2, 32) = 0.23, n.s.), incorrectly recalled (F(2, 32) = 
0.32, n.s.) or mentioned double (F(2, 32) = 0.08, n.s.). 
 Delayed recognition An effect for the reaction time of old versus new words was found, 
with the response to the new words being slower (F(1, 16) = 14.00, P < 0.01). However, no 
main effect of vardenafil treatment or interaction with stimulus type (new/old words) was 
found on reaction time (F(2, 32) = 1.72, n.s. and F(2, 32) = 0.69, n.s., respectively) or 
correct responses (F(2, 32) = 0.25, n.s. and F(2, 32) = 0.71, n.s., respectively).  
  
VLT-ERP 
 
 Only those analyses that revealed effects are reported (also for the other tasks). 
 EEG during encoding For the P300 an interaction effect of treatment and channel was 
found (F(8, 128) = 5.11, P < 0.001) during the presentation of the words. Further analyses 
showed that, the P300 was decreased after vardenafil 20 mg compared to placebo at the 
Fz, Cz and CPz, after both vardenafil conditions compared to placebo treatment at the FCz 
and Pz, and after vardenafil 20 mg compared to 10 mg treatment at the FCz and Pz (see 
also Figure 1). 
 EEG during recognition The N400 was less negative after the presentation of old stimuli 
than after new ones (F(1, 16) = 5.21, P < 0.05). Additionally, the P600 was larger after the 
presentation of old than new stimuli (F(1, 16) = 27.57, P < 0.001). Treatment interacted with 
electrode location (F(8, 128) = 2.05, P < 0.05), however further analyses revealed no 
effects. 
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Figure 1 Effects of vardenafil treatment on grand average ERPs during encoding in the VLT; generally the 
P300 was decreased after vardenafil treatment compared to placebo. Latencies are shown on the x-axis in 
milliseconds (ms), amplitudes on the y-axis in microvolts (μV) 
 
CRMT- behaviour 
 
 The overall reaction time was faster and the number of correct responses was higher 
for the old than for the new pictures (F(1, 16) = 6.11, P < 0.05 and F(1, 16) = 7.40, P < 0.05, 
respectively). Administration of vardenafil did not affect these reaction times (F(2, 32) = 
1.51, n.s.) and the correct responses (F(2, 32) = 3.28, n.s.) in this immediate picture 
recognition task (see also Table 1). Furthermore, when subdividing the responses on the old 
pictures presented 1, 3 or 10 stimuli after they had been presented for the first time, neither 
an effect of vardenafil for correct responses (F(2, 32) = 1.45, n.s.) nor for reaction time (F(2, 
32) = 1.49, n.s.) was found. However, the interval between the pictures had an effect on 
reaction time (F(2, 32) = 5.41, P < 0.05), with the interval of 10 causing a slower reaction 
time than the interval of 3 stimuli.  
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CRMT-ERP 
 
 The P150 and the P300 were more positive after the presentation of the old than new 
picture (F(1, 16) = 10.94, P < 0.01 and F(1, 15) = 21.77, P < 0.001 respectively, see also 
Fig. 2). In addition, the N200 was more negative after the new than the old pictures (F(1, 16) 
= 58.79, P < 0.001). However, no treatment effects were found for any of the ERP 
components. 
 
SMT-behaviour 
 
 Immediate recognition No effects of vardenafil treatment were found with regard to the 
reaction time (F(2, 32) = 0.32, n.s.) or number of correct responses (F(2, 32) = 1.70, n.s.) in 
the immediate recognition (see also Table 1).  
 Delayed recognition No effects of vardenafil treatment were found on reaction time (F(2, 
32) = 0.31, n.s.) and number of correct responses (F(2, 32) = 0.69, n.s.) in the delayed 
recognition.  
 
Table 1 No effects of vardenafil treatment on the behavioural performance on the memory tasks (VLT, CRMT 
and SMT) were found (mean values (±SEM)). Reaction times are presented in milliseconds (ms). n = 17  
   Placebo Vardenafil 10 mg Vardenafil 20 mg 
VLT Immediate recall Correct 48.47 (2.92) 46.24 (2.88) 47.00 (3.31) 
  Incorrect 1.12 (0.28) 1.00 (0.37) 1.00 (0.28) 
  Double 1.24 (0.37) 1.12 (0.27) 1.76 (0.48) 
 Delayed recall Correct 15.77 (1.36) 15.88 (1.21) 15.18 (1.20) 
  Incorrect 0.47 (0.15) 0.47 (0.19) 0.29 (0.14) 
  Double 0.29 (0.11) 0.29 (0.11) 0.24 (0.16) 
 Delayed  Reaction time 846.16 (28.82) 796.67 (24.06) 848.50 (31.40) 
 recognition old Correct 12.94 (0.49) 13.59 (0.40) 13.35 (0.35) 
 Delayed  Reaction time 907.69 (36.20) 862.45 (26.83) 875.58 (26.06) 
 recognition new Correct 13.47 (0.45) 13.35 (0.42) 13.41 (0.41) 
      
CRMT Immediate  Reaction time 703.46 (19.33) 719.71 (16.65) 721.33 (19.22) 
 recognition new Correct 56.94 (0.75) 56.24 (0.94) 56.94 (0.73) 
 Immediate Reaction time 668.70 (20.46) 690.65 (21.61) 692.12 (21.56) 
 recognition old Correct 58.53 (0.43) 57.65 (0.47) 58.24 (0.38) 
 Interval 1 Reaction time 661.12 (28.79) 691.86 (23.73) 697.42 (24.14) 
  Correct 19.18 (0.26) 19.47 (0.23) 19.29 0.25) 
 Interval 3 Reaction time 664.62 (18.46) 662.91 (22.72) 676.19 (21.69) 
  Correct 19.65 (0.12) 19.00 (0.33) 19.47 (0.21) 
 Interval 10 Reaction time 680.55 (18.30) 716.77 (23.29) 703.78 (22.94) 
  Correct 19.65 (0.17) 19.18 (0.20) 19.35 (0.15) 
      
SMT Immediate  Reaction time 853.40 (42.71) 820.03 (46.31) 816.81 (51.85) 
 recognition Correct 52.06 (1.03) 51.06 (1.13) 50.18 (1.14) 
 Delayed Reaction time 899.56 (62.37) 863.99 (67.18) 894.55 (59.51) 
 recognition Correct 44.29 (1.22) 45.47 (1.10) 45.35 (1.23) 
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SMT-ERP 
 
 During the encoding phase, there was an interaction between treatment and channel at 
the N400 (F(8, 128) = 3.93, P < 0.001). However, further analyses revealed no effects. In 
the immediate repetition phase, treatment and channel interacted at the P150 (F(8, 128) = 
2.22, P < 0.05) and N400 (F(8, 128) = 2.52, P < 0.05). Further analysis showed no effect for 
the P150, but the N400 response was more negative after the vardenafil 10 mg condition 
than after the placebo or vardenafil 20 mg condition at the Fz. 
 
TOL 
 
 GLM repeated measures showed that the reaction time increased (F (3, 48) = 135.39, P 
< 0.001) and the number correct responses decreased (F(3, 48) = 20.46, P < 0.001) as the 
number of steps in this executive function task that had to be taken to reach the end-
arrangement increased. However, no main effect of vardenafil treatment or interaction with 
number of steps was found for reaction time (F(2, 32) = 0.29, n.s. and F(6, 96) = 0.86, n.s., 
respectively) or correct responses (F(2, 32)  = 0.69, n.s. and F(6, 96)  = 0.34, n.s) (see also 
Table 2). 
 
Stroop-behaviour 
 
 The reaction time was slower in the incongruent than in the congruent condition of this 
attention/response inhibition task (F(1, 15) = 83.50, P < 0.001). In addition, the number of 
correct responses was higher in the congruent condition (F(1, 15) = 11.79, P < 0.01). No 
main effect of vardenafil or interaction with stimulus type (congruent/incongruent) on Stroop 
performance was found (reaction time (F(2, 30) = 0.27, n.s. and F(2, 30) = 1.20, n.s., 
respectively), correct responses (F(2, 30) = 0.52, n.s. and F(2, 30) = 0.22, n.s., 
respectively)) (see also Table 2). 
 
Table 2 No effects of vardenafil treatment on the behavioural performance on the TOL and Stroop were found 
(mean values (±SEM)). Reaction times are presented in seconds (s) for the TOL and ms for the Stroop. nTOL = 
17, nStroop = 16 
   Placebo Vardenafil 10 mg Vardenafil 20 mg 
TOL 2 steps Reaction time 4.57 (0.24) 4.27 (0.21) 4.36 (0.25) 
  Correct 9.71 (0.19) 9.24 (0.18) 9.41 (0.24) 
 3 steps Reaction time 5.77 (0.38) 5.91 (0.37) 5.68 (0.27) 
  Correct 9.53 (0.12) 9.53 (0.21) 9.35 (0.21) 
 4 steps Reaction time 8.76 (0.75) 8.89 (0.53) 9.16 (0.67) 
  Correct 8.82 (0.33) 8.76 (0.25) 8.82 (0.23) 
 5 steps Reaction time 14.78 (1.10) 13.44 (1.13) 14.51 (1.19) 
  Correct 8.06 (0.42) 7.82 (0.36) 7.65 (0.42) 
      
Stroop Congruent Reaction time 594.45 (10.90) 596.58 (11.77) 596.47 (13.95) 
  Correct 70.44 (0.36) 70.52 (0.40) 70,80 (0.32) 
 Incongruent Reaction time 695.62 (19.67) 679.15 (16.02) 692.15 (14.52) 
  Correct 68,76 (0.92) 69.32 (0.52) 69.12 (0.44) 
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Stroop-ERP 
 
 The P150 was more positive in the congruent than in the incongruent condition (F(1, 
16) = 4.50, P = 0.05). Additionally, a main treatment effect was found for the P300 (F(2, 32) 
= 3.66, P < 0.05), however post-hoc analyses showed no further effects 
 
RT task 
 
 GLM repeated measures showed an effect of hand side on the reaction time (F(1, 15) = 
4.98, P < 0.05). More specifically, the reaction time was higher when the participants had to 
respond with their right hand compared to the left hand. Furthermore, there was a treatment 
x side interaction for the correct responses (F(2, 30) = 6.84, P < 0.01). This effect was 
further analysed by examining the correct responses for both hands separately. No effect of 
treatment was found for the left hand (F(2, 30) = 0.82, n.s.), whereas an effect of treatment 
was found for the right hand (F(2, 30) = 7.11, P < 0.01). Post-hoc analyses revealed that 
more errors were made in the vardenafil 20 mg condition than in the placebo condition. 
 
Questionnaires  
 
Profile of Mood States (POMS)  
 
 No effects of vardenafil treatment on depression (F(2, 32) = 1.89, n.s.), anger (F(2, 32) 
= 0.63, n.s.), fatigue (F(2, 32) = 1.61, n.s.), vigor (F(2, 32) = 0.90, n.s.) or tension (F(2, 32) = 
0.40, n.s.) were found. 
 
Bond & Lader visual analogue scale  
 
 The participants reported no effect of vardenafil treatment on alertness (F(2, 32) = 2.71, 
n.s.). 
  
Questionnaire medical complaints  
 
 An effect of treatment was found on the report of headache (F(2, 32) = 6.34, P < 0.01) 
and feeling weak (F(2, 32) = 7.43, P < 0.01). Bonferroni post-hoc analysis revealed that 
there was an increased report of both complaints after administration of vardenafil 10 mg or 
20 mg compared to the placebo condition.  
 
DISCUSSION 
 
 The aim of this study was to investigate the effects of the PDE5-I vardenafil on 
cognition and ERP measurements in healthy volunteers. No effects of vardenafil treatment 
were found on any of the behavioural performances in the cognitive tasks measuring 
memory (VLT, CRMT and SMT) and executive functioning (TOL and Stroop task). However, 
a small effect was found on the RT task; the volunteers made more errors during this task 
with their right hand after vardenafil 20 mg treatment than placebo. For the VLT immediate 
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recall the P300 was in general decreased after vardenafil treatment during the encoding of 
the words. In addition, the N400 was increased after vardenafil 10 mg than after placebo 
treatment in the SMT immediate repetition phase at the Fz electrode. No other effects on 
ERPs after vardenafil were found, i.e. on the VLT recall and recognition, the CRMT, the 
SMT acquisition and delayed repetition, and the Stroop task. Finally, there was an increased 
report of headache and feeling weak after vardenafil treatment (10 mg and 20 mg) 
compared to the placebo condition. 
 The lack of effect of PDE5 inhibition on cognitive performance is in line with previous 
studies investigating the effects of PDE5 inhibition in healthy volunteers. Grass et al. (2001) 
demonstrated that the PDE5-I sildenafil did not affect the performance of their participants 
on a variety of psychophysical tasks including a short term memory task. In addition, they 
did find an effect on reaction time as we did in our current study. However, they found an 
improvement in performance after sildenafil treatment, while we found an impairment after 
vardenafil treatment. Furthermore, another study by Schultheiss et al. (2001) showed that 
sildenafil treatment did not affect the behavioural response on a word recognition task. 
Additionally, it was found that the sildenafil had an effect on the EEG measurements during 
this task; a reduction of their negativity was found between 150-250 ms after stimulus 
presentation. However, the authors mentioned that the meaning of this increased 
responsiveness remains to be determined. We did not find an effect of PDE5 inhibition on 
ERP measurements on the recognition part of the VLT, but found a decrease of the P300 
after vardenafil treatment during the encoding of the words whereas behavioural 
performance remained unaffected. Schultheiss et al. (2001) also found an effect of PDE5 
inhibition on the P300; they detected an increase in P300 during an auditory attention task 
after sildenafil treatment. This seems to be in contrast with our decrease in P300 during 
word encoding in the VLT after vardenafil treatment, however it has to be noted that their 
auditory attention task is completely different from our VLT which might also affect a 
possible change in the P300. 
 In our current study, we did not demonstrate any effects of vardenafil on the early and 
middle phase ERP components related to e.g. basic sensory processing, attentive 
manipulations and auditory oddball paradigms, such as the N100, P150 and N200 
(Cacioppo et al. 2000; Luck 2005). In contrast, there were effects on late phase ERP 
components P300 in the VLT and N400 in the SMT which are generally related to higher 
cognitive functioning such as (semantic) memory (Cacioppo et al. 2000; Federmeier and 
Laszlo 2009). The effect of vardenafil 10 mg on the N400 might be a spurious finding, since 
the effect seems to be quite random as it was only found at one frontal midline electrode 
while the N400 is normally predominantly generated at the left temporal lobe (Luck 2005). 
Additionally, behavioural performance remained unaffected. The decrease of the P300 
during word presentation after vardenafil treatment seems to be a more robust finding 
demonstrated at several electrode locations and at a task in which changes in P300 could 
be expected. However, vardenafil treatment did not affect the behavioural response at this 
task which makes it difficult to pinpoint the meaning of this effect.  
 It is not uncommon to find task and/or treatment effects on EEG or fMRI measurements 
in pharmalogical studies whereas no effect on behavioural performance can be found (e.g. 
Bossong et al. 2012; Linssen et al. 2011). In our current study, this apparent discrepancy 
could be explained by the fact that the decreased P300 was elicited while participants 
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watched words on a screen which they had to remember, but they did not have to execute 
an explicit behavioural response at the same time. So the vardenafil treatment might have 
affected encoding without eliciting an effect on the free recall of the learned words, possibly 
due to the fact that EEG is more sensitive to pick up changes as compared to behaviour.
 Although no effects of vardenafil administration on the POMS and the Bond & Lader 
were found, the questionnaire addressing medical complaints showed that vardenafil 10 mg 
and 20 mg increased the report of feeling weak and headache. The latter is one of the most 
commonly reported side effects after vardenafil treatment (reported by more than 10% of the 
participants from the clinical trials (EMEA 2008)). Together with the fact that maximum 
plasma concentrations of vardenafil after oral administration are reached within 30 to 120 
minutes (EMEA 2008), this finding indicates that vardenafil was very likely bioactive during 
our testing period.  
 It could be argued that the doses of vardenafil used in this study may be not be in the 
optimal dose-range for cognition-enhancing effects. In order to compare the effective doses 
in animals with the doses used in this study, we used the formula of Reagan-Shaw et al. 
(2008) to extrapolate the dosages across species. When taking into account the body 
surface area and body weight, it was shown that the doses of 1 – 3 mg/kg (per os) which 
have been found to enhance memory function in rats (e.g. Chapter 3 and Rutten et al. 2007) 
should be equivalent to 10 – 31 mg in humans (given the average weight of 64 kg of our 
participants). This indicates that although we did not find an effect of vardenafil treatment on 
cognitive performance in healthy adults, we used the translational dosages, time point and 
route of administration. 
 In rats we have shown that vardenafil crosses the blood brain barrier (Chapter 3). Since 
vardenafil was presently found to affect ERPs it might have entered the brain and could be 
biologically active there. Nevertheless, it can not be ruled out that there may not be sufficient 
vardenafil that entered the brain or that PDE5 levels in the human brain are not high enough 
to have a clear cognitive effect on its own. Along similar lines, the levels of PDE5 are 
relatively low compared to other PDEs (Lakics et al. 2010; Loughney et al. 1998) and show 
a strong decrease with aging (Reyes-Irisarri et al. 2007). Thus, PDE5-Is may not be 
effective in humans because the target may not (longer) be sufficiently available. Of note, it 
could be argued that the tasks we used were not translational enough to find an effect. 
However, previous animal studies provide ample evidence to expect effects of PDE5 
inhibition on memory and executive functioning (for review see Chapter 2) and the task we 
used, such as the VLT, TOL and Stroop, are well established tasks for studying these 
cognitive processes. Therefore, the battery of cognitive tasks used in this study should be 
sensitive enough to pick up any relevant proof of principle for the putative cognition 
enhancing effects of PDE5-Is. 
 The effects of PDE5 inhibition on cognition were not only investigated in healthy 
volunteers; Goff et al. (2009) showed that acute sildenafil treatment did not affect cognition, 
positive or negative symptoms in patients with schizophrenia. This in contrast to another 
study (Akhondzadeh et al. 2011) in which sildenafil combined with the atypical antipsychotic 
risperidone reduced the negative symptoms in these patients. Importantly, the latter study 
used chronic sildenafil treatment, as an adjunctive therapy whether the first used acute 
sildenafil treatment only. Interestingly, Shim et al. (2011) demonstrated that the performance 
of patients with ED on an assessment battery addressing frontal executive function and a 
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mini-mental state examination was improved after repeated dosing of the PDE5-I udenafil. 
Furthermore, in a mouse model of Alzheimer’s disease it was found that chronic treatment 
with sildenafil reduced amyloid-beta load and memory decline (Puzzo et al. 2009). These 
findings suggest that although the cognitive enhancing effects of a single dose of a PDE5-I 
in healthy volunteers seem limited, there are interesting options in studying (sub)chronic 
PDE5-I treatment, using a patient population and/or PDE5 inhibition as an adjunctive 
therapy. In addition, since the high level of education of our test subjects might have 
resulted in a ceiling effect, it would also be interesting to use deficit models or use low 
cognitive performers in future studies. 
 To summarize, the PDE5-I vardenafil did not affect the behavioural performance in 
different cognitive tasks. However, vardenafil treatment decreased the P300 in a memory 
task, which implies that PDE5 inhibition might even affect cognitive processing in humans, 
although the exact meaning of this effect is not clear yet. This indicates that the effects of 
PDE5 inhibition on cognition in healthy young adults need further investigation in the future, 
e.g. by using deficits models and additional tasks as well. Taken together, the PDE5-I 
vardenafil did not affect the cognitive performance of healthy adults and showed only some 
incidental and rather contradicting effects on the electrophysiological correlates of cognition. 
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 The aim of this thesis was to investigate the potential of PDE inhibition to improve 
cognition in a translational setting. In short, we studied the effects of PDE2, 5 and 10 
inhibition on memory function in rats with the use of scopolamine and MK-801 induced 
deficit models. Additionally, we investigated whether a PDE2-I or PDE10-I could affect 
sensory gating in rats, and whether a PDE5-I could affect sensory gating in both rats and 
humans, i.e. healthy volunteers. Finally, the effects of PDE5 inhibition on cognition in 
healthy volunteers were addressed by using behavioural tasks as well as EEG 
measurements. 
 
OVERVIEW MAIN FINDINGS OF THESIS 
 
PDE inhibition and object memory function in rats 
 
 In Chapter 3 and 4 we studied the effects of PDE2, 5 and 10 inhibition on object 
memory in rats. In Chapter 3, we used two different PDE5-Is to investigate these effects; 
vardenafil and UK-343,664. The first was shown to cross the BBB, the latter did not. 
Vardenafil reversed memory deficits induced by the NMDA antagonist MK-801 and 
improved memory function decay over time in the object recognition task, whereas UK-
343,664 did not have an effect. This would imply that there is PDE5 present within the brain 
that mediates the effects vardenafil on object recognition. However, the memory deficits 
induced by the muscarinic antagonist scopolamine were reversed by vardenafil as well as 
UK-343,664. Co-administration of scopolamine with vardenafil or UK-343,664 did not alter 
the brain penetration of the compounds, which suggest that the integrity of the BBB is not 
compromised. This is in line with the literature in which no evidence was found that 
scopolamine administration affects the BBB integrity. Thus, the positive effects of UK-
343,664 in the scopolamine-induced memory deficit could be mediated by systemic PDE5. 
Nevertheless, since UK-343,664 did not improve memory decay over time, nor reversed 
MK-801 induced deficits, it is most likely that the memory enhancing effects of UK-343,664 
in the scopolamine model can be attributed to its combination with central and/or peripheral 
effects of scopolamine. 
 We further investigated the effects of PDE2 and PDE10 inhibition in a MK-801- and 
scopolamine-induced memory deficit model in Chapter 4. It was found that the PDE2-I BAY 
60-7550 as well as the PDE10-I PQ-10 were able to reverse the object memory deficits 
induced by MK-801 and scopolamine. Additionally, it was demonstrated that PQ-10 was 
clearly brain penetrant at the behaviourally active dose. Contrarily, BAY 60-7550 was only 
detected in the brain at higher dosages although the brain-plasma ratio was still quite low. 
This suggests that low concentrations are probably sufficient to have a biological effect. This 
might be caused by a high expression of PDE2 in brain structures that are implicated in 
object recognition or by an effect on cyclic nucleotides signal cascades which does not 
necessarily need a high level at the beginning, but can lead to a biological response due to 
signal amplification. Additionally, it might be speculated that an active metabolite crosses 
the BBB. Finally, it could be the case that PDE2 inhibition exerts not only a central, but a 
peripheral effect as well. 
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PDE inhibition and sensory gating in rats and humans 
 
 In Chapter 5 and 6 we studied the effects of PDE inhibition on information processing in 
an auditory sensory gating paradigm. We demonstrated in Chapter 5 that rats and humans 
both showed sensory gating in the placebo condition. In rats, only the N1 peak was less 
negative after the S2 than S1 in the vertex and the hippocampus. The human volunteers 
showed sensory gating at all peaks (P1, N1 and P2) at the Fz, FCz and Cz electrodes. 
However, neither in rats nor in humans an effect of vardenafil was found on basic auditory 
information processing. Since the dosages used in the animals were able to improve 
memory function in animals (see Chapter 3), these results imply that the positive effects of 
cGMP-specific PDE5 inhibition on cognition are predominantly mediated by effects on 
higher cognitive processes and not on information processing.   
 In the follow-up study described in Chapter 6, we investigated the effects of PDE2 and 
PDE10 inhibition in the same paradigm in rats. Although auditory sensory gating was found 
in the placebo condition at the N1 peak in the hippocampus and vertex, it was not affected 
by administration of the PDE2-I BAY 60-7550 or the PDE10-I PQ-10. However, it was 
shown that BAY 60-7550 increased the P1 peak after S1 in the vertex. Furthermore, PQ-10 
affected the N1 peak in the hippocampus in general, with this peak being more negative in 
the PQ-10 than placebo condition. The dosage we used in this study showed memory 
improving effects in Chapter 4. Therefore, these findings indicate that the positive effects of 
the dual substrate PDE2-I and PDE10-I on object memory might partly be affected on more 
early phases of information processing when given before the learning trial. However, it still 
needs to be determined whether these effects are similar when given immediate after the 
learning trial or before the recognition trial.  
 
PDE inhibition and cognition in humans 
 
 The effects of vardenafil on cognition and ERP measurements in healthy humans were 
looked into in Chapter 7. No effects were found on any of the behavioural performances in 
the cognitive tasks, more specifically addressing memory function and executive functioning. 
Yet there was an effect on EEG as vardenafil treatment decreased the P300 peak after the 
immediate recall part of the VLT. There are several possible explanations for the apparent 
discrepancy between finding an effect on an ERP component and finding nothing on 
behavioural performance. EEG is more sensitive to pick up effects as compared to 
behaviour. Thus, PDE5 inhibition might have had an effect on encoding without eliciting an 
effect on the free recall of the words the participants had to learn. In addition, some 
compensatory mechanism might also have counteracted or compensated the effects of 
PDE5 inhibition, resulting in no change in behavioural performance. Unfortunately, since we 
did not find an effect of vardenafil treatment on the behavioural response on the VLT, it is 
difficult to pinpoint the exact meaning of this effect.  
 
METHODOLOGICAL CONSIDERATIONS 
 
 In the animals, we found that PDE2, PDE5 and PDE10 inhibition all had a positive 
effect on memory function. However, we did not find any effect of PDE5 inhibition on the 
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behavioural performance on a variety of cognitive tasks in our human volunteers. There 
might be several explanations for this, including type of treatment, reversal of cognitive 
deficits versus improvement of normal functioning, the environment in which the animals or 
participant reside and the type of tasks that are used in an experiment. 
 
Treatment 
 
 Since we did not find an effect of PDE5 inhibition on cognition in healthy volunteers, it 
could be argued that the dosages we used in our study might not be in the optimal dose-
range for humans to find cognition-enhancing effects. It has been demonstrated in this 
thesis (Chapter 3) as well as in other studies (Prickaerts et al. 2002; Rutten et al. 2007; van 
Donkelaar et al. 2008), that 1-3 mg/kg vardenafil administered orally improves memory 
function in rats. To extrapolate these dosages used in animals to the dosages needed in 
humans, we used the Reagan-Shaw formula (2008): Human dose equivalent (mg/kg) = 
animal dose (mg/kg) * (animal Km / human Km). Given the Km value of 6 for rats and 37 for 
adult humans, the 1-3 mg/kg in animals would be equivalent to 10-31 mg in humans (given 
the average body weight of 64 kg of the volunteers that participated in our study). Thus, the 
dosages we used in our human study (10 mg and 20 mg vardenafil) were well within this 
range and should be appropriate translational doses. 
 Another point that could be raised is the time point and route of administration. We 
started the behavioural as well as EEG measurements 45 minutes after vardenafil (or 
placebo) administration. Previous studies on pharmacokinetic properties of vardenafil by the 
EMEA (2008) have shown that peak plasma levels were reached between 30 and 120 
minutes after a single dose of 20 mg vardenafil and that the terminal half-life was around 4-5 
h. Additionally, in our own study we found an increased report of feeling weak and headache 
after vardenafil treatment. The latter was reported by more than 10% of the participants in 
previous clinical trials (EMEA 2008), which makes it one of the most reported side effects 
after vardenafil intake. Combined with the pharmacokinetic properties of vardenafil, this 
indicates that vardenafil was very likely bioactive during our testing period.  
 In order to exert an effect its target, PDE5, has to be available. As the literature shows, 
the levels of PDE5 are rather low compared to other PDEs (Lakics et al. 2010; Loughney et 
al. 1998) and decline even further as people age (Reyes-Irisarri et al. 2007). Since we 
demonstrated in Chapter 7 that vardenafil affected ERPs, it probably entered the brain, 
which was the case in rats as shown in Chapter 3. Nevertheless, it cannot be ruled out that 
PDE5 levels are not high enough or PDE5-Is, including vardenafil, do not penetrate the BBB 
to an extent that is sufficient to exert behavioural effects on cognitive tasks in humans. 
However, Shim et al. (2011) found a positive effect of chronic treatment with the PDE5-I 
udenafil on the performance on the Korean version of the mini-mental state exam and an 
assessment battery addressing executive functioning. Although they used people suffering 
from erectile dysfunction instead of healthy volunteers, the use of chronic treatment might 
be an interesting alternative to the acute treatment as used in our study. 
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Reversal of deficits versus improvement of normal function 
 
 Except for the 24 h delay interval in the ORT as used in Chapter 3, we only used deficit 
models to study the effects of PDE-Is in rats, whereas we used healthy volunteers for our 
human study. Subsequently, another explanation for the different results of PDE inhibition 
on cognition between rats and humans might be the fact that we predominantly studied the 
reversal of deficits in animals versus the improvement of normal functioning in humans. In 
the literature we found that PDE2, PDE5 as well as PDE10 inhibition improved cognition in 
unimpaired rats in a variety of behavioural tasks (e.g. Boess et al. 2004; Domek-Lopacinska 
and Strosznajder 2008; Grauer et al. 2009; Rutten et al. 2009; Singh and Parle 2003). 
However, when looking at the – rather limited – amount of literature on the effects of PDE 
inhibition on cognition in humans, we found that PDE5 inhibition had an effect on ERP 
measurements during the auditory attention and word recognition (Schultheiss et al. 2001), 
but did not affect cognitive performance in unimpaired adults (Grass et al. 2001; Schultheiss 
et al. 2001). Goff et al. (2009) did not find an effect of sildenafil treatment on cognition in 
patients suffering from schizophrenia either. However, in people suffering from erectile 
dysfunction PDE5 inhibition improved cognition as mentioned above (Shim et al. 2011). So 
although the cognition enhancing effects can be found in impaired as well as unimpaired 
rats, it might be the case that the future of PDE inhibition as cognition enhancer in humans 
is limited to people demonstrating impaired cognitive functioning. This assumption needs to 
be investigated further by using deficit models in healthy volunteers. 
 
Environment 
 
 One of the major differences in the daily life experiences of the humans and animals 
participating in our studies are the environments in which they reside. The rats were housed 
in standard, laboratory housing conditions, while humans generally live in conditions that 
may be considered as an enriched environment. Although this difference seems trivial, 
preliminary data of a recent study by Blokland et al. (2012) might prove otherwise. In this 
study the memory performance of rats that were housed in either standard housing or 
enriched environment was tested. The enriched environment animals performed similar to 
the standard housed rats in the 1 h interval, but outperformed them on the 24 h interval. 
PDE5 inhibition with vardenafil only improved object memory in the standard housed 
animals. However, in the enriched environment animals PDE5 inhibition did not enhance 
memory function. These results do not only raise questions about the housing of animals 
and the effect on their performance in experiments investigating possible cognition 
enhancers, but also suggest that the enriched environment in which our healthy human 
volunteers reside might leave little room for improvement. It would therefore be interesting to 
repeat (part of our) animal studies with rats that were housed in an enriched environment. 
 
Cognitive tasks  
 
 Finally, the lack of findings in the human volunteers might also be explained by the type 
of cognitive tasks we used in our experiments. In our sensory gating studies for example, 
the task setup and testing conditions were quite similar between rats and humans and, 
CHAPTER 8 
153 
possibly as a result of this, the results were comparable as well. However, the sensory 
gating paradigm addresses an automatic process for which no special task instructions are 
needed and in which the sensory preferences of a certain species play a role, as is for 
example the case in memory tasks. Although all memory tasks used in our experiments 
address explicit memory function, the human volunteers got specific instructions concerning 
the tasks they had to perform before testing began, whereas the rats were simply introduced 
into ORT set-up after which the measurements started. Additionally, the memory tasks for 
the humans focused on visual input, while the ORT predominantly relied on tactile 
information. These task differences can unintentionally introduce confounding factors when 
translating the results from humans to rats or vice versa.  
 On the other hand, the wide variety of cognitive tasks and animals species in which 
cognition enhancing effects of PDE inhibition were demonstrated (for review see Chapter 2) 
would provide us with ample evidence to expect effects of PDE inhibition on cognitive 
performance anyway. Especially since the tasks we used in the human study, i.e. the VLT, 
TOL and Stroop tasks, are well established tasks to investigate cognitive processes such as 
memory performance and executive functioning. However, an interesting alternative might 
be the use of operant tasks in which the task differences between animals and humans can 
be kept to a minimum and EEG responses could be measured as well. 
 
CLINICAL IMPLICATIONS AND FUTURE DIRECTIONS 
 
 Does PDE inhibition enhance cognition? Unfortunately, we did not find any effects of 
PDE5 inhibition on cognitive performance in healthy humans (Chapter 7). However, as 
demonstrated in Chapter 2, 3 and 4, PDE-Is, including PDE5-Is, can enhance cognition in 
animals, especially in rodents. The reversal of memory deficits in pharmacological models 
that mimic cognitive problems affiliated to e.g. schizophrenia and Alzheimer’s disease (see 
Chapter 3 and 4), as well as the memory improving effects in transgenic mouse models of 
Alzheimer’s disease (Cuadrado-Tejedor et al. 2011; Puzzo et al. 2009; Sierksma et al. 
2012), suggest that these compounds could have a promising future as cognition enhancers 
for people suffering from neurodegenerative and psychiatric disorders. It has indeed been 
shown that chronic administration of PDE5-Is is able to improve cognitive function in people 
suffering from erectile dysfunction (Shim et al. 2011) and even reduce positive and negative 
symptoms when used as an adjunctive therapy with risperidone in patients with 
schizophrenia. Interestingly, in contrast to PDE5 inhibition, PDE2 and PDE10 inhibition 
influenced early information processing in rats (Chapter 5 and 6). This implies that these 
compounds might be especially appealing for patients who suffer from (early) information 
processing deficits as e.g. in patients suffering from schizophrenia (McCarley et al. 1991; 
Turetsky et al. 2009).  
 Further, preclinical research should focus on behavioural tasks that can be used in a 
translational setting. In addition, clinical testing should consider the use of cognition deficit 
models as is done more often in animals. Furthermore, it is interesting to not only test the 
effects of acute administration of the PDE-Is, but to include chronic administration as well. It 
is also important to shed more light on the possibly interfering effects of housing conditions 
of the animals, i.e. can our results be replicated in animals in enriched environments. 
Finally, it is essential to explore the effects of different types of PDE-Is in more detail, in 
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order to gain further insight into the potential of PDEs as a target for cognition enhancement. 
For example, we already demonstrated that the dual substrate PDE-Is BAY 60-7550 and 
PQ-10 affected early auditory information processing, whereas the cGMP-specific PDE5-I 
vardenafil did not. This implies that the each type of PDE-I could have a more specific use to 
target the cognition impairments related to a particular disorder. In conclusion, specific PDE-
Is can improve cognition and the potential of these PDE-Is as cognition enhancers needs to 
be elucidated in future translational research. 
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 The aim of this thesis was to investigate whether PDE inhibition can improve cognition 
by using a translational approach. The general introduction (Chapter 1) described the 
rationale of this thesis and the aims of the studies we conducted. In Chapter 2 we reviewed 
and discussed the literature on the effects of PDE-Is on cognition across species. 
 
 In Chapter 3 we examined the effects of PDE5 inhibition on memory in the ORT and 
determined whether compound penetration of the BBB is required for this activity. Vardenafil 
was shown to cross the BBB, but UK-343,664 did not. Vardenafil improved time-dependent 
memory decay and reversed the MK-801-induced memory deficit whereas UK-343,664 had 
no effect. However, both PDE5-Is attenuated the memory impairment induced by 
scopolamine. Co-administration of UK-343,664 and scopolamine did not alter the brain 
partitioning of either molecule which suggests that the positive effect of UK-343,664 on 
scopolamine-induced memory decay might arise from peripheral PDE5 inhibition. The 
results imply that there may be multiple mechanisms that mediate the efficacy of PDE5 
inhibition to improve memory performance in tasks such as the ORT and that these involve 
PDE5 located both within and outside of the brain.  
 
 In Chapter 4 we presented the effects of PDE2 and PDE10 inhibition on memory 
function in the ORT using the scopolamine- and MK-801-induced memory deficit model. 
Both PDE2-I BAY 60-7550 and PDE10-I PQ-10 attenuated the scopolamine-induced as well 
as the MK-801-induced memory deficits. PQ-10 was highly brain penetrant, whereas 60-
7550 levels in the brain were very low after oral treatment. We concluded that since BAY 60-
7550 and PQ-10 reversed both scopolamine- and MK-801-induced memory deficits, this 
supports the notion that dual substrate PDE inhibitors might be suitable candidates for 
cognition enhancement.   
 
 In Chapter 5 we explored the effects of PDE5 inhibition on auditory sensory gating in 
rats and humans. Significant gating was only found for the N1 component in rats, while all 
three peaks P1, N1 and P2 showed gating in humans, i.e. the response to the second sound 
click was decreased as compared to the first for these deflections. Administration of 
vardenafil did neither have an effect on sensory gating in rats nor in humans. These results 
imply that the positive effects of PDE5 inhibition on cognition are not mediated by more early 
phases of information processing. 
 
 In Chapter 6 we focused on the effects of PDE2 (BAY 60-7550), PDE5 (vardenafil) and 
PDE10 (PQ-10) inhibition on sensory gating in rats. EEG was recorded from the 
hippocampus, striatum, and vertex.  Sensory gating was found for the N1 in the vertex and 
hippocampus, as revealed by diminished amplitudes to S2 compared to S1. Administration 
of PDE-Is did not affect sensory gating. However, PDE2 inhibition increased the P1 peak 
after presentation of S1 at the vertex and PQ-10 increased the N1 peak in general 
compared to vehicle treatment at the hippocampus. These findings suggest that the positive 
effects of PDE5 inhibition on cognition previously found in animals are possibly the result of 
an effect on higher cognitive functioning specifically whereas the cognition enhancing effects 
of PDE2 and PDE10 inhibition might also be influenced by effects on earlier stages of 
information processing.  
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 In Chapter 7 we assessed whether the PDE5-I vardenafil improves memory and 
executive functioning and affects EEG in healthy young adults. No prominent effects of 
vardenafil on cognition were found; participants only made more mistakes on a reaction time 
task after 20 mg vardenafil. During encoding of words, the P300 was generally smaller after 
vardenafil treatment. Furthermore, the N400 was larger after vardenafil 10 mg than placebo  
and 20 mg treatment in a spatial memory task at Fz. Finally, headache and feeling weak 
were reported more after vardenafil treatment. Vardenafil did not affect cognitive 
performance of healthy adults and showed only some incidental effects on ERPs. These 
findings in humans do not corroborate the cognition enhancing effects of PDE5-Is in healthy 
animals. 
 
 In Chapter 8 we evaluated the main findings of this thesis and addressed several 
methodological considerations. In addition, clinical implications and suggestions for future 
research were discussed. We concluded that specific PDE-Is can improve cognition and the 
potential of these PDE-Is as cognition enhancers needs to be elucidated in future 
translational research. 
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 Het doel van dit proefschrift was om met behulp van een translationele aanpak te 
onderzoeken of fosfodiesterase (phosphodiesterase: PDE) remming cognitie kan 
verbeteren. De algemene introductie (Hoofdstuk 1) beschreef de motivering van dit 
proefschrift en de doelen van de experimenten die we hebben uitgevoerd. In Hoofdstuk 2 
gaven we een overzicht van de literatuur over de effecten van PDE remmers op cognitie in 
verschillende diersoorten. 
 
 In Hoofdstuk 3 onderzochten we de effecten van PDE remming op geheugen in de 
object herkenningstaak (object recognition task: ORT) en bepaalden we of de PDE remmers 
de bloed-hersenbarrière moeten passeren om een effect uit te oefenen. We lieten zien dat 
vardenal de bloed-hersenbarrière passeerde, maar dat UK-343,664 dat niet deed. 
Vardenafil verbeterde tijdsafhankelijk verval van het geheugen en maakte de 
geheugengebreken die veroorzaakt werden door MK-801 ongedaan. UK-343,664 had geen 
effect. Beide PDE5 remmers wisten echter de verslechtering in geheugen die opgewekt 
werd door scopolamine ongedaan te maken. Gelijktijdige toediening van UK-343,664 en 
scopolamine had geen effect op de mate waarin deze stoffen in het brein kwamen, wat erop 
duidt dat de positieve effecten van UK-343,664 op geheugenproblemen geïnduceerd door 
scopolamine mogelijk veroorzaakt worden door perifere PDE5 remming. Deze resultaten 
impliceren dat er mogelijk meerdere mechanismen zijn die de werkzaamheid van PDE 
remming wat betreft geheugen verbetering op taken zoals de ORT kunnen beïnvloeden en 
dat deze zowel PDE5 in als buiten het brein omvatten. 
 
 In Hoofdstuk 4 presenteerden we de effecten van PDE2 en PDE10 remming op 
geheugen in de ORT waarbij het geheugen werd verslechterd door scopolamine of MK-801. 
De PDE2 remmer BAY 60-7550 en PDE10 remmer PQ-10 maakten beide de 
geheugenproblemen die veroorzaakt werden door zowel scopolamine als MK-801 
toediening ongedaan. De hoeveelheid PQ-10 in het brein was hoog na orale toediening, 
terwijl de hoeveelheid BAY 60-7550 erg laag was. We concludeerden dat PDE remmers die 
zowel effect hebben op cAMP als cGMP geschikte kandidaten zijn om cognitie te 
verbeteren.  
 
 In Hoofdstuk 5 exploreerden we de effecten van PDE5 remming op auditieve 
sensorische filtering in ratten en mensen. Significante filtering werd alleen gevonden voor de 
N1 component in ratten, terwijl bij mensen alledrie de pieken, P1, N1 en P2, filtering lieten 
zien, dat wil zeggen dat de reactie op de tweede geluidsstimulus afgenomen was ten 
opzichte van de eerste voor deze pieken. Toediening van vardenafil had geen effect op 
sensorische filtering in ratten, noch in mensen. Deze resultaten doen vermoeden dat de 
positieve effecten van PDE5 inhibitie op cognitie niet gemediëerd worden door vroegere 
fases van informatieverwerking. 
   
 In Hoofdstuk 6 hebben we ons gericht op de effecten van PDE2 (BAY 60-7550), PDE5 
(vardenafil) en PDE10 (PQ-10) remming op sensorische filtering in ratten. EEG activiteit 
werd opgenomen van de hippocampus, het striatum en de vertex. Sensorische filtering werd 
gevonden voor de N1 in de vertex en hippocampus, zoals verminderde amplitudes na de S2 
ten opzichten van de S1 lieten zien. Toediening van PDE remmers had geen invloed op 
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deze sensorische filtering. PDE2 remming vergrootte echter wel de P1 component van de 
vertex na de presentatie van S1 en PQ-10 vergrootte de N1 piek van de hippocampus in zijn 
geheel in vergelijking tot vehicle behandeling. Deze bevindingen duiden erop dat de 
positieve effecten van PDE5 inhibitie op cognitie die eerder gevonden zijn in dieren 
waarschijnlijk specifiek het resultaat zijn van een effect op hoger cognitief functioneren, 
terwijl de cognitie-verbeterende effecten van PDE2 en PDE10 remming mogelijk ook 
beïnvloed worden door effecten op eerdere fases van informatieverwerking.  
 
 In Hoofdstuk 7 hebben we onderzocht of de PDE5 remmer vardenafil het geheugen en 
executief functioneren verbetert en EEG beïnvloedt in gezonde jongvolwassenen. Er 
werden geen prominente effecten van vardenafil op cognitie gevonden; deelnemers 
maakten alleen meer fouten op een reactietaak na inname van 20 mg vardenafil. Tijdens het 
coderen van woorden was de P300 over het algemeen kleiner na behandeling met 
vardenafil. Verder was de N400 van de Fz in de spatiële geheugentaak groter na toediening 
van 10 mg vardenafil dan placebo en 20 mg. Tenslotte werd er vaker melding gemaakt van 
hoofdpijn en gevoel van zwakte na behandeling met vardenafil. Vardenafil had geen effect 
op de cognitieve prestatie van gezonde volwassenen en liet alleen enkele incidentele 
effecten op ERPs zien. Deze resultaten in mensen zijn niet in lijn met de cognitie-
verbeterende effecten van PDE remmers in gezonde dieren.  
 
 In Hoofdstuk 8 evalueerden we de belangrijkste bevindingen van dit proefschrift en 
schonken we aandacht aan enkele methodologische overwegingen. Verder werden 
klinische implicaties en voorstellen voor toekomstig onderzoek besproken. We 
concludeerden dat specifieke PDE remmers cognitie kunnen verbeteren en dat het 
potentieel van deze PDE remmers als cognitie verbeteraars verder bekeken moet worden in 
toekomstig translationeel onderzoek. 
 
  
Dankwoord 
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‘Dit is mijn dag, ik lach om zwaartekracht. Genoeg gewacht, ik lach om zwaartekracht. En 
niemand haalt mij ooit nog neer.’ (Wicked). Net als de meeste musicals, kent een promotie 
traject doorgaans een aarzelend, doch enthousiast begin, een middenstuk met pieken en 
dalen, een dramatische wending vlak voor het eind en tot slot een happy end ;). En zoals 
een musical niet alleen bestaat uit de grote naam op het affiche, heeft ook een AiO project 
nog een heel team van mensen die een bijdrage hebben geleverd. Dus hoogste tijd voor het 
meest gelezen onderdeel van een proefschrift; dames en heren, het dankwoord! 
 
Prof. dr. Harry Steinbusch, mijn promotor. Bedankt dat ik deel mocht uitmaken van de 
School for Mental Health and Neuroscience en dat u me de kans heeft gegeven te 
promoveren.  
 
Dr. Jos Prickaerts, mijn co-promotor. Beste Jos, bedankt voor je grenzeloze vertrouwen, niet 
alleen in het project, maar zeker ook in mij. Jouw uitspraak ‘het kan niet meer misgaan’, die 
je vlak voor de kerstvakantie in 2010 deed, is onbedoeld legendarisch geworden en al 
helemaal niet op de manier die je waarschijnlijk voor ogen had ;). Maar twee jaar - en de 
nodige huisbezoekjes - later is het proefschrift is af, de overgrote meerderheid zelfs 
gepubliceerd, oftewel, het is allemaal toch nog goedgekomen! (al mijd ik sneeuw en 
gladheid zoveel mogelijk tot en met de dag van de verdediging, je weet maar nooit, haha) 
 
Dr. Thomas Steckler, mein Chef in dem Jahr bei Johnson & Johnson. Thomas, sie haben 
mir wirklich viel beigebracht und es war sehr interessant um ein Jahr in der Industrie zu 
arbeiten. Die Idee eines translationalem Stroop Testes war sehr aussichtsreich; schade, 
dass die Tierchen so verdammt intelligent waren! Vielleicht hätten wir ihnen tatsächlich 
Schokolade und Wein geben sollen zur Motivation, Zeit für ein neues Experiment? 
 
Dr. Anke Sambeth. Anke, zonder jou had dit boekje er toch wel wat anders uitgezien. Jouw 
liefde voor het vak is bewonderingswaardig en ik wil je bedanken voor je eindeloze geduld 
met mij en de hulp met de EEG studies (rat en humaan). Wanneer ik Guus op de radio hoor, 
krijg ik nog regelmatig een flashback naar ons in de OK! 
 
Alle neuroscience collega’s van de UNS50 en de psychofarmacologen van de UNS40, 
bedankt voor de leuke tijd op de uni. In het bijzonder (oud) kamergenoten: Marjo, Laura, 
Linda, Kris (ondanks dat je niet meer in het PDE veld zit, toch nog altijd heel geïnteresseerd, 
top!), Ayhan, Jochen, Eva, Sven, Eva, de urologen-club, Annerieke, Marisela en natuurlijk 
Marlies. En uiteraard de rest van de MC crew waaronder Nick, Jérôme, Tim, Gunther, Daan 
(warme choco met slagroom consulten ftw ;) ), Caroline, Rianne, Caroline en Lena. Bedankt 
voor alle late/vroege (afhankelijk van hoe je het bekijkt) stapavonden, ontspannende 
koffiepauzes, luisterende oren inclusief peptalks indien nodig, assistentie bij experimenten, 
gezelligheid binnen en buiten het kantoor, en zo kan ik nog wel even doorgaan ;). En 
uiteraard dr. Blokland, door wie ik ooit bij Jos terecht ben gekomen, Arjan, bedankt! 
De dames van het secretariaat Mirèse, Akke, Sandra, Anouk, Marie-Therèse en Lisa die de 
adminstratieve zaken al die jaren in goede banen hebben geleid. Nicole, bedankt voor het 
geregel omtrent mijn verblijf bij JnJ en voor je goede adviezen! 
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De analisten, Hellen, Marjanne, Denise en Marjan, voor het eindeloze afwegen van alle 
stofjes, Cees voor het keuren van alle proefpersonen en natuurlijk de CPV’ers voor alle hulp 
omtrent de levering en huisvesting van de dieren. 
 
JnJ collega’s voor het toffe en leerzame jaar in Beerse. Bureaugenotes Ann en Wieteke 
voor het aangename gezelschap, de lol en de wisselende voorrraad snoep. Hilde voor de 
altijd vriendelijke hulp op het secretariaat, ook bij de zoveelste vraag of papierhandel. Darrel 
thanks for all the help, varying from arranging a lab ‘till sharing knowledge about previous 
experiments. Hansfried voor het ontwerpen en leveren van de test apparatus van de Stroop 
en Sigrid, Roland, Luc en Pim voor de PPI experimenten. De mensen van het LAM, met 
name Willy, Werner en Liselotte, voor het verzorgen van de beestjes. 
And last but not least the JnJ rockers John – US ‘let’s rock ‘n roll’ – T., John – UK ‘the shoes 
we shall not talk about’– A. and of course my all-time favorite chef: Laetitia. My stay at JnJ 
wouldn’t have been this legen… wait for it … dary without you guys! 
 
De studenten die hebben bijgedragen aan de uitvoer/analyse van de humane studie: Ili, 
Agnieszka, Moos, Connie en Saranne. Een speciale vermelding voor Floriaan die de boel 
draaiende heeft gehouden toen ik naar JnJ vertrok, maar de humane studie nog niet 
helemaal was afgerond; top gedaan! 
 
De leden van de leescommissie en de corona, bedankt voor de tijd die jullie hebben 
gestoken in het lezen van mijn proefschrift en de aanwezigheid bij de verdediging hiervan. 
 
En uiteraard alle pluizebollen en proefpersonen die hebben deelgenomen aan de studies; 
zonder jullie geen onderzoek. 
 
Het is bijna onmogelijk alle vrienden, familie en kennissen te bedanken die me de afgelopen 
jaren hebben gesteund in de goede en iets minder goede tijden; (nogmaals) bedankt voor 
jullie interesse en steun tijdens het hele traject en niet in de laatste plaats voor de lawine 
aan kaarten, mails, smsjes, telefoontjes, bezoek en cadeautjes de afgelopen twee jaar; het 
is onmogelijk in woorden uit te drukken hoeveel dit voor me betekend heeft :). Al zijn er toch 
een aantal mensen die ik nog even persoonlijk wil bedanken, dus daar gaan we! 
 
De mannen van Drumschool Maastricht: Pieter, Wouter en Michel die altijd voor een leuke 
drumles wisten/weten te zorgen en zo mijn stressniveau (tijdelijk) tot 0 wisten te reduceren. 
Met een motorisch gestoorde leerling soms best een opgave ;). 
 
De gezondheidszorg is vaak een onderwerp van eindeloos geklaag en gezeur. Maar laten 
we niet vergeten dat we er zonder in 99,9% van de gevallen nog heel wat slechter af 
zouden zijn. Dus in het bijzonder een woord van dank voor Ludo, René, orthopedie en 
revalidatie dankzij wie ik er de 18e april letterlijk kan staan (sorry voor de hakken ;) ). 
 
Dees, van de Veldmuiskes tot Les Couscous en van het Jeanne d’Arc tot de scouting; soms 
zijn er mensen die altijd al in je leven lijken te zijn geweest. En ook al kamperen we 
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tegenwoordig niet meer in tuinen en maken we geen tekeningen meer in het AKO gebouw, 
samen lachen en lekker eten kunnen we nog steeds als de besten!  
 
Suus, het begon ooit allemaal in B1F met twee brugmuggen die zich bezighielden met 
dingen als een gft klooster, het griezelen over (het borsthaar van) enge docenten en 
eindeloze telefoongesprekken. Bijna twintig jaar later is het via talloze logeerpartijen, idolen 
als Queen en The Boss en iets serieuzere opleidingen, uiteindelijk toch nog goed gekomen 
met ons! Es, in het begin vooral ‘het jongere zusje van’, maar dat ligt alweer jaren achter 
ons. Met ‘nne echte Sjeng (ok, vleugje exotisch Brabo-schap ;) ) kan het eigenlijk alleen 
maar gezellig zijn; om over onze zeer productieve lunches natuurlijk maar te zwijgen! En 
Geleen is natuurlijk een voorstad van Sjengenland, niets aan de hand ;).  
 
De Belgiqueskes van de psychologie opleiding. We hebben met ons groepje vele hilarische, 
maar helaas ook enkele trieste momenten beleefd. Het is fijn te weten dat we er in beide 
gevallen voor elkaar zijn. Ankiebol, mijn meest Nederlandse Belg met uitzondering van de 
charmante IE en UU klanken. Al zijn we ieder onze eigen weg gegaan na de studie, 
wanneer we samen zijn is het net alsof we ons gisteren nog gezien hebben. Pat, onze 
drukke Belg die altijd wel tijd weet te maken voor (het helpen van) andere mensen en waar 
de deur altijd wagenwijd openstaat. Ow, en perfect de militaire voertuigen in Transformers 
weet te duiden! Na al die jaren blijft het rustig bijkletsen aan jouw keukentafel in Hoeselt 
onder het genot van een steak peperroomsaus altijd een van mijn favoriete momenten. Dr. 
Peke, mijn mede-altijdgelijkhebbende, afdeling Belg(ië); ik ben blij dat je achter me staat op 
een dag als vandaag. Van ‘meezingen’ met Rammstein als we terugkwamen van een 
tentamen tot het ongeduldig wachten op de volgende aflevering van Buffy en later True 
Blood. Ondanks dat jouw leven er totaal anders uitziet dan het mijne, ben ik blij dat we 
elkaar regelmatig zien om eindeloos te ouwehoeren en de Oscarwaardige verhaallijnen van 
onze series te bediscussiëren ;).  
 
De kerels, Alex, Michiel en Ron. Bedankt voor fantasy wereld die ik dankzij jullie heb leren 
kennen. Een paar jaar terug waren comics, rpgs, fantasy evenementen en zelfs Chtulhu 
totaal onbekend voor me en nu zou ik niet meer weten hoe het er zonder was ;). Ow, en dat 
er zoiets bestaat als een 30 seconden regel en dat tentstokken & uitgaanscentrum moeilijke 
woorden zijn, waren toch wel het grootste leermomenten op Malta. We moeten jullie allleen 
wel nog in een pèkske zien te krijgen hè :P. 
 
Manuel, ook per mail kun je iemand supporteren hebben we gemerkt ;). Bedankt voor de 
vele peptalks, al moet ik nog werken aan m’n beestachtige brul *grrrrrrrrrr*! 
 
De weerwolven van Wakkerdam / pubquiz crew,  en dan vooral Lieke & Martijn, Caroline & 
Joeri, Daniëlle & Robbert, bedankt voor de extra bijnaam Olgjeweerwolfje en de vele top 
drie notaties bij de quiz. Dat we nog maar vaak mogen winnen (en lol hebben, want winnen 
is uiteráárd niet het belangrijkste (aangezien de eerste prijs niet te zuipen is :P)). 
 
Dr. Inge, op het moment dat ik dit schrijf, ben ik net jouw paranimf geweest en tegen de tijd 
dat jij dit leest, is het bijna jouw beurt :). Volgens mij ben ik sneller klaar als ik de interesses 
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en gedachtegangen opnoem die we niet delen; ‘Get out of my head Zoekeh!’ is niet voor 
niets een van onze meest gebruikte uitspraken! Bedankt voor je vastberadenheid me de 
afgelopen twee jaar gewoon overal mee naartoe te slepen, al is het in een rolstoel over het 
hellende Pinkpop terrein met 30+ graden celsius of met een rollator plus bagage in een NS 
trein die toch niet zo rollatorvriendelijk bleek te zijn ;). En als we het carrière-technisch echt 
niet meer weten, worden we gewoon de nieuwe Beavis & Butthead (of Waldorf & Statler), 
hahaha. 
 
Sandra, twee keer per week baantjes trekken in onze Hierder chloorbak is veel leuker in het 
gezelschap van ’n aander Hierder mèidske! En die zich als het even kan vooral niet 
schaamt als ze naast iemand zwemt die een veel te glimmende glitterdouchemuts als ideaal 
zwemaccessoire ziet ;). Mijn gruwelijke hekel aan baantjes trekken wordt aanzienlijk 
gereduceerd door jouw vrolijke gezelschap en de eindeloze voorraad 
gespreksonderwerpen, variërend van aubergines tot Elvis (de kat natuurlijk) en van 
piratenrokken tot Luik!  
 
Nicky, de buurvrouw die eigenlijk niet mijn buurvrouw is :P. Naast pratend wandelen (of was 
het wandelend praten?), houden we ons uiteraard ook bezig met goede doelen, zoals het 
steunen van de lokale lunchroom! En als iemand de mening deelt dat warme chocomelk 
365,25 dagen per jaar kan, dus ook bij 25+ graden, en de TLC pulp stiekem ook wel leuk 
vindt, sja, zou bijna zeggen ‘kan niet misgaa...’ :P. 
 
Tot slot wil ik natuurlijk m’n familie bedanken; we hebben geen grote familie maar de 
belangstelling van de (oud)ooms/tantes (Hans, bedankt voor het geduld en de creativiteit 
mbt de cover; simpel is niet altijd makkelijk ;) ), (achter)neven/nichten en uiteraard oma’s 
(oma Leny, bedankt voor de extra support :) ) was altijd aanwezig. En uiteraard het 
thuisfront, de (meestal) stressverlagende huisdieren - de jongens Fidel & Nigra, Visje(s) en 
de ‘kuusje’ Bientje & Jimmy - en, de laatste maar zeker niet de minste, pap & mam. Bedankt 
voor het luisteren naar mijn oneindige blijheid over de dingen die goed gingen en vooral ook 
naar het hardgrondig geknotter als het weer ’s niet ging zoals ik het voor ogen had ;). Maar 
ook bedankt voor alle ondersteuning de afgelopen jaren, niet alleen figuurlijk, maar na de 
beruchte 3e kerstdag ook letterlijk. De eindeloze blokjes om door Heer, de talloze 
ziekenhuisbezoeken en de lange kampeervakantie in de woonkamer waren toch net wel 
beter te verhapstukken met goed gezelschap :). Maargoed, daar gaan we verder geen 
bomen meer aan verspillen; het is achter de rug, het proefschrift is afgevinkt, tijd voor de 
volgende punten op de lijst! 
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AEP: auditory evoked potential 
BAY: BAY 60-7550 
BBB: blood-brain barrier 
BQL: below quantification limit 
cAMP: cyclic adenosine monophosphate 
Cb: brain concentration 
Cb:Cp: brain-to-plasma ratio 
cGMP cyclic guanosine monophosphate 
Cp: plasma concentration 
CRMT: continuous recognition memory task 
d2: (relative) measure of discrimination between the new and familiar objects 
e1: measure of the time spent in exploring both objects in T1 
e2: measure of the time spent in exploring both objects in T2 
EEG: electroencephalography 
ERP: event-related potential 
GLM: general linear model 
i.p.: intraperitoneal 
ISI: interstimulus interval 
ITI: intertrial interval 
LTP: long-term potentiation 
MK: MK-801 
NMDA: N-Methyl-D-aspartate 
n.s.: not significant 
ORT: object recognition task 
PDE: phosphodiesterase 
PDE-I: phosphodiesterase inhibitor 
p.o.: per os, orally 
POMS: profile of mood states 
PPI: prepulse inhibition 
PQ: PQ-10 
RT: reaction time 
S1: first stimulus 
S2: second stimulus 
s.c.: subcutaneous 
scop: scopolamine 
SMT: spatial memory task 
T1: trial 1 
T2: trial 2 
TOL: tower of London 
UK: UK-343,664 
Var: vardenafil 
VAS: visual analogue scale 
VLT: verbal learning task 
 
